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General introduction and outline of the thesis
Hypertensive disorders of pregnancy
Having a baby is a joyous and fulfilling experience and safe for the great majority of 
women in the Netherlands. Unfortunately, pregnancy and delivery can also cause 
a stressful life event when the mother’s or baby’s health is adversely affected, 
especially in the presence of hypertensive disorders of pregnancy.
Hypertensive disorders of pregnancy are one of the leading causes of maternal 
mortality and severe maternal morbidity, affecting approximately 6% to 8% of all 
pregnancies  worldwide.1,2,3  In  the  Netherlands,  these  disorders  constitute  the 
major cause of maternal mortality, with a Maternal Mortality Ratio (MMR, maternal 
mortality  per  100,000  live-born  children)  of  3.5  in  the  period  1993-2005.4  The 
second most frequent cause was death due to cardiovascular disease, followed by 
thromboembolism (both MMRs 1.6). Other main causes were obstetric haemorrhage 
(MMR  0.7),  genital  tract  sepsis  (MMR  0.7)  and  cerebrovascular  disorders,  as 
vascular  dissection  or  rupture  (MMR  0.6).  The  MMR  of  3.5  for  gestational 
hypertensive disorders in the Netherlands is markedly higher than the MMR of 
0.9 per 100,000 maternities in the United Kingdom for the period 2003-2005.5 In 
the United Kingdom the commonest cause of maternal deaths in this period are 
thromboembolism (MMR 1.9) and cardiovascular disorders (MMR 2.3). The major 
difference between the Netherlands and the United Kingdom may be caused by 
epidemiologic factors, classification issues, or by differences in the care of high-risk 
pregnancies. In the Netherlands substandard care is reported in cases of maternal 
mortality due to hypertensive disorders.6 Substandard care in hypertensive disease 
of pregnancy causing maternal mortality, concerned insufficient diagnostic testing, 
inadequate management of hypertension by obstetricians, no use or inadequate 
use of magnesium sulphate, inadequate stabilisation before referring to tertiary 
care centres, failure to consider timely delivery or fluid overload in women with 
PE dying as a result of ARDS.5,6 The high incidence of maternal mortality due to 
hypertensive disorders in the Netherlands, which is apparently partly associated to 
substandard care, warranted critical evaluation of the management of hypertensive 
disease in the Netherlands. Growing awareness among Dutch obstetric caregivers 
on this subject is needed to lower maternal mortality and morbidity.
The spectrum of hypertensive disorders in pregnancy ranges from mild gestational 
hypertension  (GH)  or  pre-eclampsia  (PE)  to  their  severe  condition.  Mild  GH  is 
defined as diastolic blood pressure between 90/95 - 110 mm Hg or systolic blood 
pressure between 140 - 170 mm Hg and mild PE as GH combined with 300 - 5000 
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11mg total protein within a 24-h urine collection.7,8,9 In both conditions, women were 
normotensive at the start of pregnancy until week 20 of gestational age. Severe 
hypertension  is  defined  as  diastolic  blood  pressure  ≥110  mm  Hg  or  systolic 
blood pressure ≥170 mm Hg and severe proteinuria if ≥5000 mg total protein is 
present within a 24-h urine collection.7 Hypertensive disease in pregnancy could 
progress  into  severe  maternal  and  fetal  complications  such  as  eclampsia10, 
abruptio placentae, the Haemolysis Elevated Liver enzymes and Low Platelet count 
syndrome (HELLP), asphyxia or even intra-uterine fetal death. In order to reduce 
maternal and fetal mortality and morbidity in women with hypertensive disease 
in pregnancy, proper antenatal care, early recognition and referral and adequate 
treatment is required.11 The only causal treatment of the disease is termination of 
pregnancy. 
In case of preterm pregnancies complicated by hypertensive disease, expectant 
monitoring is advocated to increase the chance of fetal maturity, as long as the risks 
for the mother remain acceptable. Two randomised trials performed in pregnancies 
between 28-34 weeks’ gestation complicated with PE, concluded that expectant 
management  was  associated  with  a  reduction  in  neonatal  complications  and 
duration of neonatal stay in the intensive care unit, without an increase in maternal 
complications.12,13 
For the management of women with GH or mild PE at term, evidence for selection of 
induction of labour versus expectant monitoring is scarce. Strong practice variation 
exists in the Netherlands for treatment of women with GH or mild PE beyond 
36  weeks’  gestation.  In  most  Dutch  centres,  the  preferred  policy  is  expectant 
monitoring, whereas in the USA and other developed countries, induction of labour 
is general practice in women with GH or mild PE at term.1,14 Until this thesis these 
recommendations have not been based on the results of a randomised clinical 
trial. Induction of labour might increase the risk of assisted vaginal delivery and 
caesarean section, thereby generating additional morbidity and costs.15,16,17 On the 
other hand, expectant monitoring might lead to severe pregnancy complications 
as eclampsia, HELLP syndrome, organ failure or an adverse neonatal outcome. 
The lack of consensus is also demonstrated by the results of an inquiry under 
Dutch gynaecologists and residents prior to the results of the Dutch randomised 
controlled trial, in which induction of labour is compared to expectant monitoring 
in pregnant women with hypertensive disease at term (HYPITAT trial; Hypertension 
and Pre-eclampsia Intervention Trial At Term) (figure 1 and 2).
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HYPITAT study
In the first part of this thesis the (cost-) effectiveness of induction of labour and 
expectant  monitoring  in  term  pregnancies  complicated  with  mild  hypertensive 
disease  is  addressed.  In  a  multicentre  randomised  controlled  trial  this  issue 
was  investigated.  The  study  is  called  HYPITAT,  implying  ‘HYpertension  and 
Pre-eclampsia Intervention Trial At Term’. The primary aim of this trial was to 
assess whether induction of labour was a beneficial treatment option compared 
to  expectant  monitoring  in  reducing  maternal  morbidity.  Secondary  aim  was 
to examine methods of delivery, neonatal outcome, maternal quality of life and 
economic consequences of both treatment strategies.
Figure 2. Prior beliefs of 
induction of labour on 
the number of unplanned 
caesarean section in women 
with mild hypertensive 
disease in pregnancy at term. 
Data from an inquire under 
Dutch gynaecologists and 
residents in March 2008.
Figure 1. Prior beliefs of 
induction of labour on 
the number of maternal 
complications in women with 
mild hypertensive disease 
in pregnancy at term. Data 
from an inquire under Dutch 
gynaecologists and residents 
in March 2008.
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13In the field of obstetrics, important clinical questions have been addressed by 
multicentre  randomised  trials,  but  only  a  limited  number  of  such  trials  have 
been carried out in the Netherlands. Implementation of the results from abroad 
is hampered, because the organisation of Dutch obstetric practice differs from 
that  abroad.  In  2003  Dutch  perinatal  centres  offered  together  some  important 
clinical issues to ZonMw. Six randomised trials, the HYPITAT trial included, were 
implemented within a national network, called the Dutch Obstetric Consortium. The 
infrastructure of the Dutch Obstetric Consortium, in which more than 40 hospitals, 
including all perinatal centres, participated, makes recruitment and data collection 
of a large group of women possible within a relative short time. This improvement 
of study quality and power is also important for subsequent implementation of the 
trial results.18 
Prediction of severe maternal morbidity in gestational hypertension or 
mild pre-eclampsia
The  results  of  the  HYPITAT  trial  concern  an  overall  recommendation  for  the 
best treatment option, i.e. induction of labour or expectant monitoring, in term 
pregnancies with hypertensive disorders. The goal of the second part of this thesis 
is to formulate more specific recommendations to improve quality of care and 
subsequently limiting maternal mortality and morbidity. For the correct choice of 
management for the individual patient, identification of women at increased risk 
of developing severe maternal outcomes is of major importance. Women who are 
at higher risk of developing complications during pregnancy should be identified 
early in pregnancy or even before conception, in order to receive preconception 
advice and more frequent antenatal visits. Early identification will benefit doctors 
and patients by helping to monitor disease severity, guide therapy and will allow 
clinicians to avoid unnecessary interventions in low-risk groups. High-risk pregnant 
women should be referred to a secondary or tertiary care centre and frequent 
blood pressure monitoring during the concluding weeks of pregnancy should be 
emphasised.
Eclampsia  is  still  the  most  feared  pregnancy  complication  in  the  Netherlands. 
The incidence of eclampsia in the Netherlands is 6.2 per 10.000 deliveries, which 
is  markedly  increased  as  compared  with  other  Western  European  countries.19 
Although the rates of eclampsia have decreased in high-income countries since 
the publication of Collaborative Eclampsia trial (1995) and the Magpie trial (2002), 
advocating  the  therapeutic  and  prophylactic  use  of  magnesium  sulphate20,21, 
accurate  prediction  of  eclampsia  still  constitutes  a  serious  clinical  challenge. 
Therefore  special  attention  is  paid  to  the  identification  of  risk  indicators  for 
eclampsia.
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From literature we know that women with a pregnancy related hypertensive disorder 
are at increased risk of developing postpartum haemorrhage as compared to low 
risk populations (10% versus 1%).22-26 Because of this 10 times higher incidence of 
postpartum haemorrhage, we aimed to identify women who are at increased risk 
of developing postpartum haemorrhage to facilitate the best management for the 
individual patient. Furthermore, the accuracy of serum uric acid and liver function 
tests in the prediction of severe maternal outcome in women with hypertensive 
disease is highlighted.
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15Outline of the thesis 
The studies in this thesis discuss the best treatment option in women with a singleton 
(nearly)  term  pregnancy  who  are  complicated  with  mild  hypertensive  disease. 
Part  I  -  The  randomised  trial:  HYpertension  and  Pre-eclampsia  Intervention 
Trial  At  Term  (HYPITAT)  -  describes  the  (cost-)  effectiveness  of  induction  of 
labour and expectant monitoring in such women.  Part II - Characteristics and 
tests in prediction of severe maternal morbidity in gestational hypertension or 
(mild)  pre-eclampsia  -  focuses  on  risk  indicators,  prognostic  models  and  test 
accuracy for identification of the individual woman with GH or PE with increased 
risk of developing severe maternal complication. Part III contains the - General 
discussion, future perspectives and summary.
Part I
The randomised trial: HYpertension and Pre-eclampsia Intervention Trial 
At Term (HYPITAT)
Chapter 2 contains the study protocol of a Dutch multicentre randomised clinical 
trial assessing the (cost-) effectiveness of induction of labour compared to expectant 
management  under  regular  monitoring  in  women  with  a  singleton  pregnancy 
complicated by GH or mild PE beyond 36 weeks’ gestation (the HYPITAT trial).
Chapter 3 describes the clinical results of the HYPITAT trial.
Chapter  4  describes  the  maternal  health-related  quality  of  life  (HR-QoL)  after 
induction of labour versus expectant monitoring in women with GH or PE beyond 
36 weeks’ gestation.
Chapter 5 describes the cost-effectiveness of induction of labour compared to 
expectant  monitoring  in  high-risk  pregnancies  due  to  hypertensive  disorders 
beyond 36 weeks’ gestation.
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Part II
Prediction of severe maternal morbidity in gestational hypertension or 
(mild) pre-eclampsia
Chapter 6 describes a cohort study in which parameters obtained before labour 
are identified to predict progression to severe disease in women with a singleton 
pregnancy complicated with GH or mild PE beyond 36 weeks’ gestation. 
Chapter 7 describes a case-control study in which risk indicators for the occurrence 
of eclampsia are identified in women with a singleton pregnancy diagnosed with 
GH or mild PE beyond 36 weeks’ gestation.
Chapter  8  describes  a  cohort  study  in  which  parameters  obtained  before  and 
during labour are identified to predict postpartum haemorrhage in women with a 
singleton pregnancy complicated with GH or mild PE beyond 36 weeks’ gestation. 
Chapter 9 presents a meta-analysis and decision analysis of the accuracy of serum 
uric acid as a predicting test for severe maternal morbidity in women diagnosed 
with PE.
Chapter 10 presents a systematic review in which precise estimates of maternal 
serum  liver  enzyme  levels  are  obtained  to  predict  adverse  maternal  and  fetal 
outcomes in women with PE.
Part III
General discussion, future perspectives and summary
Chapter 11 contains the general discussion and future perspectives.
Chapter 12 contains a summary in English and in Dutch.
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Induction of labour versus expectant 
monitoring in women with gestational 
hypertension or mild pre-eclampsia at 
term: the protocol of the HYPITAT trialABSTRACT
Background  Hypertensive  disorders,  i.e.  gestational  hypertension  and  pre- 
eclampsia, complicate 10 to 15% of all pregnancies at term and are a major cause of 
maternal and perinatal morbidity and mortality. The only causal treatment is delivery. 
In case of preterm pregnancies conservative management is advocated if the risks 
for mother and child remain acceptable. In contrast, there is no consensus on how 
to manage mild hypertensive disease in pregnancies at term. Induction of labour 
might prevent maternal and neonatal complications at the expense of increased 
instrumental vaginal delivery rates and caesarean section rates. 
Methods/  Design  Women  with  a  pregnancy  complicated  by  gestational 
hypertension or mild pre-eclampsia at a gestational age between 36+0 and 41+0 
weeks will be asked to participate in a multi-centre randomised controlled trial. 
Women will be randomised to either induction of labour or expectant management 
for spontaneous delivery. The primary outcome of this study is severe maternal 
morbidity, which can be complicated by maternal mortality in rare cases. Secondary 
outcome measures are neonatal mortality and morbidity, caesarean and vaginal 
instrumental delivery rates, maternal quality of life and costs. Analysis will be by 
intention to treat. In total, 720 pregnant women have to be randomised to show a 
reduction in severe maternal complications of hypertensive disease from 12 to 6%. 
Discussion This trial will provide evidence as to whether or not induction of labour 
in women with gestational hypertension or mild pre-eclampsia (nearly) at term is an 
effective treatment to prevent severe maternal complications.
Trial Registration The protocol is registered in the clinical trial register number 
ISRCTN08132825.
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Gestational hypertension (GH) and pre-eclampsia (PE) are common complications 
of pregnancy.1 In many cases, the clinical presentation is mild, consisting only of 
mild hypertension and/or mild proteinuria at term. In other cases however, severe 
maternal and fetal complications such as eclampsia, abruptio placentae, preterm 
delivery, the Haemolysis Elevated Liver enzymes and Low Platelet count syndrome 
(HELLP),  fetal  growth  restriction  or  even  intra-uterine  fetal  death  may  occur. 
Hypertensive disorders in pregnancy make a major contribution to maternal and 
neonatal mortality. In the Netherlands, hypertensive disorders in pregnancy are the 
largest single cause of maternal mortality.2
Approximately 10% to 15% of all pregnancies are complicated by hypertensive 
disorders. The vast majority of these cases occur after 32 weeks. The only causal 
treatment of the disease is delivery. In case of preterm pregnancies (28-34 weeks 
gestational age) complicated by PE expectant monitoring is advocated to increase 
the chance of fetal maturity, as long as the risks for the mother remain acceptable.3-5 
Expectant management reduces neonatal complications and duration of neonatal 
stay in the intensive care unit in preterm pregnancies and is not associated with an 
increase in maternal complications.4,5
In case of GH or PE at term, the situation is different from preterm disease. In women 
with mild PE complications such as abruptio placentae and small for gestational 
age are similar to normotensive pregnancies. It is unclear whether in this situation 
expectant management is beneficial for the mother and her baby, since evidence 
is lacking. Despite this lack of evidence delivery is often recommended because of 
the unpredictability of the disease.4,6 Recent observational studies indicate that 
the onset of mild GH or mild PE at or near term is associated with minimal to 
low maternal and neonatal morbidity.6-8 Despite the lack of evidence that would 
justify  intervention,  many  obstetricians  induce  labour  in  women  at  term  with 
gestational hypertension or PE. Such a policy may increase the risk of assisted 
vaginal  delivery  and  caesarean  section,  thus  generating  additional  morbidity 
and costs.9-11 On the other hand, expectant management might lead to severe 
pregnancy complications like eclampsia, severe hypertension, HELLP syndrome, 
organ failure or an adverse neonatal outcome.
Data from the Dutch National Obstetric Registration from 2002 showed that the 
yearly number of patients with hypertension (blood pressure [BP] diastolic above 
90 mmHg) without proteinuria at term is 17.000. Moreover, there are 2.000 women 
with PE at term. The lack of consensus is demonstrated by the fact that in 9.000 
Protocol of the HYPITAT trial
25women with GH or PE labour was induced, whereas labour started spontaneously 
in 10.000 women. Moreover, national data indicate no impact of induction of labour 
on neonatal outcome. In 2002 and 2003, the rate of babies born with a 5-minute 
Apgar score below 7 was 1.3% among women that delivered after a spontaneous 
onset of labour, versus 1.6% among women in whom labour was induced (OR 
1.2 95% CI 1.0 to 1.5). After adjustment for potential confounders such as fetal 
weight, proteinuria and diastolic blood pressure, this difference became statically 
insignificant despite the analysis of over 35.000 patients (OR 1.1 95% CI 0.98 to 1.2). 
Since this equivalence is also expected from the pathophysiological background of 
the problem as well as from the medical literature, we anticipate no differences in 
neonatal outcome between both strategies. 
Data from the Dutch National Obstetric Registration from Januari 2000 until Januari 
2005 show that 38.170 nullipara had a singleton pregnancy in cephalic presentation 
complicated  with  GH  or  PE.  In  18.012  women  labour  started  spontaneously, 
whereas in 18.810 labour was induced. The non-elective caesarean section rate 
among  women  in  whom  labour  started  spontaneously  was  14%  and  among 
women in whom labour was induced this rate was 22% (OR 1,7 95% CI 1,6 to 1,8). 
The vaginal instrumental delivery rates among these groups were 28% and 24% 
(OR 0,88 95% CI 0,84 to 0,93). 
At present, there is no evidence on the effectiveness and efficiency of induction of 
labour in women with GH or mild PE (nearly) at term as compared with expectant 
management with close monitoring. In post term women and women with ruptured 
membranes at term, randomised trials have indicated that induction of labour does 
not increase the instrumental delivery rate.12,13 However, the fact that the women 
were post term, might implicate that myometrial gapjunctions facilitating effective 
contractions were present.12 These data can not be extrapolated to women who 
are (nearly) at term with GH or PE. 
In view of this clinical dilemma, we propose a randomised clinical trial in which a 
policy of induction of labour, if necessary preceded by artificial cervical ripening, 
is compared with a policy of careful expectant monitoring in women with GH or 
mild PE (nearly) at term. At present - to our knowledge - no clinical study has been 
published or undertaken to investigate this issue.
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Aims
The  aim  of  this  study  is  to  investigate  whether  planned  induction  of  labour 
compared with expectant management in women with GH or mild PE at term will 
reduce severe maternal morbidity. We hypothesize that induction of labour will 
reduce maternal morbidity and mortality. The study will also provide insight on 
whether induction of labour in women with GH or PE (nearly) at term will reduce 
costs and improve quality of life as compared to expectant monitoring.
The proposed research concerns a multi-centre randomised controlled clinical trial 
in women who have GH or mild PE at gestational ages between 36+0 and 41+0 
weeks. This study is set in a national Obstetric Research Consortium, in which 40 
obstetric clinics in the Netherlands collaborate. Approximately 40 clinics, including 
academic hospitals, non-academic teaching hospitals and non-teaching hospitals 
will participate in this trial.
Participants/ Eligibility criteria
Patients 18 years of age or older will be eligible if they have GH or mild PE at a 
gestational age between 36+0 and 41+0 weeks of gestation. A diagnosis of GH is 
made in case the diastolic BP is equal to or above 95 mmHg at two occasions at 
least six hours apart in a woman who was normotensive at the start of pregnancy 
until week 20 of gestational age. A diagnosis of mild PE is made in case the diastolic 
BP is above 90 mmHg and there exists a proteinuria > 300 mg total protein in a 24 
hour urine collection. Women with a singleton pregnancy in cephalic presentation 
are eligible. Excluded were women with severe GH or PE (diastolic BP ≥ 110 mmHg, 
systolic BP ≥ 170 mmHg and/or proteinuria ≥ 5 gram in 24 hours), pre-existing 
hypertension  (BP  before  20  weeks  of  gestation  ≥  140/90  mmHg  and/or  using 
antihypertensive  medication),  diabetes  mellitus,  diabetes  gravidarum  requiring 
insulin  therapy,  renal  disease,  heart  disease,  HIV-seropositivity,  intravenous 
anti-hypertensive  medication,  a  previous  caesarean  section,  HELLP  syndrome, 
oliguria < 500 milliliter in 24 hours, pulmonary edema or cyanosis, fetal disorders, 
and abnormalities at the fetal heart rate (FHR) -monitoring are not eligible for the 
study.
Procedures, recruitment, randomisation and collection of baseline data
Eligible women will be identified by the research coordinator and/or the staff of 
participating hospitals. These women will be referred to a research midwife or 
research nurse for counselling. Before entry into the study this person will explain 
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potential hazards of the study. Subjects will be informed that their participation 
is voluntary and that they may withdraw consent to participate at any time during 
the study. They will be informed that choosing not to participate will not affect 
their care. In every centre an independent gynaecologist will be available for more 
detailed  information  both  for  patients  and  colleagues  if  required.  After  giving 
sufficient information written informed consent has to be obtained. The consent 
form must be signed before performance of any study-related activity. Patients who 
decide not to participate in this study will be treated according to one of the two 
protocols at the discretion of the attending obstetrician and analysed separately. 
The study will be an open label study, as it is impossible to blind the health care 
workers involved for the strategy to which the woman is allocated. Cross-over 
between the two strategies would complicate the interpretation of study result. 
Although it will not be possible to prevent all cross-overs, both strategies will be 
performed according to strict criteria, as mentioned below.
After a patient has given informed consent for participation in the study cervical 
length will be measured using transvaginal sonography, and vaginal examination 
will be performed (Bishop score), both to assess cervical ripeness. At study entry 
all  women  will  have  baseline  demographic,  past  obstetric  and  medical  history 
recorded.  After  explanation  of  the  study  and  informed  consent,  but  prior  to 
randomisation, we will perform a baseline measurement for quality of life (SF-36, 
HADS, EuroQol 6D3L) and additional questions on intervention preparedness and 
personal experience of the pregnancy. Subsequently, the patient will be randomised 
to either a policy that aims termination of pregnancy (intervention group) or a policy 
that  aims  expectant  management  for  spontaneous  delivery  (expectant  group). 
Randomisation will be performed through a web-based database which is hosted 
at the Academic Medical Centre (AMC) in Amsterdam. Randomisation will be 1:1 for 
intervention and expectant management, and it will be stratified for centre, parity 
and proteinuria according to the criteria above. Patients fill out additional quality 
of life questionnaires 6 weeks after delivery and 6 months after delivery (SF-36, 
HADS, EuroQoL 6D3L, SCL-90) and additional questions on personal experience 
of the delivery.
At  local  centres  data-collection  will  be  the  responsibility  of  the  local  research 
coordinator  and  the  regional  research  midwives  or  nurses.  The  data  collected 
in this study will be coded and processed with adequate precautions to ensure 
patient confidentially.
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Intervention group
In  the  intervention  group,  patients  will  be  induced  within  24  hours  after 
randomisation. In patients with a Bishop cervix score > 6 at vaginal examination 
labour will be induced by amniotomy and, if needed, augmentation with oxytocin. If 
this score is 6 or lower cervical ripening will be stimulated with use of intracervical 
or intravaginal prostaglandins according to the local protocol. In case the cervix is 
judged to be unripe the day after ‘priming’, the cervical ripening will be repeated. 
If the cervix remains ‘unripe’, day 3 will be a rest day. Cervical ripening will be 
repeated at day 4 and 5. All patients in the intervention group will be monitored 
clinically until after delivery. 
Expectant group
In the expectant group, patients will be monitored until the onset of spontaneous 
delivery. Monitoring will consist of assessment of fetal movements as reported by 
the mother, as well as electronic FHR-monitoring according to the local protocol. 
Maternal evaluation consists primarily of frequent evaluation of blood pressure 
measurement and screening of urine for protein using a dipstick or protein/creatinin 
ratio and 24 hour urine collection for protein in case of positive screening. Blood 
tests (platelet count, liver enzymes and renal function) will be performed according 
to the local protocol. 
In  the  expectant  monitoring  group,  intervention  is  recommended  in  case  fetal 
condition does not justify expectant management anymore (no fetal movements 
reported  by  the  mother,  non-optimal  FHR-monitoring).  Moreover,  induction  of 
labour is recommended in case the diastolic blood pressure is ≥ 110 mmHg or 
the systolic blood pressure is ≥ 170 mmHg, in case 24 hours proteinuria exceeds 
5  gram,  in  case  intravenous  anti-hypertensive  or  prophylactic  anti-convulsive 
medication is started, in case eclampsia or the HELLP syndrome occurs. In case in 
the expectant group any other indication rises for induction of labour, for example 
prelabour  rupture  of  membranes  for  >  24  hours  or  meconium  stained  liquor, 
patients will be induced.
Follow up of women and infants
All details of delivery, maternal assessments and admission during pregnancy are 
recorded in the case record form that is accessible through the website. Maternal 
mortality and morbidity will be specified until date of discharge from hospital and 
six weeks postpartum. In case of admittance of the baby to the neonatal intensive 
care,  high  care,  medium  care  unit  or  maternal  ward,  details  of  this  admission 
are  also  documented.  Neonatal  mortality  and  morbidity  will  be  specified  until 
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29date  of  discharge  from  hospital.  We  will  register  the  diagnosis  at  discharge: 
small for gestational age, hypoglycemia, respiratory distress syndrome, chronic 
lung disease, meconium aspiration, pneumothorax, apneu, asphyxia, necrotizing 
enterocolitis, intraventicular haemorrhage, periventricular leucomalacia, neonatal 
sepsis and neonatal meningitis.
A plan for long-term follow up of the mothers is in preparation. Long-term follow up 
of children will not be performed, because we do not expect differences between 
both policies during childhood.  
Outcome measures 
Primary outcome measure
The primary outcome measure will be severe maternal morbidity, which can be 
complicated by maternal mortality in rare cases. Severe maternal morbidity will 
be defined as diastolic BP ≥ 110 mmHg, systolic BP ≥ 170 mmHg, proteinuria 
≥ 5 g per 24 h, major postpartum haemorrhage, eclampsia, HELLP syndrome, 
pulmonary  edema,  trombo-embolic  disease  and/or  abruptio  placentae.14  Major 
postpartum haemorrhage is defined as blood loss > 1000 ml within 24 hours after 
delivery.15 Eclampsia is defined as severe GH or PE resulting in maternal seizures.16 
HELLP syndrome is defined as a complication of severe PE involving Haemolysis, 
Elevated Liver functions, and Low Platelets.17 Trombo-embolic disease is defined 
as deep-vein thrombosis, pulmonary embolism or both. Patients will be examined 
for deep-vein thrombosis by duplex doppler if thrombosis is suspected from clinical 
examination. A diagnosis of pulmonary embolism will be confirmed by pulmonary 
angiography, computed tomography, magnetic resonance imaging or a ventilation-
perfusion lung scan.18,19,20
Secondary outcome measures
Secondary outcomes will be neonatal mortality or neonatal morbidity, caesarean 
section rate, instrumental vaginal delivery rate, maternal quality of life and quality 
of recovery and costs. Adverse neonatal outcome will be defined as a 5-minute 
Apgar score below 7, an umbilical artery pH below 7.05 or admission to the neonatal 
intensive care.
Statistical issues
Sample size
The aim of induction of labour is to reduce the rate of severe complications of 
hypertensive  disease,  such  as  postpartum  haemorrhage,  sever  hypertension 
(diastolic BP ≥ 110 mmHg), eclampsia and HELLP syndrome. In women with a 
singleton pregnancy in cephalic presentation at term (>36 weeks), the prevalence of 
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of induction of labour outweigh the advantages when the complication rate is 
reduced to 6%. In order to detect such a difference, we will need two groups of 
360 patients (two-sided test, alpha .05; beta .80).
Data analysis
The analysis will be performed by intention to treat, and stratified for centre, parity 
and for underlying disease (PE or GH). Quality of life as well as pain scores will be 
analysed using repeated measures analysis of variance.22 Relative risks and 95% 
confidence intervals will be calculated for the relevant outcome measures.
Moreover, we will evaluate whether the relative benefits of induction of labour 
will be stronger in women with a ripe cervix at baseline and in women with a 
short cervical length at transvaginal sonography. In case of equivalence between 
outcomes, the analysis will be repeated on a par protocol basis. 
Economic analysis
The process of care is distinguished into three cost stages (antenatal stage, delivery/ 
childbirth, postnatal stage) and three cost categories (direct medical costs [all costs 
in the health care sector], direct non-medical costs [costs outside the health care 
sector that are affected by health status or health care] and indirect costs of the 
pregnant women and her partner [costs of sick level]). For each stage and each cost 
category, costs are measured as the volumes of resources used multiplied with 
appropriate valuations (cost-per-unit estimates, fees, national reference prices). Cost 
volumes in the antenatal stage consist of direct medical costs (e.g. home/ hospital 
care,  outpatients’  visits,  fetal  monitoring  [FHR-monitoring,  ultrasound,  Doppler] 
and maternal monitoring [various labtests; hospital care]). Direct non-medical and 
indirect costs in that stage may occur if role patterns or household routines shift. 
As we anticipate an improvement of between maternal outcomes after induction 
of labour the economic analysis is expected to be a cost-effectiveness analysis. 
Serious adverse events will be reported to an independent data safety monitoring 
committee. A formal interim analysis is not planned.
Ethical considerations 
The study protocol has been approved by the Medical Ethical Committee of the 
University Medical Centre of Leiden (p04.210). The protocol is registered in the 
clinical trial register number ISRCTN08132825.
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Gestational hypertension and pre-eclampsia are important hypertensive disorders 
during  pregnancy  which  are  associated  with  increased  maternal  and  neonatal 
morbidity and mortality. There is no consensus on how to manage mild hypertensive 
diseases at term. Induction of labour might prevent maternal complications, but is 
also thought to increase the caesarean and vaginal instrumental delivery rate. This 
trial is designed to provide evidence on the effectiveness of induction of labour in 
women with mild GH or PE (nearly) at term to prevent severe maternal and neonatal 
complications.
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Induction of labour versus 
expectant monitoring for gestational 
hypertension or mild pre-eclampsia 
after 36 weeks’ gestation (HYPITAT): 
a multicentre, open-label randomised 
controlled trialABSTRACT
Background Robust evidence to direct management of pregnant women with mild 
hypertensive disease at term is scarce. We investigated whether induction of labour 
in women with a singleton pregnancy complicated by gestational hypertension or 
mild pre-eclampsia reduces severe maternal morbidity.
Methods We undertook a multicentre, parallel, open-label randomised controlled 
trial in six academic and 32 nonacademic hospitals in the Netherlands between 
October,  2005,  and  March,  2008.  We  enrolled  patients  with  a  singleton 
pregnancy at 36–41 weeks’ gestation, and who had gestational hypertension or 
mild pre-eclampsia. Participants were randomly allocated in a 1:1 ratio by block 
randomisation with a web-based application system to receive either induction 
of  labour  or  expectant  monitoring.  Masking  of  intervention  allocation  was  not 
possible.  The  primary  outcome  was  a  composite  measure  of  poor  maternal 
outcome—maternal mortality, maternal morbidity (eclampsia,
HELLP  syndrome,  pulmonary  oedema,  thromboembolic  disease,  and  placental 
abruption),  progression  to  severe  hypertension  or  proteinuria,  and  major 
post-partum haemorrhage (>1000 mL blood loss). Analysis was by intention to 
treat and treatment effect is presented as relative risk. This study is registered, 
number ISRCTN08132825.
Findings  756  patients  were  allocated  to  receive  induction  of  labour  (n=377 
patients) or expectant monitoring (n=379). 397 patients refused randomisation but 
authorised use of their medical records. Of women who were randomised, 117 
(31%) allocated to induction of labour developed poor maternal outcome compared 
with  166  (44%)  allocated  to  expectant  monitoring  (relative  risk  0.71,  95%  CI 
0.59–0.86, p<0.0001). No cases of maternal or neonatal death or eclampsia were 
recorded.
Interpretation Induction of labour is associated with improved maternal outcome 
and  should  be  advised  for  women  with  mild  hypertensive  disease  beyond  37 
weeks’ gestation.
Funding ZonMw, project number 945-06-553.
383
chapter
INTRODUCTION
About 6–8% of pregnancies are complicated by hypertensive disorders.1,2 Such 
disorders in pregnancy make a substantial contribution to maternal and neonatal
morbidity and mortality worldwide.3 In the Netherlands these disorders are the 
primary cause of maternal mortality.4,5 Most hypertensive disorders present after 
36 weeks’ gestation. For the management of women with gestational hypertension 
(GH) or mild pre-eclampsia (PE) at term, evidence for selection of induction of 
labour versus expectant monitoring is scarce. Induction of labour is thought to 
prevent severe maternal and neonatal complications such as eclampsia, HELLP 
syndrome (haemolysis, elevated liver enzymes, and low platelet count), placental 
abruption, maternal death, and asphyxia. Conversely, induction might increase the 
risk of instrumental vaginal delivery and caesarean section, and thereby generate 
additional morbidity and costs.6–8
To  our  knowledge,  no  randomised  clinical  trial  on  this  subject  has  yet  been 
published.  Strong  practice  variation  exists  in  the  Netherlands  for  treatment  of 
women with GH or mild PE beyond 36 weeks’ gestation. Therefore we aimed to 
assess whether induction of labour in such women reduces poor maternal outcome 
compared with expectant monitoring.
METHODS
Patients
We performed a multicentre, parallel, open-label randomised controlled trial in the 
Netherlands, in which six academic and 32 non-academic hospitals participated. 
We  recruited  women  with  a  singleton  pregnancy  and  a  fetus  in  cephalic 
presentation at a gestational age of between 36+0 and 41+0 weeks, and who had 
GH or mild PE. GH was defined as diastolic blood pressure of 95 mm Hg or higher 
measured on two occasions at least 6 h apart. Mild PE was defined as diastolic 
blood pressure of 90 mm Hg or higher measured on two occasions at least 6 h 
apart, combined with proteinuria (two or more occurrences of protein on a dipstick, 
>300 mg total protein within a 24-h urine collection, or ratio of protein to creatinine 
>30 mg/mmol).9–11
Patients were excluded if they had severe GH or severe PE, defined as systolic 
blood pressure of 170 mm Hg or higher, diastolic blood pressure of 110 mm Hg 
or higher, or proteinuria of 5 g or higher per 24 h. Other exclusion criteria were 
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gestational  diabetes  needing  insulin  treatment,  renal  disease,  heart  disease, 
previous caesarean section, HELLP syndrome, oliguria of less than 500 mL per 
24  h,  pulmonary  oedema  or  cyanosis,  HIV  seropositivity,  use  of  intravenous 
antihypertensive drugs, fetal anomalies, suspected intrauterine growth restriction,12 
and abnormalities detected during fetal-heart-rate monitoring.
Patients were seen by research nurses and midwives who provided counselling, 
obtained  informed  consent,  monitored  the  study  protocol  in  every  centre  and 
collected  the  data.  Before  randomisation,  cervical  length  was  measured  by 
transvaginal  sonography  and  vaginal  digital  examination  was  done.  Patient 
data were then entered into a password-protected web-based database and a 
web-based application was used for block randomisation with a variable block size 
of 2–8. Randomisation was stratified for centre, parity, and hypertensive-related 
disease (GH or PE). Women were randomly allocated in a 1:1 ratio to receive either 
induction of labour or expectant monitoring. In this open-label trial, masking of 
participants, obstetricians, and outcome assessors was not possible for allocation 
of the randomisation number or intervention.
The trial was approved by the Institutional Review Board of the University of Leiden, 
and had local approval from the boards of the other participating hospitals. Written 
informed consent was obtained from all patients before randomisation. Patients 
who did not give informed consent for randomisation, but who gave authorisation 
for the use of their medical records, were treated according to one of the two 
protocols at the discretion of the attending obstetrician.
Procedures
Patients allocated to induction of labour were induced within 24 h of randomisation. 
If the patient had a Bishop score13 of more than 6 at vaginal examination, labour 
was induced with amniotomy and, if needed, augmentation with oxytocin. If the 
Bishop score was 6 or lower, cervical ripening was stimulated with intracervical or 
intravaginale prostaglandins or a balloon catheter. Use of oxytocin or prostaglandins 
depended on local protocols, which were based on national guidelines of the Dutch 
Society for Obstetrics and Gynaecology.14
Patients  allocated  to  expectant  monitoring  were  monitored  until  the  onset  of 
spontaneous delivery. Maternal monitoring consisted of frequent blood pressure 
measurements  and  screening  of  urine  for  protein  with  a  dipstick  specimen  or 
with the ratio of protein to creatinine. In cases of positive screening for protein, 
urine was collected for 24 h to quantify proteinuria. Laboratory tests were done on 
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patients with increased blood pressure or proteinuria. Fetal monitoring consisted 
of assessment of fetal movements as reported by the mother, as well as electronic 
fetal-heart-rate  monitoring  and  ultrasound  examination.  Expectant  monitoring 
was done in either a hospital or outpatient setting, dependent on the condition 
of the patient. Induction of labour was recommended for patients allocated to 
expectant monitoring if they had systolic blood pressure of 170 mm Hg or higher, 
diastolic blood pressure of 110 mm Hg or higher, proteinuria of 5 g or higher per 
24 h, eclampsia, HELLP syndrome, suspected fetal distress, prelabour rupture of 
membranes lasting more than 48 h, meconium stained amniotic fluid, or a fetus 
with gestational age beyond 41 weeks.
Figure 1. Trial profile
1153 eligible women  
756 enrolled and randomly assigned to treatment 
 
397 refused randomisation  
  73 had induction of labour   
324 had expectant monitoring 
379 assigned to expectant monitoring  
173 had induction of labour  
200 had spontaneous onset of labour
   6 had planned caesarean section 
 
377 assigned to induction of labour  
366 had induction of labour  
  10 had spontaneous onset of labour
     1 had planned caesarean section 
 
 
379 women were analysed  377 women were analysed  
The  primary  outcome  was  a  composite  measure  of  poor  maternal  outcome, 
defined as maternal mortality, maternal morbidity (eclampsia, HELLP syndrome, 
pulmonary oedema, thromboembolic disease, or placental abruption), progression 
to severe disease (at least one measurement during ante-partum or post-partum 
[less than 48 h after delivery] period of systolic blood pressure ≥170 mm Hg, 
diastolic blood pressure ≥110 mm Hg, or proteinuria ≥5 g per 24 h),9 and major 
post-partum haemorrhage. In a separate analysis, progression to severe disease 
was diagnosed from severe hypertension measured on at least two occasions that 
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41were a minimum of 6 h apart. Eclampsia was defined as the presence of seizures.15 
The diagnosis of HELLP syndrome was made in patients with decreased platelet 
count (<100×109/L) and increased liver enzymes (aspartate aminotransferase >70 
U/L or alanine aminotransferase >70 U/L). Thromboembolic disease was defined as 
deep-vein thrombosis or pulmonary embolism.16 Major post-partum haemorrhage 
was defined as blood loss of more than 1000 mL within 24 h of delivery.17 Secondary 
outcome  measures  were  method  of  delivery,  neonatal  mortality,  and  neonatal 
morbidity. For neonatal morbidity, we used a composite outcome consisting of 
a 5-min Apgar score of lower than 7, umbilical artery pH of lower than 7.05, or 
admission to a neonatal intensive care unit.
Statistical analysis
The composite measure of poor maternal outcome in the expectant monitoring 
group was thought to be 12%, on the basis of data obtained from the National 
Dutch Perinatal Registry of 2003 and 2004. We anticipated that induction of labour 
would reduce this occurrence to 6%. A sample size of 720 women, 360 women 
per treatment group, was needed for 80% power and a 5% type 1 error probability 
(two-sided).18 We assumed a 5% protocol violation and planned to randomise 750 
women.
Data were analysed on an intention-to-treat basis. All randomised women could be 
included in the trial analysis because missing data for relevant outcome measures 
were  negligible.  Analysis  of  data  included  comparison  of  maternal  condition 
with: laboratory findings at randomisation, maternal mortality and morbidity until 
hospital discharge and 6 weeks post partum, neonatal mortality and morbidity until 
hospital discharge, method of delivery, type of hospital care, and days of maternal 
and neonatal hospital admission.
After we established the distribution using the Kolmogorov-Smirnov test, differences 
between groups with normally distributed data were tested with the Student’s t 
test. For data with a skewed distribution, a non-parametric Mann-Whitney U test 
was  applied.  Categorical  data  were  analysed  with  χ²  statistics.  Calculation  of 
the percentages was based on the number of valid observations. We included 
footnotes in tables and figures if any observations were missing. Treatment effect 
is presented as relative risk (RR) with 95% CIs, and where appropriate as absolute 
risk reduction with 95% CIs, relative risk reduction with 95% CIs, and number 
needed  to  treat.  Since  the  randomisation  was  stratified  for  centre,  parity,  and 
presence of proteinuria, we also did a stratified analysis using logistic regression, 
presented as odds ratios (ORs) for the primary outcome. A p value of less than 0.05 
indicated statistical significance.
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Table 1. Demographic and clinical characteristics of randomised and non-randomised patients
Characteristic Randomised patients Non-randomised patients
Induction of 
labour
(n=377)
Expectant 
monitoring
(n=379)
Induction of 
labour
(n=73)
Expectant 
monitoring 
(n=324)
Nulliparous 269 (71%) 272 (72%) 52 (71%) 248 (77%)
Maternal age (years) 29.0 (26.0-33.0) 29.0 (26.0-33.0) 30.0 (27.0-33.0) 31.0 (29.0-34.0)
Gestational age (weeks) 38.4 (37.6-39.4) 38.6 (37.6-39.4) 38.4 (37.4-39.6) 38.4 (37.4-39.4)
Ethnic origin
White 317 (84%) 298 (79%) 60 (82%) 261 (81%)
Other 35 (9%) 47 (12%) 11 (15%) 32 (10%)
Unknown 25 (7%) 34 (9%) 2 (3%) 31 (10%)
Education*
Primary school (4 to 12 years) 6 (2%) 6 (2%) 0 0
Secondary school (12 to 16/18 
years)
12 (3%) 12 (3%) 3 (4%) 7 (2%)
Lower professional school 39 (10%) 36 (9%) 6 (8%) 15 (5%)
Medium professional school 112 (30%) 106 (28%) 10 (14%) 64 (20%)
Higher professional school 55(15%) 58 (15%) 17 (23%) 49 (15%)
University 17 (5%) 12 (3%) 3 (4%) 34 (10%)
Unknown 135 (36%) 149 (39%) 34 (47%) 155 (48%)
Maternal smoking† 52 (15%) 50 (14%) 7 (10%) 23 (8%)
Body mass index (kg/m2)
First antenatal appointment 26.0 (22.8-30.6) 26.0 (22.7-29.7) 24.8 (22.1-28.1) 24.3 (21.9-28.4)
Baseline 32.5 (28.7-36.4) 32.3 (28.5-35.9) 30.1 (27.8-33.3) 30.5 (27.4-34.1)
Blood pressure (mmHg)
First antenatal appointment
Systolic  120 (110-130) 120 (111-130) 120 (110-130) 120 (110-130)
Diastolic 75 (70-80) 75 (70-80) 70 (65-80) 75 (70-80)
Baseline
Systolic  140 (140-150) 144 (140-150) 140 (137-150) 140 (137-150)
Diastolic  100 (95-100) 100 (95-100) 100 (95-100) 98 (95-100)
Bishop score
<2 93 (25%) 82 (22%) – –
2 to 6 225 (60%) 244 (64%) – –
>6 16 (4%) 12 (3%) – –
Unknown 43 (11%) 41 (11%)
Cervical length with transvaginal 
sonography (mm)
30.0 (23.0-37.0) 30.0 (22.0-37.0) – –
Haemoglobin (mmol/L) 7.5 (7.0-8.0) 7.4 (6.9-8.0) 7.5 (6.9-8.0) 7.6 (7.1-8.1)
Packed cell volume (L/L) 0.36 (0.34-0.38) 0.36 (0.34-0.37) 0.36 (0.33-0.38) 0.36 (0.34-0.38)
Platelets (x109/L) 230 (192-277) 232 (192-280) 219 (177-269) 219 (189-263)
Uric acid (μmol/L) 310 (260-360) 310 (270-360) 310 (260-390) 320 (270-370)
Creatinine (μmol/L) 59.0 (52.0-70.0) 60.0 (51.8-70.0) 61.0 (55.0-73.0) 62.0 (54.0-70.0)
Aspartate aminotransferase (U/L) 20.0 (16.0-25.0) 20.0 (16.0-25.0) 20.0 (17.0-26.0) 20.0 (16.0-24.8)
Alanine amino transferase (U/L) 12.0 (9.0-17.0) 12.0 (10.0-17.0) 13.0 (9.0-18.3) 12.0 (10.0-17.0)
Lactate dehydrogenase (U/L) 294 (199-374) 287 (200-366) 331 (254-395) 316 (226-380)
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effect in the trial between different categories of patients. Treatment effects are 
represented by forest plots. Patients were characterised by gestational age of the 
fetus (36–37, 37–38, 38–39, 39–40, and 40–41 weeks’ gestation), parity (nulliparous 
and  multiparous  women),  hypertensive-related  diseases  (GH  and  PE),  systolic 
blood pressure at study entry (<140 and ≥140 mm Hg), Bishop score (<2, 2–6, and 
>6) and vaginal examination (cervical dilatation, effacement, consistence, position, 
length, and engagement). The engagement process is described with the levels of 
Hodge.13 Statistical analyses were done with SPSS software (version 16.0).
This study is registered, number ISRCTN08132825.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, 
data interpretation, writing of the report, or the decision to submit the paper for 
publication. The corresponding author had full access to all data and had final 
responsibility for the decision to submit for publication.
RESULTS
Between October, 2005, and March, 2008, we identified 1153 eligible women, of 
whom 756 gave informed consent for randomisation. We randomly assigned 377 
patients to induction of labour and 379 to expectant monitoring (figure 1). Of the 
397 patients who refused randomisation, most (82%) had expectant monitoring 
and only 18% had induction of labour. Baseline characteristics of all eligible women 
Table 1. (cont)
Characteristic Randomised patients Non-randomised patients
Induction of 
labour
(n=377)
Expectant 
monitoring
(n=379)
Induction of 
labour
(n=73)
Expectant 
monitoring 
(n=324)
Diagnosis
Gestational hypertension  244 (65%) 252 (66%) 45 (62%) 232 (72%)
Pre-eclampsia  123 (33%) 123 (32%) 28 (38%) 84 (26%)
Unknown 10 (3%) 4 (1%) 0 8 (2%)
Proteinuria in women with pre-
eclampsia (mg/24 hrs)
450 (300-1140) 600 (350-970) 735 (365-1800) 655 (463-1400)
Data are number of patients (%) or median (IQR). Data are at baseline unless otherwise indicated. 
–=data  unavailable  because  not  routinely  measured.  *Lower,  medium,  and  higher  professional 
schools denote preparatory, intermediate, and higher vocational education, respectively. †Data are 
missing for some participants: n=353 for induction of labour (randomised), n=360 for expectant 
monitoring (randomised), n=67 for induction of labour (non-randomised), and n=303 for expectant 
monitoring (non-randomised).
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(table 1) showed that women in the randomised group, compared with those in the 
non-randomised group, had a higher median body-mass index at their first antenatal 
appointment (26.0 kg/m², IQR 22.8–30.0 vs 24.5 kg/m2, IQR 22.0–28.1; p<0.0001), 
smoked more frequently (14% [n=102 patients] vs 8% [n=30], p=0.003), and, for 
those whom information was available, had a lower education level (30% [n=142] 
vs 50% [n=103] had finished higher professional school or university, p<0.0001).
Outcome data were available for all patients who were randomised (table 2). Median 
time between randomisation and onset of labour was almost 1 week shorter in 
the induction group than the expectant monitoring group (table 2). Of the women 
allocated to induction of labour, few had spontaneous onset of labour (table 2). 
For those whose labour was induced (n=366 patients), 288 (79%) were induced 
Table 2. Pregnancy outcome and onset of labour in randomised patients
Induction of 
labour 
(n=377)
Expectant 
monitoring
 n=379)
Relative risk
 (95% CI)
or p-value
Absolute risk 
reduction
(95% CI)
Time between randomisation 
and onset of labour (days)
0.79 (0.67-1.0) 6.3 (3.7-10.9) <0.0001 NA
Gestational age at delivery 
(weeks)
38.7 (37.9-39.8) 39.9 (38.9-40.4) <0.0001 NA
Onset of labour
Spontaneous 10 (3%) 200 (53%) 0.05 
(0.03-0.09; <0.0001 )
50.12% 
(44.64-55.24)
Planned caesarean section 1 (<1%) 6 (2%) 0.17 (0.02-1.39; 0.059) NS
Induction  366 (97%) 173 (46%) 2.13 
(1.90-2.38; <0.0001)
-51.44% 
(-56.54 to-45.93)
Indications for induction of labour*
Randomised to treatment  366 (100%) 0 NA NA
Maternal indications 0 94 (54%) NA NA
Severe hypertension 
(mmHg)
NA 78 (45%) NA NA
Severe proteinuria NA 3 (2%) NA NA
HELLP syndrome NA 7 (4%) NA NA
Use of anticonvulsive drugs NA 37 (21%) NA NA
Use of intravenous 
antihypertensive drugs
NA 28 (16%) NA NA
Suspected fetal distress 0 18 (10%) NA NA
Time since prelabour rupture 
of membranes >48 hours
0 9 (5%) NA NA
Gestational age >41 weeks 0 24 (14%) NA NA
Chose induction 0 48 (28%) NA NA
Data are median (IQR) and numbers of patients (%). NA=not applicable. NS=not stated because 
indicator was not significantly associated. HELLP=haemolysis, elevated liver enzymes, and low 
platelet count. *Some patients had more than one clinical feature; percentages are given for women 
who were induced (366 patients randomised to induction of labour, 173 patients randomised to 
expectant monitoring).
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11 (3%) were induced 2–4 days after randomisation, and two (1%) were induced 
4 days after randomisation. In 17 (5%) women the period between randomisation 
and successful induction was longer than expected (3 days) because the induction 
method with prostaglandins failed (median 4.0 days, IQR 4.0–6.5). These women 
were given lengthened treatment with prostaglandins, followed by treatment with 
Table 3. Maternal outcome
Induction of 
labour
(n=377)
Expectant 
monitoring 
(n=379)
Relative risk 
(95% CI)
or p-value
Absolute risk 
reduction 
(95% CI)
Composite adverse maternal 
outcome
117 (31%) 166 (44%) 0.71 
(0.59-0.86; <0.0001)
12.76% 
(5.87-19.49%)
Maternal death  0 0 NA NA
Severe hypertension (mmHg)
Systolic BP  55 (15%) 88 (23%) 0.63 
(0.46-0.86; 0.003)
8.63% 
(3.05-14.16%)
Diastolic BP  62 (17%) 103 (27%) 0.61 
(0.46-0.80; <0.0001)
10.73% 
(4.85-16.52%)
Severe proteinuria* 3 (2%) 4 (2%) 0.91 (0.21-4.02; 0.90) NS
HELLP syndrome 4 (1%) 11 (3%) 0.37 
(0.12-1.14; 0.07)
NS
Eclampsia 0 0 NA NA
Lung oedema  0 2 (1%) NA NA
Postpartum haemorrhage 35 (9%) 40 (11%) 0.88 (0.57-1.35; 0.55) NS
Thromboembolic disease 1 (<1%) 0 NA NA
Placental abruption 0 0 NA NA
Severe hypertension measured twice (mmHg)
Systolic BP  26 (7%) 44 (12%) 0.60 
(0.38-0.95; 0.03)
4.71%
 (0.57-8.92%)
Diastolic BP  28 (7%) 50 (13%) 0.56 
(0.36-0.87; 0.01)
5.77% 
(1.42-10.16%)
Drugs
Oral antihypertensive 67 (18%) 111 (29%) 0.61
 (0.47-0.80; <0.0001)
11.52% 
(5.48-17.45%)
Intravenous antihypertensive  13 (3%) 39(10%) 0.34 
(0.18-0.62; <0.0001)
6.84% 
(3.28-10.59%)
Intravenous anticonvulsive  24 (6%) 46 (12%) 0.53 
(0.33-0.84; 0.01)
5.77% 
(1.64-9.98%)
Maternal hospital care
Intensive care 6 (2%) 14 (4%) 0.41 (0.16-1.07; 0.059) NS
Medium care 14 (4%) 15 (4%) 0.90 (0.44-1.84; 0.777) NS
Maternal ward 340 (94%) 319 (92%) 1.03 (0.99-1.07; 0.145) NS
Unknown 17 (5%) 31 (8%)
Duration of hospital stay (days) 2.0 (1.0-3.0) 2.0 (1.0-4.0) 0.12 NA
Data are median (IQR) or numbers of patients (%). BP=blood pressure. HELLP=haemolysis, elevated 
liver enzymes, and low platelet count. NA=not applicable. NS=not stated because indicator was not 
significantly associated.*Data are missing for some participants: n=157 for induction of labour, and 
n=191 for expectant monitoring.
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oxytocin; five women delivered spontaneously, five had an instrumental delivery 
(four due to failure to progress, and one due to fetal distress), and seven had a 
caesarean section (six due to failure to progress, and one due to fetal distress). 
During induction with prostaglandins, one patient developed an allergic reaction 
against  latex  and  consequently  induction  was  discontinued.  This  patient  then 
underwent  a  planned  caesarean  section  because  of  suspected  cephalopelvic 
disproportion.
Almost half of women allocated to expectant monitoring had their labour induced 
(table 2), of whom 125 (72%) had at least one medical reason for induction, and the 
remainder chose to be induced (table 2). Six patients had planned caesarean section, 
and in four of these patients, pregnancy was complicated by severe hypertension, 
of whom two also developed HELLP syndrome. One planned caesarean section 
was done because abnormalities were detected during fetal-heart-rate monitoring, 
and another was done for a patient with a history of total hip replacement on 
both sides and a triple pelvic osteotomy, who had a hip luxation during expectant 
monitoring.
The number of missing values for each of the variables of the primary outcome 
ranged  from  0%  for  maternal  mortality  and  eclampsia  to  2%  for  post-partum 
haemorrhage. Occurrence of the primary outcome of the composite poor maternal 
outcome was significantly lower for women allocated to induction of labour than 
for those allocated to expectant monitoring (table 3; OR 0.58, 95% CI 0.43–0.78, 
p<0.0001). Therefore, allocation to induction of labour corresponded to a relative 
Table 4. Method of delivery
Induction of 
labour 
(n=377)
Expectant 
monitoring 
(n=379)
Relative risk
 (95% CI)
or p-value
Spontaneous 273 (72%) 253 (67%) 1.09 (0.99-1.19; 0.091)
Vaginal instrumental delivery 50 (13%) 54 (14%) 0.93 (0.65-1.33; 0.694)
Caesarean section 54 (14%) 72 (19%) 0.75 (0.55-1.04; 0.085)*
Clinical features indicating that 
caesarean section was needed
Arrest of first stage of labour 15 (28%) 24 (33%)
Arrest of second stage of 
labour
3 (6%) 7 (10%)
Failed instrumental delivery 4 (7%) 2 (3%)
Fetal distress 17 (31%) 20 (27%)
Failure to progress and fetal 
distress
12 (22%) 8 (11%)
Maternal complication 2 (4%) 7 (10%)
Elective 1 (2%) 4 (6%)
Data are number of patients (%). *Absolute risk reduction is 4.67% (95% CI -0.65 to 9.98%). 
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47risk reduction of 29.14% (95% CI 13.40–44.50), and a number needed to treat of 
8 (95% CI 5–17). A similar treatment effect was shown by stratified analysis (OR 
0.56, 95% CI 0.41–0.77, p<0.0001). No women who were randomised died from 
hypertensive disease in pregnancy, eclampsia, or placental abruption. One woman 
died 9 months post partum from sudden unexpected death due to epilepsy.
Overall, 2% (n=15) of patients developed HELLP syndrome, and the difference 
between intervention groups was not significant (table 3). One patient allocated 
to labour induction had a pulmonary embolism, and pulmonary oedema occurred 
in two women allocated to expectant monitoring, one of whom developed acute 
Table 5. Neonatal outcome
Induction of 
labour 
(n=377)
Expectant 
monitoring 
(n=379)
Relative risk
 (95% CI)
or p-value
Birthweight (g) 3220 
(2890-3565)
3490
 (3080-3810)
<0.0001
Composite adverse neonatal outcome 24 (6%) 32 (8%) 0.75 (0.45-1.26; 0.276)*
Fetal deaths 0 0 NA
Apgar score of <7 after 5 min  7 (2%) 9 (2%) 0.79 (0.30-2.09; 0.632)
Arterial pH <7.05† 9 (3%) 19 (6%) 0.46 (0.21-1.00; 0.043))‡
Admission to intensive care 10 (3%) 8 (2%) 1.26 (0.50-3.15; 0.625)
Neonatal hospital care
Medium care 68 (18%) 69 (18%) 0.99 (0.73-1.34; 0.952)
High care 12 (3%) 10 (3%) 1.21 (0.53-2.76; 0.656)
Intensive care 10 (3%) 8 (2%) 1.26 (0.50-3.15; 0.625)
Duration of stay in a neonatal medium, high, 
or intensive care unit (days)
3.0 (2.0-6.0) 4.0 (2.8-7.0) 0.077
Reasons for admission to an neonatal 
intensive care unit**
Asphyxia 3 (1%) 3 (1%) 
Low birthweight 3 (1%) 0 NA
Hypoglycaemia 0 2 (1%) NA
Infant respiratory distress syndrome 1 (<1%) 1 (<1%) NA
Meconium aspiration 0 1 (<1%) NA
Neonatal sepsis 0 1 (<1%) NA
Hyperbilirubinaemia 2 (1%) 0 NA
Persistent pulmonary hypertension 0 1 (<1%) NA
Down syndrome with congenital heart 
defect
1 (<1%) 0 NA
Inguinal hernias 1 (<1%) 0 NA
Interhemispheric cyst 1 (<1%) 0 NA
Data are median (IQR) or number of patients (%). NA=not applicable. *Absolute risk reduction 
is 2.08% (95% CI -1.71 to 5.91%). †Data are missing for some participants: n=311 for induction 
of  labour,  and  n=301  for  expectant  monitoring.  ‡Absolute  risk  reduction  (95%  CI)  3.42%  (0.06 
to 7.02%). **Some neonates had more than one clinical features to indicate that admission to a 
neonatal intensive care unit was needed.
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respiratory distress syndrome (table 3). Progression to severe disease occurred in 
88 women in the induction group and in 138 women in the expectant monitoring 
group (23% vs 36%; RR 0.64, 95% CI 0.51–0.80, p<0.0001); several women had 
more than one severe disease at the same time. The treatment effect was similar 
when  progression  to  severe  disease  was  diagnosed  from  high  blood  pressure 
measured on at least two occasions more than 6 h apart (11% [n=42] vs 19% [n=73]; 
0.58, 0.41–0.82, p=0.002). Significantly fewer women randomised to induction, 
Subgroup
 
Induction of
labour
(n=377) 
Expectant
monitoring
(n=379)  
Relative Risk
(95% CI)   
Gestational age at randomisation 
(weeks)  
 
 
36-37  18/40 (45%)  15/35 (43%)  1.05 (0.63-1.76) 
37-38  32/96 (33%)  41/92 (45%)  0.75 (0.52-1.08) 
38-39  27/99 (27%)  40/93 (43%)  0.63 (0.43-0.94) 
39-40  27/83 (33%)  43/103 (42%)  0.78 (0.53-1.15) 
40-41  13/59 (22%)  27/56 (48%)  0.46 (0.26-0.79) 
       
Parity        
Nulliparous   83/269 (31%)  123/272 (45%)  0.68 (0.55-0.85) 
Multiparous   34/108 (32%)  43/107 (40%)  0.78 (0.55-1.13) 
       
Pregnancy related hypertension*        
Gestational hypertension  75/244 (31%)  96/252 (38%)  0.81 (0.63-1.03) 
Pre-eclampsia   41/123 (33%)  67/123 (55%)  0.61 (0.45-0.82) 
       
Systolic blood pressure at baseline   
(mmHg)  
     
<140   8/66 (12%)  29/73 (40%)  0.31 (0.15-0.62) 
≥140   109/311 (35%)  137/306 (45%)  0.78 (0.64-0.95) 
       
Bishop Score at baseline*        
<2   36/93 (39%)  45/82 (55%)  0.71 (0.51-0.97) 
2 to 6   66/225 (29%)  98/244 (40%)  0.73 (0.57-0.94) 
>6   9/16 (31%)  5/12 (42%)  0.75 (0.28-2.02) 
       
Cervical dilatation at baseline (cm)*          
0    62/174 (36%)  86/163 (53%)  0.68 (0.53-0.87) 
1    34/121 (28%)  48/131 (37%)  0.77 (0.53-1.10) 
2    16/53 (30%)  25/55 (46%)  0.66 (0.40-1.10) 
>2      4/16 (25%)  3/17 (18%)  1.41 (0.37-5.37) 
       
Cervical effacement at baseline*      
≤25%   53/169 (31%)  78/161 (48%)  0.65 (0.49-0.85) 
>25%   62/192 (32%)  81/199 (41%)  0.79 (0.61-1.03) 
       
Cervical consistence at baseline*         
Stiff  22/61 (36%)  36/65 (55%)  0.65 (0.44-0.97) 
Moderately to very weak    92/301 (31%)  125/297 (42%)  0.73 (0.59-0.90) 
       
Engagement at baseline*        
Hodge 1  102/316 (32%)  127/304 (42%)  0.77 (0.63-0.95) 
>Hodge 1   9/32 (28%)  25/48 (52%)  0.54 (0.29-1.00) 
       
Cervical position at baseline*        
Posterior  65/207 (31%)  96/188 (51%)  0.62 (0.48-0.79) 
Median to anterior     50/153 (33%)  62/168 (37%)  0.89 (0.66-1.20) 
       
Cervical length at baseline (cm)*        
≥4   24/68 (35%)  38/64 (59%)  0.59 (0.41-0.87) 
<4   90/285 (32%)  118/291 (41%) 
 
 
 
0.78 (0.63-0.97)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.25                                  1.0                      2.5 
Induction of
labour better   
Expectant
monitoring better   
Relative Risk
(95% CI) 
Figure 2a. Risk on composite poor maternal outcome in subgroups. *Data are missing for some 
participants.
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49Figure 2b. Risk on caesarean section in subgroups NA=not applicable. *Data are missing for some 
participant.
Subgroup   Induction of 
labour  
(n=377)  
Expectant 
monitoring 
(n=379)  
Relative Risk   Relative Risk 
(95% CI)  
Gestational age at randomisation 
(weeks)  
36-37  7/40 (18%)  9/35 (26%)  0.68 (0.28-1.64) 
37-38  14/96 (15%)  14/92 (15%)  0.96 (0.48-1.90) 
38-39  11/99 (11%)  15/93 (16%)  0.69 (0.33-1.42) 
39-40  13/83 (16%)  21/103 (20%)  0.77 (0.41-1.44) 
40-41  9/59 (15%)  13/56 (23%)  0.66 (0.31-1.42) 
       
Parity       
Nulliparous   47/269 (18%)  67/272 (25%)  0.71 (0.51-0.99) 
Multiparous   7/108 (7%)  5/107 (5%)  1.39 (0.45-4.23) 
       
Pregnancy related hypertension*        
Gestational hypertension   31/244 (13%)  42/252 (17%)  0.76 (0.50-1.17) 
Pre-eclampsia   22/123 (18%)  29/123 (24%)  0.76 (0.46-1.24) 
       
Systolic blood pressure at baseline   
(mmHg)  
     
<140   7/66 (11%)  15/73 (21%)  0.52 (0.22-1.19) 
≥140   47/311 (15%)  57/306 (19%)  0.81 (0.57-1.15) 
       
Bishop Score at baseline*         
<2   16/93 (17%)  24/82 (29%)  0.59 (0.34-1.03) 
2   to 6   34/225 (15%)  35/244 (14%)  1.05 (0.68-1.63) 
>6   1/16 (6%)  2/12 (17%)  0.38 (0.04-3.67) 
       
Cervical dilatation at baseline (cm)*        
0  31/174 (18%)  47/163 (29%)  0.62 (0.41-0.92) 
1  18/121 (15%)  14/131 (11%)  1.39 (0.72-2.68) 
≥2   4/69 (6%)  8/72 (11%)  0.52 (0.17-1.65) 
       
Cervical effacement at baseline*      
≤ 25%   31/169 (18%)  37/161 (23%)  0.80 (0.52-1.22) 
> 25%   23/192 (12%)  29/199 (15%)  0.82 (0.49-1.37) 
       
Cervical consistence at baseline*      
Stiff  8/61 (13%)  23/65 (35%)  0.37 (0.18-0.77) 
Moderately   to very weak   46/301 (15%)  46/297 (16%)  0.99 (0.68-1.44) 
       
Engagement at baseline*        
Hodge 1  52/316 (17%)  58/304 (19%)  0.86 (0.61-1.21) 
>Hodge 1   0/32 (0%)  6/48 (13%)  NA 
       
Cervical position at baseline*        
Posterior  30/207 (15%)  44/188 (23%)  0.62 (0.41-0.94) 
Median to anterior   23/153 (15%)  23/168 (14%)  1.10 (0.64-1.88) 
       
Cervical length at baseline  (cm)*        
≥4   12/68 (18%)  17/64 (27%)  0.66 (0.35-1.28) 
<4   40/285 (14%)  53/291 (18%) 
 
 
0.77 (0.53-1.12) 
 
 
 
0.1          0.25     0.5       1.0           2.5       5.0 
Induction of
labour better   
Expectant
monitoring better   
compared with those allocated to expectant monitoring, were prescribed both 
oral and intravenous antihypertensive drugs (20% [n=77] vs 33% [n=124]; 0.63, 
0.49–0.81, p<0.0001) and prophylactic anticonvulsive drugs.
Although fewer patients had caesarean sections in the induction group than in 
the expectant monitoring group, the difference was not significant (table 4). Most 
caesarean sections were done for patients with arrest of the first stage of labour, 
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failure to progress, or fetal distress (table 4). In both the induction and expectant 
monitoring groups, the proportion of caesarean sections was higher for women 
with  a  composite  poor  maternal  outcome  (23%  [n=27]  vs  27%  [n=45];  0.85, 
0.56–1.29, p=0.44) than for those who were not classed as having poor maternal 
outcome (10% [n=27] vs 13% [n=27]; 0.82, 0.50–1.35, p=0.44). Occurrence of 
vaginal  instrumental  delivery  was  much  the  same  between  the  induction  and 
expectant monitoring groups (table 4).
No  fetal  or  neonatal  deaths  occurred  in  either  of  the  intervention  groups,  and 
the difference in composite neonatal morbidity was not significant between the 
interventions (table 5). However, a lower number of neonates had an arterial pH of 
less than 7.05 in the induction group than the expectant monitoring group (table 5). 
Both groups had similar proportions of neonates who had a 5-min Apgar score of 
lower than 7 or were admitted to an intensive care unit; table 5 shows the reasons 
for admission to an intensive care unit and total admission time. In the induction 
group, neonates were born at an earlier stage of pregnancy than in the expectant 
monitoring group, and therefore their birth weight was significantly lower.
In almost all subgroups a trend toward a better maternal outcome was found for 
patients who were induced than those who had expectant monitoring (figure 2). 
Only women randomised at a gestational age of 36–37 weeks or with cervical 
dilatation of more than 2 cm might benefit from expectant monitoring (figure 2a). 
Subgroup analyses on the risk of caesarean section showed that the favourable 
effect of induction of labour was not present in women who were multiparous, had 
a Bishop score of 2–6, had cervical dilatation of 1 cm, or had median or anterior 
position of the cervix (figure 2b).
The proportion of patients who had the composite poor maternal outcome in the 
non-randomised group was 43% (n=31) for those allocated to induction and 38% 
(n=123) for those allocated to expectant monitoring. The occurrence of caesarean 
sections in these patients was 4% (n=3) for those allocated to induction and 16% 
(n=52) for those allocated to expectant monitoring.
DISCUSSION
The results of this study show that induction of labour was associated with a 
lower composite risk of poor maternal outcome, which was mainly ascribed to 
progression to severe disease, than was expectant monitoring. Overall, 13 per 
100 fewer women allocated to induction of labour had a poor maternal outcome, 
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sections were needed in the induction group than the expectant monitoring group. 
Adverse neonatal outcomes did not differ significantly between the groups.
The  number  of  women  with  progression  to  severe  disease  was  higher  than 
expected from the sample size calculation before the trial began. Consequently, 
we recorded a high occurrence of the primary outcome with both interventions. 
This underestimation might be attributable to the absence of some useful data in 
the National Dutch Perinatal Registry, on which the calculation was based. First, 
systolic blood pressure was part of our primary outcome, but this variable was not 
recorded in the registry, and therefore not considered in the sample size calculation. 
We decided to include systolic blood pressure in our primary composite outcome 
since accumulating evidence suggests that systolic blood pressure is a risk factor 
for serious maternal morbidity, especially cerebrovascular accidents.19,20 Second, 
the large number of women with high blood pressure in the trial might be explained 
by the fact that we used only one measurement of severe hypertension to fulfil 
the definition of progression to severe disease, whereas two measurements are 
needed for diagnosis, according to the National Dutch Perinatal Registry. Use of 
an endpoint based on a minimum of two measurements of high blood pressure at 
least 6 h apart might have underestimated the occurrence of severe hypertension, 
since in clinical practice the decision to treat a patient with antihypertensives or 
induction of labour is often based on only one measurement. However, when we 
recalculated the occurrence of the primary endpoint with progression to severe 
disease diagnosed from at least two measurements of high blood pressure, the 
treatment benefit of induction was also clear.
We found that fewer caesarean sections were needed in the induction group than 
the  expectant  monitoring  group.  Randomised  trials  in  women  with  post-term 
pregnancies or those with pre-labour rupture of membranes at term showed similar 
proportions of caesarean section done for women receiving induction of labour and 
expectant monitoring.21,22 The association of induction of labour with increased 
numbers of caesarean sections is based on results from non-randomised studies 
alone.6–8 The reduced risk of caesarean section that we recorded after induction 
of labour could be caused by decreased occurrence of severe maternal morbidity 
with this intervention. To support this theory, stratified analysis in women with and 
without poor maternal outcome showed that an increased proportion of women 
with poor maternal outcome needed caesarean section, but no difference was 
recorded between those receiving induction of labour or expectant monitoring in 
either group of women.
523
chapter
In this trial, the primary outcome was defined as a composite measure of poor 
maternal  outcome  consisting  of  several  conditions.  We  decided  to  include 
progression  to  severe  hypertension  because  this  disease  is  associated  with 
severe maternal morbidity, such as eclampsia, pulmonary oedema, and cerebral 
encephalopathy or haemorrhage.23–25 If we had restricted our primary outcome to 
conditions of severe morbidity, such as eclampsia, we would have had to extend 
the power of the study substantially. Such a target was not feasible for our study 
group. Moreover, since induction of labour reduces the risk of progression to severe 
disease, and because this intervention probably reduces the risk of caesarean 
section, we think that a larger study excluding progression to severe disease is not 
needed.
Major post-partum haemorrhage was also part of our composite primary outcome, 
because it has been recognised as an important risk factor in pregnant women with 
hypertensive disorders.26–28 We postulated that induction of labour would reduce 
the risk of progression to severe disease and thereby reduce the risk of major 
post-partum haemorrhage. We recorded 10% of women with a major post-partum 
haemorrhage, which exceeded the 1.33% risk of haemorrhage (>1000 mL) that has 
been reported in low-risk populations,29 but induction of labour did not reduce the 
occurrence of severe haemorrhage.
In  the  subgroup  analyses  we  found  that  the  beneficial  effect  of  induction  of 
labour was absent in women with fewer than 37 weeks’ gestation, but the result 
is unreliable because of the low number of women in this subgroup. Our study 
was  not  sufficiently  powered  to  detect  differences  in  subgroup  analyses,30 
and consequently we are hesitant to extrapolate trial results to women with a 
gestational age of 36–37 weeks.
The treatment effect that we found was pronounced in women with an unfavourable 
cervix (eg, cervical dilation 0 cm, cervical effacement ≤25%, or posterior position 
of cervix).31 This paradoxal finding is explained by the fact that in such women 
who were allocated to expectant monitoring, time to delivery was longer relative 
to those with a favourable cervix, thereby increasing the risk that the maternal 
condition could deteriorate. Since the effect of an unfavourable cervix was reduced 
in women allocated to induction of labour, the benefit of induction increases in 
women with an unfavourable cervix.
Effective management of women with hypertensive disease beyond 36 weeks’ 
gestation is strongly controversial in the Netherlands. In most participating centres, 
the  protocol  recommended  expectant  monitoring,  which  was  the  preferred 
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countries, induction of labour in women with GH or mild PE at term is already 
general practice, but until now this recommendation has not been based on the 
results of randomised clinical trials.1,32
The results of our trial are important for both developed countries in which induction 
of labour in women with hypertensive disease beyond 36 weeks’ gestation has 
been controversial, and for developing countries in which maternal morbidity and 
mortality rates are substantially increased.3 Our finding that induction of labour 
was associated with a reduced risk of severe hypertension or HELLP syndrome 
and subsequent reduced need for caesarean section, emphasises the importance 
of frequent blood pressure monitoring during the concluding weeks of pregnancy. 
We believe that induction of labour should be advised for women with GH and a 
diastolic blood pressure of 95 mm Hg or higher or mild PE at a gestational age 
beyond 37 weeks.
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Health-related quality of life after 
induction of labour versus expectant 
monitoring in gestational hypertension 
or pre-eclampsia at termABSTRACT
Objective  Gestational  hypertension  (GH)  and  pre-eclampsia  (PE)  are  major 
contributors to maternal and neonatal morbidity and mortality. In GH or PE, labour 
may  be  either  induced  or  monitored  expectantly.  We  studied  maternal  health-
related quality of life (HR-QoL) after induction of labour versus expectant monitoring 
in GH or PE at term. We performed the HR-QoL study alongside a multi-centre 
randomised controlled trial comparing induction of labour to expectant monitoring 
in women with GH or PE after 36 weeks. 
Methods We used written questionnaires, covering background characteristics, 
condition-specific  issues  and  validated  measures:  the  Short  Form  (SF-36), 
European Quality of Life (EuroQoL 6D3L), Hospital Anxiety and Depression scale 
(HADS), and Symptom Check List (SCL-90). Measurements were at time points 
baseline, 6 weeks postpartum, and 6 months postpartum. A multivariate mixed 
model with repeated measures was defined to assess the effect of the treatments 
on the physical (PCS) and mental (MCS) components of the SF-36. Analysis was by 
intention to treat.
Results We analysed data of 491 randomised and 220 non-randomised women. 
We did not find treatment effect on long-term HR-QoL (PCS: p=.09; MCS: p=.82). 
The PCS improved over time (p<.001), and was better in non-randomised patients 
(p=.02).
Conclusion Despite a clinical benefit of induction of labour, long-term HR-QoL is 
equal after induction of labour and expectant management in women with GH or 
PE beyond 36 weeks of gestation.
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INTRODUCTION
Pregnancy-related hypertensive complications are a major contribution to maternal 
and neonatal morbidity and mortality worldwide.1 Gestational hypertension (GH) or 
pre-eclampsia (PE) occur in 6% to 8% of pregnant women, of which the majority 
occurs after 36 weeks of gestation.2,3 Eventually, the only causal treatment for GH 
and PE is delivery. Induction of delivery is therefore thought to prevent development 
of  severe  maternal  complications  such  as  placental  abruption,  eclampsia, 
haemolysis, elevated liver enzymes, and low platelets (HELLP syndrome), even 
maternal  death,  and  neonatal  complications  such  as  asphyxia.  However,  the 
benefit of induction of labour is balanced against an increased risk of instrumental 
vaginal  delivery  and  caesarean  section,  with  consequent  long-term  maternal 
morbidity.4-6 Prior to our study, most pregnancies with GH or PE were monitored 
expectantly in the Netherlands in order to avoid increased risk of instrumental 
delivery and caesarean section, resulting in a low incidence of inductions of labour, 
as compared to neighbouring countries.7 The low induction rate was caused by the 
lack of scientific evidence for its effectiveness in GH or PE. 
In  order  to  investigate  the  effectiveness  and  safety  of  induction  of  labour  as 
compared to expectant monitoring, multiple outcomes need to be defined. Besides 
maternal  and  neonatal  medical  outcomes,  information  about  other  treatment 
outcomes (e.g. self-reported health on the short- and long-term, treatment burden, 
costs) are needed in order to gain insight into the consequences of both treatment 
options. Especially when differences in primary outcome are small or absent these 
HR-Qol measures become even more important. Only with full knowledge about the 
treatment options, an informed choice can be made about which treatment is best. 
Alongside the nationwide multi-centre randomised controlled clinical trial HYPITAT 
(HYpertension or Pre-eclampsia Intervention Trial At Term; ISRCT08132825) we 
investigated the impact of induction of labour versus expectant monitoring on the 
maternal health-related quality of life (HR-QoL). In the trial, the effectiveness of 
induction of labour was compared to expectant monitoring in women with GH or PE 
beyond 36 weeks of gestation.8,9 For this study we identified the following relevant 
aspects of HR-QoL: short- and long-term self-reported health, anxiety, depression, 
and physical and mental symptoms. We also followed two non-randomised groups 
in order to adjust for any study participation effects.
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Participating women and clinical study
The HR-QoL study was conducted alongside the HYPITAT trial. The HYPITAT study 
included women with a singleton pregnancy with a fetus in cephalic presentation 
at study entry, between 36+0 to 41+0  weeks of gestation, complicated with GH 
(defined as diastolic blood pressure ≥95 mmHg) or mild PE (defined as diastolic 
blood pressure ≥90 mmHg, combined with ≥2+ protein on dipstick, >300 mg total 
protein within a 24-hour urine collection or protein/creatinine ratio >30 mg/mmol). 
Exclusion criteria were maternal age below 18 years, previous caesarean section, 
ruptured  membranes,  pre-existing  hypertension  treated  with  anti-hypertensive 
medication,  severe  high  blood  pressure  (RR  diastolic  >110;  RR  systolic  >170), 
diabetes  mellitus,  gestational  diabetes  requiring  insulin  therapy,  renal  disease, 
oliguria,  HIV,  and  HELLP  syndrome  (Haemolysis  Elevated  Liver  enzymes,  Low 
Platelet count) upon presentation. Details of the study design have been described 
elsewhere.8,9
A total of 38 Dutch hospitals (six academic and 32 non-academic) participated 
in the HYPITAT trial. The HYPITAT trial was approved by the Institutional Review 
Board of the University of Leiden and had local approval from the boards of all 
participating  hospitals.  Women  who  were  eligible  for  inclusion  in  the  HYPITAT 
study received study information from an obstetrician, resident, or midwife during 
consultation,  or  during  additional  counselling  by  a  research  nurse  or  midwife. 
During the counselling, the research nurse entered the patient’s clinical record form 
into a database using a login restricted web form. The web-based randomisation 
was a block randomisation with stratification for centre, parity, and hypertensive 
related disease (i.e. GH or PE). Women were randomly allocated to either induction 
of labour or expectant monitoring. Women who did not give informed consent 
for  randomisation  were  asked  to  participate  in  the  study  as  non-randomised 
participant, and were treated according to local protocol. Their data were also 
entered into the database.
Interventions and procedure
In  women  allocated  to  induction,  labour  was  initiated  within  24  hours  after 
randomisation.  Women  with  a  Bishop  score  >6  were  induced  by  amniotomy 
and,  if  needed,  augmented  with  oxytocin.  Women  with  a  lower  Bishop  score 
were primed with intra-cervical or intra-vaginal prostaglandins. Women allocated 
to the expectant group were monitored either in an outpatient setting or in the 
hospital, with frequent assessment of the maternal condition, i.e. blood pressure 
624
chapter
measurement, screening of urine for protein, laboratory tests, and assessment 
of fetal condition, i.e. fetal movements as reported by the mother, electronic fetal 
heart rate monitoring, and biophysical profile by ultrasound if indicated. Induction 
of labour was recommended in case maternal or fetal condition did not justify the 
assigned treatment. The study interventions have been described in more detail 
elsewhere.9
Background characteristics and clinical data (obstetric history, medical treatment, 
maternal  and  neonatal  outcome,  and  interventions  during  hospital  stay)  were 
collected by local research midwives or nurses using a web-based case record 
form.  Measures  of  maternal  and  neonatal  mortality  and  morbidity  as  well  as 
diagnoses at discharge were recorded until hospital discharge.
HR-QoL procedure and measures
For logistical reasons, inclusion to the HR-QoL study started February 2006; 5 
months after the start of the clinical trial. Participating women received a folder 
containing HR-QoL questionnaire instructions, four HR-QoL questionnaires, four 
pre-stamped  return  envelopes,  and  reminder  stickers  –the  women  could  stick 
these stickers in their agenda or on their calendar as a self-reminder for filling 
out a questionnaire on the appropriate date. The questionnaires included general 
filling instructions. Even though the validated questionnaires are straightforward, 
we provided a telephone number and an email address for women who needed 
assistance with the questionnaires.
The four HR-QoL questionnaires were to be filled out at four different time points: 
at baseline (inclusion) before randomisation (B1), at baseline after randomisation or 
participation (B2), 6 weeks postpartum (6W), and 6 months postpartum (6M). We 
chose 6W as the first post-partum time point because six weeks is the normal time 
frame for recovery after delivery; any differences between the strategy groups at 
that time point could be considered as relevant effects. We expected the maternal 
health to have stabilized at 6M, such that we considered this time point to be a 
good measure of long-term HR-QoL outcome. The questionnaires were available 
in either Dutch or English. Each questionnaire took between 10 and 30 minutes 
to complete. Women who did not return questionnaire 6W within 7 weeks after 
delivery or questionnaire 6M within 7 months after delivery received a written 
reminder and a new copy of the questionnaire with a pre-stamped return envelope.
Questionnaire B1 contained questions on background characteristics, e.g. date 
of birth, educational level, employment characteristics, household composition, 
obstetric history, ethnicity, length, and weight before pregnancy. The validated 
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(SF-36; questionnaires B1, 6W, 6M), the European Quality of Life 6 dimensions 3 
levels (EuroQoL 6D3L) with subsequent general health Visual Analogue Scale (VAS; 
questionnaires B2, 6W, 6M), the Hospital Anxiety and Depression Scale (HADS; 
questionnaires B2, 6W, 6M), and the Symptom Check List (SCL-90; questionnaires 
B2, 6M), all validated in Dutch and English.10-16 While some of our used measures 
are not typical HR-QoL measures, we chose to include these into the questionnaires 
because of their contribution to insight into the short- and long-term self-reported 
health, anxiety, depression, and physical and mental symptoms –our definition of 
maternal HR-QoL. The HADS and SCL-90 are more sensitive to any differences 
in the anxiety, depression (HADS), and physical and mental symptoms (SCL-90) 
planes than typical HR-QoL measures such as the SF-36. Also, while the SF-36 and 
EuroQoL are able to detect large effects, the HADS and SCL-90 are able to detect 
any potentially relevant small effects on the subscales.
The SF-36 is a generic HR-QoL questionnaire with eight health-status subscales: 
physical  functioning,  role  limitations  due  to  physical  health  problems,  bodily 
pain,  general  health  perception,  vitality,  social  functioning,  role  limitations  due 
to emotional health, and general mental health. The scores on the subscales are 
aggregated  into  the  standardized  summary  scores  Physical  (PCS)  and  Mental 
Component Score (MCS). A standardized score of mean=50 and SD=10 represents 
the general population average.10,11 The EuroQoL 6D3L is an instrument to describe 
general health status with six dimensions (mobility, self-care, usual activities, pain/
discomfort,  anxiety/depression,  and  cognitive  functioning).  An  individual’s  (or 
population’s) health description can be expressed in a value between 0 (death) and 
1 (perfect health), using an algorithm to combine the six dimensions into one overall 
utility score.12,17 The subsequent VAS in our study is a vertical scale (‘thermometer’) 
with values 0 ‘worst possible health state’ (lower anchor) to 100 ‘best possible 
health state’ (upper anchor). Women indicated their health state by marking the 
VAS, while considering the anchors.18 The HADS is a self-report rating scale that 
exists of two 7-item scales: one for anxiety and one for depression each with a 
score range of 0 to 21; a score of 9-12 is indicative of a depressive episode.14,19 
Finally, the 90-item SCL-90 aims to measure a person’s psychological symptom 
status. The SCL-90 exists of one overall score ‘psychoneurosis’, and eight symptom 
subscales:  anxiety,  agoraphobia,  depression,  somatic  complaints,  insufficiency 
of acting and thinking, interpersonal sensitivity, hostility, and sleeping problems. 
Higher scores indicate worse psychological health.16,20
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Analysis
We checked the HR-QoL data for selective response and missing data regarding 
the clinical determinants composite maternal and neonatal outcome. Composite 
adverse  maternal  outcome  consisted  of  maternal  mortality,  eclampsia,  HELLP 
syndrome,  pulmonary  edema,  thrombo-embolic  disease,  placental  abruption, 
progression  to  severe  hypertension,  and/or  major  postpartum  haemorrhage.8 
Composite  adverse  neonatal  outcome  consisted  of  5-minute  Apgar  score  <7, 
umbilical artery pH <7.05, and/or admission to a neonatal intensive care unit.8 
The HR-QoL data were analyzed according to the intention-to-treat (ITT) principle. 
We  calculated  difference  scores  between  the  baseline  and  the  postpartum  (6 
weeks and 6 months) measures. Difference scores per summary measure were 
compared between randomised groups using one way ANOVA. To explain the 
change in the SF-36 PCS and MCS subscales over time, we used a linear mixed 
model regression with the following characteristics: time of assessment (baseline; 
6 weeks postpartum; 6 months postpartum), intervention following ITT (expectant; 
induction),  randomised  status  (randomised;  not  randomised),  age  (≤27;  28-33; 
≥34), parity (nulliparous; multiparous), time before conception (<1 year; ≥1 year), 
pre-pregnancy BMI (≤25; >25), educational level (lower; higher), employed (no; 
yes), time of assessment*randomisation, and time of assessment*intervention. 
Analyses were conducted using SPSS 15.0 for Windows (SPSS Inc, Chicago, IL). A 
p-value <0.05 (two sided) was considered to indicate statistical significance.
With respect to the sample size of HR-QoL data, we considered a 5-point difference 
in the PCS scale and MCS scale week as clinically relevant. To find a relevant 
difference in HR-QoL, we needed two groups of 250 women (alpha .05; beta .80; 
SD 20). As the measurements at multiple time points allow for repeated measures 
analysis, this sample size was sufficient for testing effects over time, including 
overall difference and trends.
RESULTS
Baseline characteristics
Of the 1153 participants to the HYPITAT study, 756 (66%) were randomised and 397 
(34%) women participated in the non-randomised part of the study. Of the randomised 
women, 539 (71%) also participated in the HR-QoL study, versus 282 (71%) of the 
non-randomised women. Overall, 711 (87%) of the women that were included in the 
HR-QoL study responded to at least one questionnaire (figure 1). Response rates 
were: 96% for questionnaire B1, 88% for B2, 74% for 6W, and 65% for 6M.
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65Figure 1. Flowchart of participants to the HYPITAT trial, number of inclusions in the HR-QoL study, 
and response percentages. HR-QoL = Health-related Quality of Life; RCT = randomised controlled 
trial; P = non-randomised treatment following protocol.
Included for HR-QoL  
N=821 (100.0%)  
P Expectant n=227   P Induction n=55   RCT Induction n=268  
 
 
RCT Expectant n=271 
Response n=711  
(86.6%) 
P Expectant n=183   P Induction n=37   RCT Induction n=245   RCT Expectant n=246 
Participants to HYPITAT 
trial n=1153  
P n=397   RCT n=756  
P Expectant n=324   P Induction n=73   RCT Induction n=377  
 
 
RCT Expectant n=379  
Excluded: At inclusion 
questionnaires not 
available, n=332 
Excluded : No response, 
n=110 (13.4%)  
Table 1. Baseline characteristics of the randomised (RCT) and non-randomised women (i.e. with 
prior treatment preference, P) participants who followed induction of labour or expectant monitoring, 
and the women who did not return the any HR-QoL questionnaire (Non-response). Analyses of the 
randomised vs. non-randomised and responses vs. non-responses.
HR-QoL response, n=711
Non-response
n=117
Total RCT vs. 
total P
p
Response vs. 
Non-response
p
Induction 
RCT
n=245
Expectant 
RCT
n=246
Induction 
P
n=37
Expectant 
P
n=183
Total 
Response
n=711
Age: mean (SD) 30.4 (4.6) 30.2 (4.6) 30.2 (3.8) 32.0 (3.8) 30.7 (5.0) 30.6 (4.9) < .001 .820
Months to conceive: mean (SD) 9.4 (16.3) 9.2 (12.7) 4.8 (6.4) 6.9 (9.9) 8.5 (13.0) n/a a < .001 n/a
BMI pre-pregnancy: mean (SD) 26.9 (5.5) 26.5 (5.3) 24.5 (3.2) 25.5 (4.5) 26.3 (5.1) 27.0 (5.8) .009 .209
Dutch origin: % 92.6 88.8 94.1 92.7 85.5 60.9 .321 <.001
Has a job: % 86.0 88.7 93.9 95.5 90.9 n/a .002 n/a
Lives with partner: % 96.0 97.0 97.1 98.9 97.5 n/a .135 n/a
Nulliparous: % 71.0 78.5 81.1 77.6 76.0 65.5 .323 .019
High educational level b: % 33.5 27.2 38.2 51.4 38.0 16.4 < .001 <.001
a  These values are not available because they were asked by HR-QoL questionnaire
b  Higher vocational training or university
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Baseline  characteristics  of  the 
randomised and non-randomised 
HR-QoL participants and of the 
non-responding  women  (i.e. 
women who did not respond to 
any  questionnaire)  are  shown 
in Table 1. Randomised women 
were  significantly  younger 
(p<.001),  had  tried  longer  to 
become  pregnant  (p<.001), 
had  a  higher  pre-pregnancy 
BMI  (p=.01),  were  less  often 
employed  (p<.01),  and  were 
less likely to have had a higher 
educational  level  (p<.001)  as 
compared  to  non-randomised 
women. Compared to the non-responding women, the responding women were 
more often of Dutch origin (p<.001), were more likely to be nulliparous (p=.02), and 
were more likely to have had a higher educational level (p<.001).
We tested if our sample contained an overrepresentation of very good or bad cases 
in  terms  of  maternal  outcome  and  neonatal  outcome.  At  6  weeks  postpartum 
there were no differences between responding and non-responding women in 
the proportion of adverse composite maternal outcome (35% vs. 33%; p=.53), 
the proportion of adverse composite neonatal outcome (5.7% vs. 9.0%; p=.08), 
caesarean  section  rates  (17%  vs.14%;  p=.22),  and  the  proportion  of  assisted 
vaginal delivery (14% vs. 16%; p=.41). At 6 months postpartum there were also 
no differences between responding and non-responding women in the proportion 
of adverse composite maternal outcome (36% vs. 32%; p=.26), the proportion of 
adverse composite neonatal outcome (6.6% vs. 7.1%; p=.78), caesarean section 
rates (17% vs. 14%; p=.25), and the proportion of assisted delivery (13% vs. 17%; 
p=.14).
Summary measures
At  baseline,  none  of  the  summary  scores  was  significantly  different  between 
the randomised induction of labour and expectant management groups. One of 
the domain scores (i.e. a sub-measure) was significantly different between the 
randomised groups (SCL Hostility, difference=0.3 in favour of induction of labour, 
p=.04). The mean difference scores of the randomised induction of labour and 
expectant management groups at both 6 weeks and 6 months postpartum are 
Table 1. Baseline characteristics of the randomised (RCT) and non-randomised women (i.e. with 
prior treatment preference, P) participants who followed induction of labour or expectant monitoring, 
and the women who did not return the any HR-QoL questionnaire (Non-response). Analyses of the 
randomised vs. non-randomised and responses vs. non-responses.
HR-QoL response, n=711
Non-response
n=117
Total RCT vs. 
total P
p
Response vs. 
Non-response
p
Induction 
RCT
n=245
Expectant 
RCT
n=246
Induction 
P
n=37
Expectant 
P
n=183
Total 
Response
n=711
Age: mean (SD) 30.4 (4.6) 30.2 (4.6) 30.2 (3.8) 32.0 (3.8) 30.7 (5.0) 30.6 (4.9) < .001 .820
Months to conceive: mean (SD) 9.4 (16.3) 9.2 (12.7) 4.8 (6.4) 6.9 (9.9) 8.5 (13.0) n/a a < .001 n/a
BMI pre-pregnancy: mean (SD) 26.9 (5.5) 26.5 (5.3) 24.5 (3.2) 25.5 (4.5) 26.3 (5.1) 27.0 (5.8) .009 .209
Dutch origin: % 92.6 88.8 94.1 92.7 85.5 60.9 .321 <.001
Has a job: % 86.0 88.7 93.9 95.5 90.9 n/a .002 n/a
Lives with partner: % 96.0 97.0 97.1 98.9 97.5 n/a .135 n/a
Nulliparous: % 71.0 78.5 81.1 77.6 76.0 65.5 .323 .019
High educational level b: % 33.5 27.2 38.2 51.4 38.0 16.4 < .001 <.001
a  These values are not available because they were asked by HR-QoL questionnaire
b  Higher vocational training or university
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67shown in Table 2. At 6 weeks postpartum, none of the average difference scores 
was significantly different between the randomised groups. Only one of the domain 
scores  was  significantly  different  between  the  randomised  groups  (EuroQoL 
Mobility, p= .03). At six months postpartum, none of the average difference scores 
were significantly different between the randomised groups. 
Figure 2 shows the mean scores of the SF36 PCS and MCS for the randomised 
groups  at  baseline,  6  weeks  postpartum,  and  6  months  postpartum.  The  PCS 
increased  substantially  over  time  between  baseline  and  6  months  postpartum 
(p<.001); the PCS was even higher than the Dutch population average. The MCS 
decreased at 6 weeks postpartum (p<.001), and slightly recovered after 6 months 
postpartum (p=.03). 
Table  2.  Average  HR-QoL  difference  scores  (Δ)  per  summary  measure:  comparisons  between 
randomised groups (Ind=induction of labour;  Exp=expectant monitoring) at 6 weeks and 6 months 
postpartum. P-values were calculated with one-way ANOVA analyses.
Summary measure Δ inclusion, 6 weeks 
postpartum, n=351
Δ inclusion, 6 months 
postpartum, n=313
Ind
n=188
Exp
n=163
p Ind
n=167
Exp
n=146
p
SF-36 Physical Component Score 11.1 10.1 .37 15.1 14.7 .70
SF-36 Mental Component Score -2.3 -3.0 .55 -0.6 -1.1 .67
EuroQoL summary score 0.13 0.15 .32 0.16 0.18 .30 
    EuroQoL Mobility 0.02 0.04 .03 0.03 0.05 .10
    EuroQoL Self-care 0.02 0.01 .39 0.02 0.02 .88
    EuroQoL Activity 0.07 0.07 .92 0.08 0.08 .72
    EuroQoL Pain/Discomfort 0.02 0.02 .90 0.03 0.03 .56
    EuroQoL Anxiety/Depression 0.00 0.01 .40 0.01 0.01 .64
VAS general health 8.5 8.4 .95 9.8 9.1 .68
HADS Anxiety -1.45 -1.29 .63 -1.18 -1.27 .88
HADS Depression -2.09 -2.80 .61 -1.96 -2.17 .64
SCL-90 Psychoneurosis a - - -13.0 -13.5 .90
    SCL-90 Anxiety - - -1.4 -1.6 .68
    SCL-90 Agoraphobia - - -0.3 -0.5 .29
    SCL-90 Depression - - -2.5 -3.2 .50
    SCL-90 Somatic complaints - - -4.0 -4.3 .75
    SCL-90 Insufficient acting and thinking - - -2.9 -1.8 .07
    SCL-90 Interpersonal sensitivity - - -1.5 -0.7 .31
    SCL-90 Hostility - - -0.1 -0.2 .78
    SCL-90 Sleeping problems - - -2.9 -3.0 .891
a  The SCL-90 has only been conducted at inclusion and at 6 months postpartum.
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Multivariate mixed model
Table 3 shows the results of the multivariate mixed model displaying the impact 
of each covariate on PCS and MCS over time, taking into account the patient’s 
background  characteristics,  and  characteristics  of  design  and  intervention 
(following ITT). The β-coefficients represent the change in PCS and MCS when the 
covariate changes with one unit of measurement. PCS improved substantially after 
childbirth (6 weeks postpartum: β=9.3, p<.001; 6 months postpartum: β=14.0, 
p<.001). The MCS first declined and then improved (6 weeks postpartum: β=-3.6, 
p<.001; 6 months postpartum: β=-1.7, p=.05). There was a significant negative 
effect of being randomised on PCS (β=-2.0, p=.02) but not on MCS (β=-1.1, p=.22). 
Intervention according ITT was not significant on either PCS (Induction of labour: 
β=-1.4, p=.09) or MCS (β=-0.2, p=.82). Of the background characteristics, being 
multiparous had a positive impact on PCS (p=.04), having a job had a positive 
impact on both the PCS (p<.01) and MCS (p=.01), and a higher pre-pregnancy BMI 
had negative impact on PCS (p<.01) but a positive impact on MCS (p=.01); none of 
the background characteristics had clinically significant effect (i.e. non of the betas 
Figure 2. Error bars with 95% confidence interval (CI) of the randomised groups for induction of 
labour or expectant monitoring on the PCS and MCS at inclusion, at 6 weeks postpartum, and at 6 
months postpartum. The horizontal lines indicate mean Dutch population norm scores.
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69reached the clinical significant threshold of about 5). None of the interactions was 
statistically significant.
Table 3. Multivariate mixed model: estimates of main and interaction effects and covariates with 95% 
Confidence Interval (CI) on the SF-36 Physical Component Scale (PCS) and the Mental Component 
Scale (MCS). The β-coefficient represents the change in PCS and MCS when the covariate changes 
with one unit of measurement. n=434.
Parameter
PCS MCS
Estimate 
(β)
95% CI p Estimate 
(β)
95% CI p
Intercept 41.81 36.38 to 47.25 <.001 57.12 51.60 to 62.63 <.001
Time
Baseline Ref Ref
6 Weeks postpartum (6Wpp) 9.28 7.49 to 11.06 <.001 -3.63 -5.38 to -1.88 <.001
6 Months postpartum (6Mpp) 13.97 12.36 to 15.55 <.001 -1.73 -3.48 to 0.03 .054
Intervention following ITT a
Expectant monitoring Ref Ref
Induction of labour 1.43 -0.23 to 3.09 .091 -0.19 -1.47 to 1.86 .819
Randomisation status
Not randomised Ref Ref
Randomised -2.01 -3.72 to -0.23 .021 -1.07 -2.78 to 0.65 .223
Age
≤ 27 years Ref Ref
28 to 33 years 0.86 -2.37 to 0.65 .263 -0.63 -2.23 to 0.96 .435
≥ 34 years 0.31 -1.49 to 2.10 .735 -0.88 -2.71 to 0.95 .347
Parity
Nulliparous Ref Ref
Multiparous 1.53 0.07 to 2.99 .040 -1.17 -2.75 to 0.40 .142
Time to conceive
< 1 year Ref Ref
≥ 1 year 0.77 -0.67 to 2.20 .294 -0.45 -2.12 to 0.97 .465
BMI pre-pregnancy
< 25 Ref Ref
≥ 25 -1.80 -2.99 to -0.60 .003 1.64 0.35 to 2.92 .013
Educational level
Lower Ref Ref
Higher 0.20 -1.03 to 1.44 .749 1.03 0.98 to 2.36 .128
Employed
No Ref Ref
Yes 3.73 1.51 to 5.96 .001 3.03 0.64 to 5.42 .013
Interactions
6Wpp * Randomized -0.75 -3.07 to 1.58 .527 -0.93 -3.22 to 1.37 .428
6Mpp * Randomized -0.91 -3.00 to 1.17 .388 -0.65 -2.94 to 1.64 .579
6Wpp * Induction of labour ITT -0.79 -3.05 to 1.47 .490 -0.52 -2.74 to 1.71 .649
6Mpp * Induction of labour ITT -0.08 -2.11 to 1.95 .940 -0.88 -3.11 to 1.36 .441
a ITT = Intention to treat
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DISCUSSION
In  this  study  we  investigated  the  effect  of  induction  of  labour  compared  to 
expectant  monitoring  on  health-related  quality  of  life  (HR-QoL)  in  women  with 
gestational hypertension (GH) or mild pre-eclampsia (PE) at term. Physical health 
in both groups improved considerably over time while mental health was about 
stable. We did not find any significant impact of induction of labour or expectant 
monitoring on HR-QoL postpartum. Our findings in the non-randomised groups 
were comparable to those in the randomised groups. 
In both randomised groups a part of the women crossed to the other strategy.8 
In the expectant monitoring group, labour eventually was induced in 173 (46%) 
of the 379 women after an average waiting period of 6.4 days (95% CI 0.83 to 
19.9).  In  10  (3%)  of  the  377  women  allocated  to  the  induction  group,  labour 
started spontaneously. Our intention to treat analysis is in agreement with real-life 
clinical decision-making, showing that long term HR-QoL on average is the same, 
regardless of whether induction or expectant monitoring is initiated. While we 
cannot exclude any effect of cross-over on HR-QoL, our results are generalizable 
in the sense that any effect of being randomised or not (-2.01 on a 0-100 scale) has 
no clinical significance. 
Our  HR-QoL  study  might  be  limited  by  three  factors.  First  of  all,  the  first 
postpartum assessment of HR-QoL was at 6 weeks. We did not assess HR-QoL 
between childbirth and 6 weeks. Low physical HR-QoL scores are typical for a 
limited period following childbirth, inherent to the mode of delivery and maternal 
morbidity  postpartum.  Since  the  caesarean  section  rates  in  the  total  study 
population differed only marginally between strategies (14% vs. 19%; RR 0.75 
(95% CI 0.55-1.04)), it is unlikely that differences in mode of delivery had an impact 
on HR-QoL differences directly after childbirth.8 Maternal morbidity, however, was 
lower after induction of labour (31% vs. 44%; RR 0.71 (95% CI 0.59-0.86)).8 We 
cannot exclude that these differences may have affected short term HR-QoL after 
childbirth. Even if short term HR-QoL differences would exist, these apparently 
did not translate in long term HR-QoL differences. Second, we did not evaluate 
the impact of waiting on HR-QoL during expectant monitoring. Waiting may either 
improve HR-QoL, for example because of the more ‘natural’ procedure by avoiding 
artificial interventions. Expectant monitoring, however, may also decrease HR-QoL 
because of an increased level of anxiety, stress or uncertainty while waiting. One 
study  revealed  that  the  negative  impact  of  anxiety  and  uncertainty  during  the 
waiting period on HR-QoL can be substantial.21 The overall impact of waiting on 
HR-QoL, either a positive or negative impact, is probably small since the average 
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71period of waiting is limited. Finally, while most women returned the postpartum 
questionnaires on time, others needed the written reminder for response, which 
might have delayed response –by a maximum of two weeks. We did not assess the 
potential impact of this study adherence on HR-QoL. Focussing on the randomised 
groups, however, we do not assume that there was effect of study adherence. 
The rationale is that study adherence is likely to be influenced by differences in 
baseline characteristics, which were absent in the randomised group between the 
strategy groups.
Our findings can be considered generalizable. First, we found several covariables 
of  selective  response  (Table  1)  but  none  these  appeared  to  have  a  clinically 
relevant  impact  on  HR-QoL  (Table  3).  Moreover,  HR-QoL  differences  were  the 
same in randomised and non-randomised women. Given the absence of HR-QoL 
differences, induction of labour appears to be a safe strategy, without compromising 
maternal HR-QoL on the group level. Our clinical analysis already showed a clear 
benefit of induction with respect to the prevention of progression to severe disease 
and a reduction in caesarean section rate, although the latter difference did not 
reach  statistical  significance.8  Decision-making  about  the  optimal  treatment 
strategy may also be guided by economic aspects (i.e. the optimal strategy is 
the one with lowest costs) or, alternatively, by patient’s treatment preferences. 
Despite the absence of differences in HR-QoL between strategies, most (82%) of 
the non-randomised women were managed expectantly, which supports the idea 
that prior preferences existed. Whether or not prior treatment preferences have an 
impact on treatment satisfaction and quality of life is part of future research.
Summarizing, while the HYPITAT trial shows that induction of labour resulted in 
significantly better maternal outcome and comparable neonatal outcome without 
higher caesarean section rate8, our study adds that induction of labour in women 
with GH or PE at term does not affect long term maternal HR-QoL. Unless either 
economic analyses or analyses of patients’ preferences show large advantages of 
expectant management, induction of labour is the preferred policy in women with 
GH or PE beyond 36 weeks of gestation.
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An economic analysis of induction of 
labour and expectant monitoring in 
women with gestational hypertension 
or pre-eclampsia at term (HYPITAT 
trial)ABSTRACT
Objective To assess the economic consequences of labour induction compared 
to  expectant  monitoring  in  women  with  gestational  hypertension  (GH)  or 
pre-eclampsia (PE) at term. 
Design  An  economic  analysis  alongside  the  HYpertension  and  Pre-eclampsia 
Intervention Trial At Term (HYPITAT). Setting: Obstetric departments of 6 university 
and 32 teaching and district hospitals in the Netherlands.
Population  Women  diagnosed  with  GH  or  PE  between  36+0  and  41+0  weeks 
gestation, randomly allocated to either induction of labour or expectant monitoring.
Methods A trial-based cost-effectiveness analysis was performed from a societal 
perspective during a one year time horizon. Main outcome measures: One year 
costs were estimated and health outcomes were expressed as the prevalence of 
poor maternal outcome defined as either maternal complications or progression to 
severe disease.
Results The average costs of induction of labour (n = 377) were €7.077 versus 
€7.908 for expectant monitoring (n = 379), with an average difference of -€831 
(95% confidence interval: - €1.561 to - €144). This 11% difference predominantly 
originated  from  the  ante  partum  period:  per  woman  costs  were  €1.259  for 
induction  versus  €2.700  for  expectant  monitoring.  During  delivery  more  costs 
were generated following induction (€2.190) as compared to expectant monitoring 
(€1.210). No substantial differences were found in the postpartum, follow-up and 
non-medical costs.
Conclusion In women with GH or mild PE at term, induction of labour is less costly 
than expectant monitoring, due to differences in resource utilization in the ante 
partum period. As the trial already demonstrated that induction of labour results in 
less progression to severe disease without resulting in a higher caesarean section 
rate, both clinical and economic consequences are in favour of induction of labour 
in these women. 
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INTRODUCTION
Six to eight percent of all pregnancies are complicated by gestational hypertension 
(GH)  or  pre-eclampsia  (PE).1,2  Although  outcome  in  most  cases  is  good, 
hypertensive diseases remain a major cause of morbidity and mortality for both 
mother and child.3 Moreover, the care for women with hypertensive disease in 
pregnancy imposes a substantial economic burden.
Most  hypertensive  diseases  occur  at  or  near  term.4  Because  evidence  on  the 
choice between induction of labour and expectant monitoring for women with GH 
or mild PE at term is lacking, we recently performed a randomised clinical trial 
on that subject:5,6 the HYpertension and Pre-eclampsia Intervention Trial At Term 
(HYPITAT,  number  ISRCTN08132825).  Induction  of  labour  significantly  resulted 
in  fewer  women  with  progression  to  severe  disease,  whereas  the  caesarean 
section rate was lower albeit not significant. Apart from these clinical outcomes, 
knowledge on the cost is also of importance, in order to decide whether induction 
should be applied or not. At present, evidence on costs and cost-effectiveness of 
management of women with GH or PE at term is limited.
This  study  reports  the  results  of  the  economic  evaluation  that  we  performed 
alongside  the  HYPITAT  trial.  We  performed  a  cost-effectiveness  analysis 
comparing induction of labour to expectant monitoring in high-risk pregnancies 
due to hypertensive disorders beyond 36 weeks of gestation.
METHODS
Trial design
Full details of the HYPITAT trial were reported previously.5 The trial was approved 
by the Institutional Review Board of the University of Leiden (p04·210) and had local 
approval from the Boards of the other participating hospitals. The trial has been 
registered in the clinical trial register as ISRCTN08132825.
In short, the study was a multicentre randomised controlled clinical trial conducted 
between October 2005 and March 2008 in obstetric departments of 6 university 
and 32 teaching and district hospitals in the Netherlands. Women diagnosed with 
GH or PE beyond 36 weeks of pregnancy were allocated to either induction of 
labour or expectant monitoring.
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case the cervix was ripe, labour was induced with amniotomy and, if labour did not 
start within 1 hour, augmentation with oxytocin was used. In case the cervix was 
judged to be ‘unripe’, cervical ripening was stimulated with use of intracervical or 
intravaginal prostaglandins, according to the local protocol.
In the expectant group, patients were monitored by local protocol until the onset of 
spontaneous delivery. Maternal monitoring consisted of frequent blood pressure 
measurements and laboratory tests. Fetal monitoring consisted of assessment of 
fetal movements as reported by the mother, as well as electronic FHR-monitoring 
and ultrasounds examination. Intervention was only recommended in case of one 
or more of the following conditions: diastolic blood pressure ≥110 mmHg, systolic 
blood pressure ≥170 mmHg, proteinuria ≥ 5 grams/ 24 hours, eclampsia, HELLP 
syndrome, suspected fetal distress, prelabour rupture of membranes lasting > 48 
hours, meconium stained amniotic fluid or gestational age beyond 41 weeks.
Women  who  did  not  give  informed  consent  for  randomisation,  but  who  gave 
authorization for the use of their medical records, were treated according to one 
of the two protocols at the discretion of the attending obstetrician. Data of these 
patients were analyzed to compare them with the randomised data.
The  primary  outcome  in  this  trial  was  a  composite  measure  of  poor  maternal 
outcome, defined as maternal mortality, maternal morbidity (eclampsia, HELLP 
syndrome, pulmonary edema, thrombo-embolic disease or placental abruption), 
progression  to  severe  disease  (at  least  one  measurement  during  antenatal 
or  postpartum  period  of  diastolic  blood  pressure  ≥110  mmHg,  systolic  blood 
pressure ≥ 170 mmHg and proteinuria ≥5 gram/ 24 hours) or major postpartum 
haemorrhage.6 Secondary outcomes were: method of delivery, neonatal mortality, 
and neonatal morbidity. For neonatal morbidity we used a composite outcome 
consisting of a 5-minute Apgar score of lower than 7, umbilical artery pH of lower 
than 7.05, or admission to a neonatal intensive care unit (NICU). 
Analysis  of  the  clinical  endpoints  showed  less  cases  of  severe  disease  in  the 
induction group (31% versus 44%, relative risk 0·71; 95% CI 0·59-0·86). No maternal 
or neonatal death or eclampsia occurred in both groups. There was no difference 
in neonatal morbidity rate (6% versus 8%, relative risk 0.75; 95% CI 0.45-1.26) and 
caesarean section rate (14% versus 19%, relative risk 0.75; 95% CI 0·55-1·04).6 
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Economic evaluation
An economic analysis was performed alongside the trial. As one strategy was found 
to be more effective the economic evaluation was set up as a cost-effectiveness 
analysis.7,8 All unit costs were expressed in 2007 Euros using the consumer pricing 
index.9
We used a societal perspective which means that we included both medical and 
non-medical  costs  to  examine  the  economic  impact  of  both  strategies  on  the 
whole society. We compared costs and effects from the moment of randomisation 
to one year postpartum. Thereby, we differentiated different cost categories (direct 
medical,  non-medical  and  indirect  costs)  and  provided  details  on  utilization  of 
health care resources. Discounting the costs was unnecessary because all costs 
occurred within one year.
Measuring resource utilization
Resources  utilization  was  documented  by  extending  the  Case  Record  Form 
(CRF)  with  specific  items  on  health  care  use  and  by  administering  additional 
questionnaires. In the CRF the following resource items were collected: maternal 
and neonatal admissions, method of delivery, induction method, hours in labour 
room  and/or  operation  room,  outpatient  visits,  medication,  maternal  laboratory 
tests, fetal monitoring, third stage delivery activities and neonatal monitoring.
Maternal  admissions  were  differentiated  into  three  phases:  the  antenatal,  the 
delivery  and  the  postpartum  phase.  For  each  admission,  hospital  stay  was 
differentiated according to the level of care: intensive care, medium care, maternal 
ward, and home care, as different levels have different costs.
The time in the labour room was calculated as the time from admission to labour 
room to time of birth plus one hour extra for recovery care. Assuming that induction 
of labour takes place inside the labour room, it will be expected that the mean 
number of hours in the labour room are higher in the induction group due to time 
needed for induction. In case a caesarean section was performed, hours in the 
operation theatre were also calculated.
For each neonatal admission, hospital stay was differentiated according to the 
level of care as well: intensive care, high care, medium care, medium care on 
maternal ward, and maternal ward, as different levels have different costs. Duration 
of neonatal admission was calculated as the number of days between birth and 
hospital discharge. For neonatal admission to the maternal ward no extra costs 
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the mother.
The long term use of health care from hospital discharge to one year postpartum 
was  collected  by  using  an  additional  questionnaire  sent  to  a  consecutive 
subsample of 99 randomised women and 48 non-randomised women one year 
after their childbirth. The questionnaire documented visits to health care providers 
and hospital admissions for their child and for themselves and medication use. In 
addition to these medical costs, sick leave from work (indirect non-medical costs), 
modes of travelling to hospital and the use of informal care given by partner and/ or 
family (direct non-medical costs) were assessed.
Unit costs
Different methods and sources were used to estimate unit costs as valuations for 
documented volumes of resource utilization (table 1). For maternal and neonatal 
admissions, third stage delivery and neonatal monitoring, unit cost estimates were 
available from the financial departments of one participating academic and one 
participating general hospital.
For use of the labour room and the operation theatre, unit costs were calculated 
per hour, using a bottom-up approach, in which all personnel, use of materials, and 
overhead calculated as a square meter price were integrated. Costs per type of 
delivery were then calculated by multiplying duration in labour room by the price 
for one hour in labour room and by counting up time in operation room multiplied 
by price per hour in operation theatre.
For  some  cost  units  (outpatient  visit,  specialist  care,  general  practitioner  visit, 
paramedical  and  home  care,  travel  costs,  informal  care,  and  productivity  loss)     
national  standardized  prices  were  used,  and  for  laboratory  testing  tariffs  were 
used.10,11 Medication prices were estimated by using the Pharmacotherapeutic 
Compass.12
The value of productivity loss was calculated using the friction cost method from 
age-and sex-stratified data of the Dutch population.10,11 This method assumes that 
workers that are withdrawn from work due to ill health will be replaced after some 
adaptation period – the “friction period”. Consequently, costs from an individual 
woman’s production loss are limited to a period of 10 weeks.
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Analyses
Group  differences  in  resource  use  were  tested  by  using  the  nonparametric 
Mann-Whitney test, as resources generally have a skewed distribution. Resource 
use per patient was multiplied by unit costs, and total costs per patient were 
calculated. Mean costs and median costs per patient were estimated, and mean 
cost  differences  between  study  groups  were  calculated.  The  95%  confidence 
intervals around the difference in mean costs, and incremental cost-effectiveness 
ratios (ICERs) were determined by bootstrapping. An ICER is the ratio of costs 
Table 1. Cost-analyses: units of resource use, unit costs, valuation method and volume source
Unit Unit costs Valuation method (source) Volume 
source
Medical costs
Admission mother*
hospital stay - ward day 346 Top-down calculation CRF
hospital stay - medium care day 526 Top-down calculation CRF
hospital-stay - intensive care day 1,679 Top-down calculation CRF
Admission child*
hospital stay - medium care day 526 Top-down calculation CRF
hospital stay - high care day 1,409 Top-down calculation CRF
hospital-stay - NICU day 1,459 Top-down calculation CRF
Specialist care hour 69 Dutch costing guidelines (11) CRF/AQ
Outpatient visit*  visit 82 Top-down calculation CRF/AQ
Psychologist hour 34 Dutch costing guidelines (11) AQ
Midwife hour 34 Dutch costing guidelines (11) AQ
General practitioner visit 21 Dutch costing guidelines (11) AQ
Paramedical visit 25 Dutch costing guidelines (11) AQ
Home care hour 32 Dutch costing guidelines (11) AQ
Day care day 242 Dutch costing guidelines (11) CRF
Induction methods** gift 15 Pharmacotherapeutic website (12) CRF
Antihypertensive medication 
and antibiotics**
dose per 
day
7 Pharmacotherapeutic website (12) CRF
Analgesics during labour** procedure 161 Top-down calculation CRF
Neonatal monitoring** procedure 90 Top-down calculation CRF
Operation room* hour 140 Bottom-up calculation CRF
Labour room* hour 82 Bottom-up calculation CRF
Non-medical costs
Travel costs- car km 0.17 Dutch costing guidelines (11) AQ
Travel costs- public transport km  0.17 Dutch costing guidelines (11) AQ
Informal care hour 8.78 Dutch costing guidelines (11) AQ
Productivity loss hour 26 Dutch costing guidelines (11) AQ
AQ= additional questionnaire; CRF= Case Report Form.
* The mean of the unit costs for an academic hospital and for a general hospital is presented.
** The mean of several methods/medications is presented.
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Bootstrap methods are based on generating multiple replications of the statistic of 
interest by sampling with replacement from the original data.7,8 Analyses were by 
intention-to-treat.
Thirteen univariate sensitivity analyses were performed to explore the impact of 
different assumptions and alternative unit-cost estimates on the results of the 
costs analysis. Several assumptions were made in estimating labour and operation 
room costs by using a bottom-up method, such as time spent in labour room and/
or  operation  room  by  obstetricians  and  gynaecologists.  In  the  first  sensitivity 
analysis some variations of these assumptions were made to find out their impact 
on the final results (model 1). We examined several other ways of estimating the 
delivery costs using a top-down method (model 2) and a combination of both 
methods (model 3). Because most cost differences were expected ante partum 
due to longer maternal hospital stays in the expectant group, we wanted to find 
out the impact of lower valuation of the ante partum admissions by assuming 
several other monitoring strategies: Medium Care instead of Intensive Care (IC) 
admissions (model 4), day care instead of inpatient care (model 5), outpatient visits 
plus CTGs instead of inpatient care (model 6) and home care instead of inpatient 
care (model 7). In our base case analysis we included no costs for the neonatal 
ward admissions because we assumed this was covered by the maternal ward 
admissions. In model 8 we priced neonatal ward admissions to check its impact. In 
the base case analysis we separated all admissions into four different phases. In a 
sensitivity analysis we examined the impact of no separation into phases (model 9). 
In another sensitivity analysis (model 10) operation room costs were calculated by 
assuming one hour operation room time per patient instead of the actual measured 
hours in the original study. Finally the impact of using lower or higher unit costs 
during all the phases was studied in model 11, 12 and 13.
A  subgroup  analysis  was  performed  to  assess  the  consistency  of  the 
cost-effectiveness effect in patients with GH and patients with mild PE.
Statistical,  economic  and  simulation  analyses  were  performed  using  SPSS 
software (version 16.0, Chicago, IL) and Microsoft Excel.
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RESULTS
Resource use
For the cost analysis we used data of all 756 randomised women and all 397 
non-randomised women. Of the randomised women, 377 were assigned to the 
induction  group  and  379  to  the  expectant  monitoring  group.  Among  the  397 
non-randomised patients, labour was immediately induced in 73 patients, whereas 
324 patients were initially managed expectantly. Additional data on resource use 
during  follow-up  acquired  by  questionnaires  were  available  for  55  randomised 
women,  32  allocated  to  induction  and  23  to  expectant  management.  In  the 
non-randomised group 41 women returned a questionnaire, of which 6 women had 
been allocated to induction and 35 had been monitored expectantly.
Average  volumes  of  resource  utilization,  total  costs  in  each  study  group,  and 
average costs per patient are presented in table S1a & S1b in the Appendix. Most 
remarkable differences in resource use between groups were generated during the 
antenatal and delivery period. There were more outpatient visits in the expectant 
group (9% in induction group versus 66% in expectant group, p<0.001) and a 
longer antenatal stay in hospital (3 days in the induction group versus 6 days in the 
expectant group, p<0.001). Stay at the labour room or operation theatre was longer 
for induced women (21 hours versus 10 hours, p<0.001). Until 1 year after childbirth 
women in the expectant group stayed a little longer in hospital than the women in 
the induction group (3.5 days induction versus 4.0 days expectant, p<0.001). The 
number of hospital days for the children were comparable between both groups 
(4.2 days induction and 4.3 days expectant, p=0.014). The average duration of sick 
leave after the three months permitted maternal leave as is common practice in 
the Netherlands, until 1 year follow-up was comparable (3.0 days versus 2.3 days, 
p=0.39).
Costs
A summary of mean and median costs per patient is presented in table 2. In the ante 
partum period costs per patient appeared to be higher in the expectant monitoring 
group because of longer maternal stays (difference: - €1.441). During delivery the 
costs in the induction group were higher than in the expectant monitoring group 
(difference: €980). This is due to longer stays in the labour room associated with 
the  induction  procedure.  Until  one  year  postpartum,  women  in  the  expectant 
monitoring group generated slightly more costs than women in the induction group 
(difference: - €398), because of longer maternal stays, longer neonatal intensive 
care stays, and more specialist visits. There were no substantial differences in 
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19.726) for induction and €7.908 (95% CI 2.561 to 27.037) for expectant monitoring 
(difference - € 831 (95% CI -1.561 to -144)).
Table 3 shows mean and median costs per patient in the nonrandomised groups. 
Because only 6 women from the nonrandomised induced group returned the follow-
up questionnaire, estimates of costs generated during follow-up and non-medical 
costs for this group are not very reliable. If follow-up and non-medical costs are 
excluded  total  mean  costs  between  randomised  and  nonrandomised  induced 
patients are comparable (€5554 versus €5670). Mean costs per nonrandomised 
Table 2. Comparison of costs between randomised induction of labour and expectant monitoring 
Induction (n=377) Expectant management (n=379)
Mean  Median (IQR) Mean Median (IQR)
Maternal admission  993 574 (0-1435) 2136 1215 (0-2835)
CTGs and ultrasounds 168 116 (87-203) 287 232 (145-377)
Outpatient visits 12 0 (0-0) 131 59 (0-280)
Assessments and medication 81 63 (31-116) 137 116 (62-187)
Laboratory tests 5 4 (2-6) 9 8 (4-12)
Total antepartum 1259 822 (234-1786) 2700 1817 (631-3466)
Admission because of labour 319 287 (0-574) 285 287 (0-405)
Induction material 64 45 (1-90) 20 0 (0-1)
Medication during labour 73 0 (0-161) 64 0 (0-161)
Mode of delivery  1734 960 (584-1691) 841 640 (324-1053)
Total delivery 2190 1292 (815-2446) 1210 927 (567-1546)
Maternal admission  1098 861 (574-1435) 1291 861 (574-1435)
Neonatal admission 967 0 (0-0) 1012 0 (0-0)
Paediatrician and monitoring 42 0 (0-69) 42 69 (0-69)
Total postpartum 2105 1148 (810-2094) 2345 1148 (643-2417)
Primary and specialist care 486 458 (458-559) 772 957 (957-1452)
Maternal admission 0 - 114 103 (103-146)
Neonatal admission 240 218 (218-218) 0 -
Total follow-up 726 677 (677-867) 886 759 (759-1066)
Travel costs*  22 37
Informal care* 703 686
Productivity loss* 72 44
Total non-medical care 797 767
Total cost 7077 5530 (4142-7949) 7908 6235 (4508-9331)
Differential mean cost** 
(95% CI)***
-831 (-1561 to -144)
IQR= Interquartile range
* No median and interquartile percentiles are presented, because these are extrapolated data.
**Induction minus expectant management.
*** Non-parametric confidence interval based on 1000 bootstrap replications.
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patient  in  the  expectant  management  group  were  lower  than  the  randomised 
expectant monitoring patient in all phases, except for the delivery phase.
The subgroup analysis showed mean costs per woman with mild PE of € 7.870 
(n=123,  median  €  6.347,  interquartile  range  [IQR]  €  4.826  to  €  9.429)  in  the 
induction group and € 10.387 (n=123, median € 8.069, IQR € 6.019 to € 12.792) in 
the expectant management group. Mean costs per woman with only GH were € 
6.679 (n= 244, median 5.115, IQR € 3.789 to € 7.647) in the induction group and € 
6.682 (n= 252, median 5.377, IQR € 4.100 to € 7.876) in the expectant management 
group.
Table 3. Costs per patient in nonrandomised groups 
NR Induction (n=73) NR Expectant management (n=324)
Mean  Median (IQR) Mean Median (IQR)
Maternal admission  1465 574 (0-1325) 1378 405 (0-1722)
CTGs and ultrasounds 187 145 (116-218) 233 203 (145-290)
Outpatient visits 78 0 (0-59) 142 104 (0-208)
Assessments and medication 81 54 (31-124) 117 93 (41-171)
Laboratory tests 7 6 (4-8) 7 6 (4-10)
Total antepartum 1818 951 (290-1550) 1882 1113 (414-2231)
Admission because of labour 309 287 (0-574) 257 287 (0-405)
Induction material 56 45 (1-90) 27 0 (0-45)
Medication during labour 71 0 (0-161) 60 0 (0-161)
Mode of delivery  1358 960 (589-1529) 983 653 (385-1234)
Total delivery 1795 1267 (819-2364) 1327 945 (560-1711)
Maternal admission  1309 861 (810-1435) 1110 861 (574-1435)
Neonatal admission 719 0 (0-0) 665 0 (0-0)
Paediatrician and monitoring 30 0 (0-69) 45 69 (0-69)
Total postpartum 2057 1148 (836-2091) 1818 930 (724-1843)
Primary and specialist care 491 471 (471-530) 579 526 (526-709)
Maternal admission 0 - 0 -
Neonatal admission 0 - 179 161 (161-227)
Total follow-up 491 471 (471-530) 758 687 (687-933)
Travel costs* 35 25
Informal care* 220 403
Productivity loss* 0 112
Total non-medical care 255 540
Total cost 6416 4924 (3443-7151) 6325 5037 (3441-7695)
IQR= interquartile range; NR= not randomised.
* No median and interquartile percentiles are presented, because these are extrapolated data.
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With an estimated difference in progression to severe disease between the two 
strategies of 13% in favour of induction of labour, and a mean difference in costs 
per patient of €831 also in favour of induction of labour, induction of labour was the 
dominant strategy.
We also assessed uncertainty in the estimated ICERs (bootstrap analysis), depicted 
in a cost effectiveness plane. Figure 1 shows that with high certainty induction is 
a cost saving strategy compared to expectant monitoring in pregnant women with 
GH or mild PE. In the upper right quadrant a strategy is considered cost-effective 
if the ICER is located below the line reflecting willingness-to-pay (how much one 
is willing to pay for one unit gain in health outcome). A strategy will always be 
cost-effective,  irrespective  of  willingness-to  pay,  if  all  bootstrap  estimates  of 
incremental cost-effectiveness ratios are located in the lower right quadrant.
Sensitivity analyses
In table 4 results of the sensitivity analyses are shown. If we increase the labour 
and operation room costs from € 80 to € 115 and from €140 to € 224 per hour, this 
increases mean costs in both groups but decreases the difference to - €470, and 
expectant monitoring remains the most expensive strategy (model 1). Top-down 
calculation (model 2) or a combination of bottom-up and top-down calculation 
(model 3) of the delivery costs resulted in higher mean costs per patient in the 
expectant  group  and  lower  mean  costs  per  induced  patient.  The  ante  partum 
intensive care (IC) admissions were valued for medium care prices, to find out if 
Figure 1. Cost-effectiveness plane Additional costs: difference in average costs per patient between 
the  induction  group  and  the  expectant  group  (in  2007  Euros).  Additional  effects:  difference  in 
proportion of maternal complications between the induction group and the expectant group.
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it impacts the total costs per group. The mean costs per patient in the expectant 
group decreased a little. Because costs for the induced patient remained rather the 
same, the mean cost difference reduced to - €438 (model 4). Replacing antepartum 
inpatient care by other monitoring strategies (model 5, 6 and 7) decreased the mean 
costs per patient in both groups, but expectant management remains the most 
expensive strategy. Including neonatal ward admissions (model 8), summarizing 
all  admissions  without  separate  phases  (model  9)  or  standardizing  operation 
room time (model 10) increases mean costs per patient in both groups, but the 
differences remain rather the same. We also estimated costs by using higher and 
lower unit prices for hospital stay and outpatient visits. If we only use the unit costs 
from the academic centre, the mean costs per patient in both groups increase 
and the difference increases to - €1496 (model 11). If we only use the unit costs 
from the general hospital, the mean costs per patient decrease, but the differences 
between groups remain the same (model 12). If we estimate costs associated 
with in-patient admissions by using the Dutch national standardized unit costs the 
difference between groups increases (model 13).
DISCUSSION
This study assessed the economic consequences of induction of labour or an 
expectant monitoring strategy in pregnant women with GH or mild PE at term, 
Table 4. Sensitivity analyses results
Model Description Induction Expectant 
management
Difference 
Base case scenario € 7,077 € 7,908 - € 831 
1 Higher labour (€115) and operation (€224) room costs  € 7,774 € 8,244 - € 470 
2 Top-down calculation of delivery costs € 6,660 € 8,456 - € 1,796
3 Bottom-up and top-down calculation of delivery 
costs (combining registered days of induction and 
top down unit prices for delivery)
€ 6,897 € 8,551 - € 1,654
4 Ante partum IC admissions priced as Medium Care € 7,007 € 7,445 - € 438 
5 Value antepartum admissions by day-care prices € 6.817 € 7.460 - € 643
6 Replace antepartum admissions by outpatient visits 
and CTGs
€ 6.438 € 6.804 - €  366
7 Replace antepartum admissions by home care € 6.854 € 7.523 - €  669
8 Value neonatal ward admissions  € 7.579 € 8.309 - € 730
9 Summarize all admissions without separate phases € 8.189 € 8.899 - € 710
10 Standardize time in operation room to 1 hour (plus 1 
hour recovery time)
€ 7.093 € 7.939 - € 846
11 Value admissions by using academic unit prices only € 8,169 € 9,665 - € 1,496
12 Value admissions by using general unit prices only € 6,591 € 7,359 - € 768
13 Value admissions by using Dutch standard prices (11) € 7,555 € 8,774 - € 1,219
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the  HYPITAT  trial.6  To  our  knowledge  it  is  the  first  economic  evaluation  that 
prospectively compared these strategies.
Our analyses show that the mean costs per patient generated by induction of 
labour were €831 (95% CI -1.561 to -144) lower as compared to those for expectant 
monitoring. Unsurprisingly, the difference in costs predominantly originated in the 
ante partum period, due to longer hospital stays before childbirth for women in the 
expectant group. On the other hand, during delivery more costs were generated 
following induction due to the longer duration in labour room because of induction 
itself. In our base-case analysis we assumed that induction was done in the labour 
room and we estimated delivery costs by using number of hours in labour room and 
unit costs for one hour in the labour room. In sensitivity analyses we examined the 
consequences if delivery costs were estimated using a top-down calculation, i.e. 
using unit costs per method of delivery. As a result the cost difference between both 
strategies doubled. This means that if induction time is not included separately in 
the costs analyses (it is assumed that these costs are already included in the costs 
of hospital admission), the costs difference during delivery in favour of expectant 
monitoring disappears and expectant monitoring even becomes more expensive. 
However, in our opinion top-down calculation for estimating delivery costs is not 
an appropriate method, because it underestimates costs due to induction and the 
time spent on induction itself.
In the period from childbirth until one year postpartum medical costs appeared to 
be  €398 higher for women in the expectant monitoring group, mostly due to longer 
maternal and neonatal stays in the hospital and more postpartum specialist visits. 
Clinical results of the HYPITAT trial already indicated that induction of labour results 
in less progression to severe disease and that it has a lower caesarean section rate. 
The higher postpartum costs for women in the expectant group are a consequence 
of  these  findings.  During  delivery,  expectant  monitoring  remained  less  costly 
despite more caesarean sections in this group. Higher caesarean section costs for 
induced patients are caused by the longer stay in the labour and operating theatre. 
No substantial differences were found in the non-medical costs. These costs and 
the above mentioned follow-up costs were estimated in a subgroup of the total 
trial population by using an additional questionnaire. Because of the small number 
of participants, this results in broad confidence intervals around the follow-up and 
non-medical costs, and thus higher uncertainty around these estimates. On the 
other hand, we were able to estimate the impact of both strategies on indirect 
costs and for a longer time horizon than the trial duration, which improves the 
relevance from a societal perspective.
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In the Netherlands, women are permitted a maternal leave for three months after 
childbirth. In estimating the yearly costs of productivity loss we only included the 
remaining nine months after the maternal leave. Therefore, before generalizing 
non-medical costs to other countries, the local arrangements for maternal leave 
need to be considered.
The prospective design of the trial, the large number and diversity of participating 
hospitals and the well-organized structure of randomisation and data-collection 
within the Dutch Obstetric Consortium13 are likely to extend both the internal and 
external validity of our results.
Overall, costs per randomised patient in the expectant group were higher than the 
costs per non-randomised patient, except for the delivery phase. From the clinical 
data it can be observed that randomised women had little more bad maternal 
outcomes after expectant management than nonrandomised women (44% versus 
38%). For that reason the randomised women might be admitted more and longer 
in hospital before and after childbirth and this might explain the higher costs per 
randomised patient in these groups. Children in the randomised expectant group 
stayed longer in MC/HC than the nonrandomised children. This is probably not a 
trial effect (better monitoring in the randomised group), because this effect was 
not seen within the induced groups.
According to the clinical results of the HYPITAT trial induction of labour should be 
advised in women with GH and a diastolic blood pressure ≥95 mmHg or mild PE 
at a gestational age beyond 37 weeks.6 The results as described in this economic 
evaluation study indicate that this strategy is also associated with lower average 
costs per patient.
In summary, induction of labour is found to be a less costly and more effective 
strategy as compared to expectant management in women with GH or PE beyond 
36 weeks of gestation.
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93Table S1. Resource use, mean costs per patient and total costs, medical care (2007 Euros)
   Induction (n=377) Expectant monitoring (n=379)
Unit % patients
using care
Mean
volume*
Total
Costs (€)
Mean
Costs pp (€)
% patients
using care
Mean
volume*
Total
Costs (€)
Mean
Costs pp (€)
Difference
(I-EM)
Total antepartum phasea 474,741 1,259 1,023,383 2,7 -1,441
Maternal admission IC days 2% 3 34,307 91 6% 8.4 223,989 591 -500
Maternal admission MC days 11% 3.6 74,269 197 11% 4.9 112,184 296 -99
Maternal admission ward days 52% 4.4 263,146 698 57% 7.1 463,896 1224 -526
Home care days 4% 5.5 2,639 7 11% 7.6 9,854 26 -19
CTGs and Ultrasounds procedure 100% 8.8 63,261 168 100% 12.6 108,773 287 -119
Outpatient visits visit 9% 3 4,807 13 66% 4.7 49,649 131 -118
Assessments and lab tests procedure 99% 13 32,087 85 100% 21.8 54,375 144 -58
Medication# 226 0,6 663 1,75 -1,15
Total delivery phase 823,704 2,19 456,695 1,21 980
Admission because of labour b day 54% 1.7 120,263 319 55% 1.5 108,015 285 34
Induction material Gift 92% 4.7 24,087 64 41% 4.8 7,58 20 44
Medication during labour#  Unit 50% - 27,521 73 42% - 24,256 64 9
Spontaneous route of delivery  hours 72% 17.6 384,54 1,025 67% 8.6 174,34 465 560
Instrumental delivery  hours 13% 26.0 105,183 279 14% 13.1 57,608 152 127
Caesarean delivery  hours 15% 36.8 162,11 430 19% 14.5 84,896 224 206
Total postpartumc 776,62 2,105 788,699 2,345 -238
Maternal admission IC days 2% 2.5 19,981 53 3% 5 82,622 218 -165
Maternal admission MC days 4% 3.3 23,751 63 4% 3.5 25,393 67 -4
Maternal admission ward days 90% 3.4 368,329 977 85% 3.7 379,758 1002 -25
Neonatal admission IC days 3% 4.0 64,467 171 2% 7.3 84,517 223 -52
Neonatal admission HC days 4% 6.9 129,311 343 3% 7.3 104,604 276 67
Neonatal admission MC days 19% 5.0 170,781 453 19% 6.0 194,427 513 -60
Total follow-up 273,702 726 462,001 886 -160
Primary care visit 94% 15.5 122,902 326 87% 16 116,732 308 18
Specialist care visit 28% 2.4 60,32 160 22% 5.6 301,684 464 -304
Maternal admission days 0% 0 0 0 4% 2 43,206 114 -114
Neonatal admission days 3% 1 90,48 240 0% 0 0 0 240
* of patients using care. # medication costs are an summation of several medications, therefore 
no unit and mean volume is given. a ante partum admissions: time from hospital admission to the 
discharge date (only if the discharge date was prior or equal to the child’s birth date) or to birth date 
(if discharge date was after child’s birth date) and if the reason of admission was not equal to labour. 
Table S2. Resource use, mean costs per patient and total costs, non-medical (2007 Euros)
Induction (n=377) Expectant management (n=379)
Unit % patients
using care
Mean
volume*
Total
Costs (€)
Mean
Costs pp (€)
% patients Mean
volume*
Total
Costs (€)
Mean
Costs pp (€)
Difference
(I-EM)
Total non-medical care 300,469 797 using care 290,693 767 30
Travel costs (car or public 
transport)
km 66% 132 8,294 22 65% 225 14,023 37 -15
Informal care hours 68% 80 265,031 703 78% 77 259,994 686 17
Productivity loss days 9% 3 27,144 72 22% 2.3 16,676 44 28
Total costs  2,668,029 7,077 2,995,995 7,908 -831
* of patients using care
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Maternal admission MC days 11% 3.6 74,269 197 11% 4.9 112,184 296 -99
Maternal admission ward days 52% 4.4 263,146 698 57% 7.1 463,896 1224 -526
Home care days 4% 5.5 2,639 7 11% 7.6 9,854 26 -19
CTGs and Ultrasounds procedure 100% 8.8 63,261 168 100% 12.6 108,773 287 -119
Outpatient visits visit 9% 3 4,807 13 66% 4.7 49,649 131 -118
Assessments and lab tests procedure 99% 13 32,087 85 100% 21.8 54,375 144 -58
Medication# 226 0,6 663 1,75 -1,15
Total delivery phase 823,704 2,19 456,695 1,21 980
Admission because of labour b day 54% 1.7 120,263 319 55% 1.5 108,015 285 34
Induction material Gift 92% 4.7 24,087 64 41% 4.8 7,58 20 44
Medication during labour#  Unit 50% - 27,521 73 42% - 24,256 64 9
Spontaneous route of delivery  hours 72% 17.6 384,54 1,025 67% 8.6 174,34 465 560
Instrumental delivery  hours 13% 26.0 105,183 279 14% 13.1 57,608 152 127
Caesarean delivery  hours 15% 36.8 162,11 430 19% 14.5 84,896 224 206
Total postpartumc 776,62 2,105 788,699 2,345 -238
Maternal admission IC days 2% 2.5 19,981 53 3% 5 82,622 218 -165
Maternal admission MC days 4% 3.3 23,751 63 4% 3.5 25,393 67 -4
Maternal admission ward days 90% 3.4 368,329 977 85% 3.7 379,758 1002 -25
Neonatal admission IC days 3% 4.0 64,467 171 2% 7.3 84,517 223 -52
Neonatal admission HC days 4% 6.9 129,311 343 3% 7.3 104,604 276 67
Neonatal admission MC days 19% 5.0 170,781 453 19% 6.0 194,427 513 -60
Total follow-up 273,702 726 462,001 886 -160
Primary care visit 94% 15.5 122,902 326 87% 16 116,732 308 18
Specialist care visit 28% 2.4 60,32 160 22% 5.6 301,684 464 -304
Maternal admission days 0% 0 0 0 4% 2 43,206 114 -114
Neonatal admission days 3% 1 90,48 240 0% 0 0 0 240
* of patients using care. # medication costs are an summation of several medications, therefore 
no unit and mean volume is given. a ante partum admissions: time from hospital admission to the 
discharge date (only if the discharge date was prior or equal to the child’s birth date) or to birth date 
(if discharge date was after child’s birth date) and if the reason of admission was not equal to labour. 
Table S2. Resource use, mean costs per patient and total costs, non-medical (2007 Euros)
Induction (n=377) Expectant management (n=379)
Unit % patients
using care
Mean
volume*
Total
Costs (€)
Mean
Costs pp (€)
% patients Mean
volume*
Total
Costs (€)
Mean
Costs pp (€)
Difference
(I-EM)
Total non-medical care 300,469 797 using care 290,693 767 30
Travel costs (car or public 
transport)
km 66% 132 8,294 22 65% 225 14,023 37 -15
Informal care hours 68% 80 265,031 703 78% 77 259,994 686 17
Productivity loss days 9% 3 27,144 72 22% 2.3 16,676 44 28
Total costs  2,668,029 7,077 2,995,995 7,908 -831
* of patients using care
b Admission during labour: the time between admission and discharge date, 
if the discharge date was prior or equal to the child’s birth date and the 
reason for admission was labour. c Postnatal admissions: the days between 
admission date after or equal to the child’s birth and the discharge date. 
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Prediction of progression to severe 
disease in women with gestational 
hypertension or mild pre-eclampsia 
at termABSTRACT
Objective To evaluate whether progression to severe disease is predictable in 
women with gestational hypertension (GH) or mild pre-eclampsia (PE) at term. 
Methods Women with a singleton pregnancy, a fetus in cephalic position, between 
36 and 41 weeks of gestation, complicated by GH or mild PE that were managed 
expectantly, were selected from the HYPITAT trial. We evaluated the predictability 
of progression to severe disease. Logistic regression was used to determine the 
predictive value of clinical characteristics or laboratory findings and to generate a 
prediction model for clinical deterioration. The predictive value of this model was 
assessed  with  receiver-operating-characteristic  (ROC)  analysis,  calibration  and 
internal validation.
Results We included 703 women, of whom 244 (34.7%) had progression to severe 
disease. After multivariable analysis nulliparity (OR 1.87), maternal age (OR 1.05 per 
year), gestational age (OR 0.88 per week), previous abortion (OR 1.26), ethnicity 
(OR  2.05  for  non-Caucasian  ethnicity),  diastolic  (OR  1.04  per  mmHg),  systolic 
blood pressure (OR 1.02 per mmHg), and the laboratory parameters proteinuria, 
haemoglobin,  platelets,  uric  acid  and  alanine  aminotransferase  were  included 
in the final model. The area under the ROC-curve of this model was 0.71 (95% 
CI, 0.67-0.74). Even though the goodness of fit was moderate (p=0.40), internal 
validation showed the model could hold in the overall population.
Conclusion In women with GH or mild PE at term progression of severe disease 
can  be  predicted.  Therefore,  identified  predictors  can  guide  physicians  in  the 
treatment of an individual patient with GH or mild PE at term.
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INTRODUCTION
Severe  hypertension  is  associated  with  maternal  morbidity,  such  as  eclampsia, 
pulmonary oedema, cerebrovascular accidents encephalopathy and haemorrhage.1-3 
The majority of these hypertensive disorders occur after a gestational age of 36 
weeks. Until recently, a strong controversy on the management of women with mild 
hypertensive disease at term existed in the Netherlands. The majority of individual 
hospital protocols recommended expectant monitoring, but uniformity was lacking. 
We performed a randomised clinical trial, which showed that induction of labour 
reduces the risk of clinical deterioration to severe disease compared to expectant 
monitoring in women with gestational hypertension (GH) or mild pre-eclampsia (PE) 
at term. This reduction occurs without increasing the caesarean section rate and 
with similar neonatal outcome.4
However, it is questionable if induction of labour is the best treatment option in all 
patients with GH or mild PE at term. For instance, in women with a uterine scar, 
induction of labour is associated with increased risk of uterine rupture.5 Hence; 
identification of patients at increased risk of developing severe maternal morbidity 
is of the utmost importance. Several studies have demonstrated that factors such 
as parity, gestational age (GA), blood pressure, liver function, and kidney function 
are  predictors  of  maternal  morbidity  in  women  with  hypertensive  disorders  of 
pregnancy.6-9 However, the prognostic value of these indicators in a multivariate 
approach remains unclear.
In the present study, we assessed the prognostic capacity of clinical characteristics 
and laboratory findings with respect to progression to severe disease in women 
with GH or mild PE at term. Furthermore, we propose a new prognostic model, 
which can aid clinicians in the treatment of individual patients.
METHODS
We used data from patients managed by expectant monitoring in the context of a 
randomised clinical trial in the Netherlands that was performed between October 
2005  and  March  2008  (the  HYPITAT  trial).4  In  short,  patients  with  a  singleton 
pregnancy with a child in cephalic position and a GA between 36+0 and 41+0 weeks 
whose pregnancy was complicated by GH or mild PE were asked to participate in 
the trial. GH was defined as diastolic blood pressure (BP) ≥95 mmHg measured 
on two occasions at least six hours apart. Mild PE was defined as diastolic BP 
≥90 mmHg measured at two occasions at least six hours apart combined with 
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101proteinuria. Proteinuria was defined by local protocol as ≥2+ protein on dipstick, 
>300 mg total protein in a 24 hour urine collection or protein/creatinine ratio >30 
mg/mmol. Exclusion criteria were presence of severe GH or PE (defined as diastolic 
BP ≥110 mmHg and/or systolic BP ≥170 mmHg), proteinuria ≥5 gram in 24 hours, 
pre-existing  hypertension  treated  with  anti-hypertensive  drugs,  haemolysis, 
elevated liver enzymes, and low platelets (HELLP) syndrome, use of intravenous 
anti-hypertensive medication or a caesarean section in history.
Patients  who  had  given  informed  consent  were  randomly  allocated  to  either 
induction of labour or expectant monitoring. Patients who did not give consent for 
randomisation, but who provided consent for the use of their medical data, were 
treated according to local protocol. Patients in the expectant group were monitored 
until the onset of spontaneous delivery or until there was a medical indication for 
delivery. Monitoring consisted of frequent maternal blood pressure measurements, 
assessments  of  proteinuria,  laboratory  tests  and  regular  assessment  of  fetal 
condition.
The present study was limited to patients managed expectantly, and combined 
both the randomised and the non-randomised women in one cohort. The primary 
endpoint was a composite outcome of progression to severe disease which was 
defined as the occurrence of any of the following: eclampsia, HELLP syndrome 
(platelet count <100×109/L and AST >70 U/L or ALT >70 U/L), maternal mortality, 
diastolic BP ≥110 mmHg, systolic BP ≥170 mmHg and/or proteinuria ≥5 gram in 
24 hours. 
We  evaluated  whether  this  composite  endpoint  was  predictable  from  clinical 
characteristics (maternal age, ethnicity, parity, body mass index, diastolic BP, systolic 
BP, proteinuria), vaginal examination (cervical dilatation, effacement, consistency, 
engagement, position, length and the overall Bishop score) or laboratory findings 
(haemoglobin, haematocrit, platelets, uric acid, creatinine, lactate dehydrogenase 
(LDH),  aspartate  aminotransferase  (AST),  alanine  aminotransferase  (ALT) 
and  proteinuria)  measured  at  baseline.  Cervical  length  measurements  (using 
transvaginal sonography) and vaginal digital examination were performed before 
randomisation. In case of non-randomisation these examinations were not always 
performed at baseline.
Missing data
There were no missing data for the composite endpoint, but several potentially 
prognostic variables had varying percentages of missing values. Missing data of 
the predictive variables were imputed, because exclusion would lead to a loss of 
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statistical power in multivariable analysis and, more seriously, potentially biased 
results.  In  multivariable  prognostic  research  complete  case  analysis  should 
be avoided and multiple imputation methods are known to be superior to other 
imputation methods.10 Multiple imputation was performed using PASW Statistics 
17.0 (SPSS inc. Chicago, Illinois), in which we generated 5 imputed datasets.
Data analysis
Using the imputed multiple dataset, logistic regression was performed to predict 
occurrence of the primary endpoint from clinical characteristics and laboratory 
findings. For both dichotomous and continuous variables univariate pooled odds 
ratios, and 95% confidence intervals (CI), as well as p-values, were calculated. 
Subsequently, multivariable logistic regression analysis with a stepwise backward 
selection procedure of predictors was performed to construct a prediction model 
for  progression  to  severe  disease.  Confounding  variables  were  excluded  in 
multivariate analysis. Since the purpose of the prediction model is to reach optimal 
predictive power, our multivariate analysis was not limited to significant prognostic 
variables but considered all prognostic variables with a significance level of <0.40 
in the univariate analysis.11
To evaluate the discriminative performance of the logistic model, the area under 
the Receiver Operating Characteristic (ROC) curve was calculated, comparing the 
actual outcome to the outcome predicted by the model.
We also evaluated the calibration of the prediction model by plotting observed 
and predicted event rates for 10 subgroups of patients on the basis of deciles 
of  the  predicted  probability  of  deterioration.12  The  reliability  of  the  model  was 
estimated with the Hosmer and Lemeshow test for goodness-of-fit. Calculations 
were performed with the PASW Statistics 17.0 (SPSS inc. Chicago, Illinois) and 
graphs were produced using GraphPad Prism (GraphPad Software, Inc. La Jolla, 
USA).  Internal  validation  and  extent  of  overfitting  of  the  model  was  assessed 
with  bootstrapping  in  R.13  Two  hundred  bootstrap  samples  were  drawn  from 
each imputation set. In each bootstrap sample, the entire modelling process was 
repeated. The bootstrap procedure yields an ROC area corrected for optimism and 
a shrinkage factor to adjust the model for overfitting.
RESULTS
We identified 1153 eligible women for participation in the HYPITAT trial. In total 756 
women gave informed consent for randomisation, of whom 379 patients (50%) 
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refused randomisation, 324 patients (82%) were initially managed expectantly (fig. 
1). We combined both the 379 randomised and the 324 non-randomised patients 
who  were  managed  expectantly  into  one  cohort  (n=703).  Figure  1  also  shows 
onset of labour and mode of delivery for both expectant management groups. In 
both groups labour was eventually induced in almost half of the women, of whom 
50% had at least one maternal medical reason to induce (e.g. severe hypertension/
proteinuria, HELLP syndrome, use of anticonvulsive/intravenous antihypertensive 
drugs,  prelabour  rupture  of  membranes  >48h  or  gestational  age  >41  weeks). 
Suspected  fetal  distress  was  the  reason  for  induction  of  labour  in  18  (10%, 
randomised group) versus 9 (6%, non-randomised group) of the women. Elective 
induction of labour occurred in 48 (28%) versus 46 (30%) of the patients.
Figure 1. Trial profile of the HYPITAT trial.
Progression to severe disease occurred in 244 (34.7%) patients, as determined by 
one or more of the following variables: diastolic blood pressure ≥110 mmHg (n= 
173, 25%); systolic blood pressure ≥170 mmHg (n= 147, 21%); proteinuria ≥5 gram 
(n= 8, 2.5%) and HELLP syndrome (n=17, 2.4%). Neither eclampsia nor maternal 
death occurred.
Baseline  patient  characteristics  of  the  women  with  progression  versus  no 
progression to severe disease, together with the amount of missing values per 
variable are presented in Table 1. Primary outcome was available for all 703 women. 
Women in the group with progression to severe disease had younger GA at the 
1153 women were eligible 
756 randomly assigned   397 refused randomisation 
377 (50%) assigned to
induction of labour 
379 (50%) assigned to
expectant management   
73 (18%) labour was
induced  
324 (82%) expectant
management  
Onset of labour: 
- 200 (52.8%) spontaneous 
- 173 (45.6%) induction 
-  6 (1.6%) primary caesarean section   
Mode of delivery: 
- 253 (66.8%) spontaneous 
-  52 (13.7%) vacuum extraction 
  -  2 (0.5%) forcipal extraction  
-  72 (19.0%) caesarean 
 
Onset of labour:
- 171 (52.8%) spontaneous 
- 152 (46.9%) induction 
-  1 (0.3%) primary caesarean section   
Mode of delivery: 
- 214 (66.0%) spontaneous 
-  56 (17.3%) vacuum extraction   
-  2 (0.6%) forcipal extraction  
-  52 (16.0%) caesarean 
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Table 1. Baseline patient characteristics: progression versus no progression to severe disease. 
Original data.
Characteristics Progression to severe 
disease (n=244, 34.7%)
No progression to severe 
disease (n=459, 65.3%)
p Value Patients with 
available data 
n (%)
Value Patients with 
available data
n (%)
Nulliparous 188 (77.0%) 244 (100) 332 (72.3%) 459 (100) .18
Maternal age (year) 30.0 (22.0-39.0) 244 (100) 30.0 (22.9-38.0) 459 (100) .06
Gestational age (week) 38.1 (36.2-40.3) 243 (100) 38.6 (36.4-40.4) 458 (100) .004
Previous abortion 67 (27.5%) 244 (100) 100 (21.8%) 459 (100) .09
Maternal smoking  26 (11.4%) 228 (93) 47 (10.8%) 435 (95) .82
Body Mass Index  (kg/m2) 31.8 (24.0-41.9) 124 (51) 31.3 (24.6-42.3) 247 (54) .32
Ethnic origin  218 (89) 420 (92) .02
Caucasian 182 (83.5%) 377 (89.8%)
Non-Caucasian 36 (16.5%) 43 (10.2%)
Education level 140 (57) 259 (56) .72
High 52 (37.1) 101 (39.0%)
Low 88 (62.9%) 158 (61.0%)
Blood pressure (mmHg)
Systolic 145 (121-169) 243 (100) 140 (120-160) 459 (100) <.001
Diastolic 98 (90-110) 244 (100) 95 (85-105) 459 (100) .002
Bishop Score 139 (57) 240 (52) .02
< 2 47 (33.8) 50 (20.8)
2-6 87 (62.6) 182 (75.8)
> 6 5 (3.6) 8 (3.3)
Laboratory findings
Dipstick 195 (80) 374 (81) .03
Negative 59 (30.3) 125 (33.4)
Trace 42 (21.5) 110 (29.4)
+ 50 (25.6) 90 (24.1)
++ 35 (17.9) 37 (9.9)
+++ 9 (4.6) 12 (3.2)
Haemoglobin (mmol/L) 7.40 (6.30-8.60) 230 (94) 7.60 (6.43-8.70) 424 (92) .03
Haematocrit (L/L x 10) 3.6 (3.0-4.1) 204 (84) 3.6 (3.0-4.1) 383 (83) .04
Platelets (x109/L) 217 (139-334) 228 (93) 228 (139-359) 421 (91) .02
Uric acid (mmol/L x 10) 3.20 (2.20-4.70) 223 (91) 3.10 (1.90-4.40) 405 (88) .08
Creatinine (μmol/L) 62.0 (45.3-86.8) 224 (92) 61.0 (43.0-83.0) 395 (86) .03
Aspartate 
aminotransferase (U/L)
21.0 (10.0-42.8) 191 (78) 19.0 (10.0-37.0) 351 (76) .10
Alanine aminotransferase 
(U/L)
12.0 (6.0-35.8) 191 (78) 12.0 (6.0-30.0) 358 (78) .76
Lactate dehydrogenase 
(U/L)
287 (160-457) 155 (64) 305 (158-469) 312 (68) .53
Mode of delivery 244 (100) 459 (100) <.001
Spontaneous 142 (58.2%) 325 (70.8%)
Vacuum/forcipal 
extraction
36 (14.7%) 76 (16.6%)
Caesarean section 66 (26.6%) 58 (12.6%)
Data are median (5th -95th percentile) or number (%).
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105start of expectant management (p=0.004) were more frequently of non-Caucasian 
ethnicity  (p=0.02)  had  more  severe  proteinuria  at  dipstick  (p=0.03),  a  lower 
Bishop Score at vaginal examination (p=0.02) and had higher systolic (p<.001) and 
diastolic blood pressure (p=0.002) at study entry. The laboratory findings showed 
lower  haemoglobin  (p=0.03),  lower  haematocrit  (p=0.04)  and  lower  platelets 
levels (p=0.02) as well as higher creatinine (p=0.03) in the group of women with 
progression to severe disease. 
In  the  randomisation  group  cervical  length  was  measured  using  transvaginal 
sonography  and  vaginal  digital  examination  was  performed,  both  prior  to 
randomisation.  In  the  non-randomised  group  vaginal  examination  was  only 
performed in about 5% of the women. As a consequence Bishop Scores were 
Table 2. Vaginal examination characteristics in randomised expectant monitoring group: progression 
versus no progression to severe disease.
Characteristics Progression to severe disease 
(n=143, 37.7%)
No progression to severe disease 
(n=236, 62.3%)
p Value Patients with 
available data
Value Patients with 
available data
Bishop Score 127 (89) 211 (89) .01
< 2 42 (33.3) 40 (19.0)
2 to 6 80 (63.0) 164 (77.7)
> 6 5 (3.9) 7 (3.3)
Dilatation (cm) 0.0 (0.0-2.0) 139 (97) 1.0 (0.0-3.0) 227 (96) .03
Effacement  136 (95) 224 (95) .14
0% 44 (32.4) 48 (21.4)
25% 25 (18.4) 44 (19.6)
50% 42 (30.9) 91 (40.6)
75% 17 (12.5) 32 (14.3)
100% 8 (5.9) 9 (4.0)
Consistency  138 (97) 224 (95) .07
Stiff 33 (23.9) 32 (14.3)
Moderate 85 (61.6) 155 (69.2)
Week 20 (14.5) 37 (16.5)
Engagement  131 (92) 221 (94) .66
Hodge 1 112 (85.5) 192 (86.9)
Hodge 2 19 (14.5) 28 (12.7)
Hodge 3 0 (0.0) 1 (0.5)
Position  135 (94) 221 (94) .002
Posterior 84 (62.2) 104 (47.1)
Median 51 (37.8) 106 (48.0)
Anterior 0 (0.0) 11 (5.0)
Length (mm) 31 (13-48) 133 (93) 29 (10-45) 221 (94) .001
Data are median (5th -95th percentile) or number (%).
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missing in 43% of women with progression to severe disease vs. 48% of women 
without progression to severe disease. Multiple imputation was not possible for 
these variables with these percentages of missing values. We decided to evaluate 
the vaginal examination characteristics in the randomised group only and not to 
include this variable in the overall prediction model. Women with progression to 
severe disease had less dilatation of the cervix (p=0.03), more frequently a posterior 
cervix position (p=0.002) in stead of median or anterior and a longer cervix length 
(p=0.001) and consequently a lower Bishop Score (p=0.01) (Table 2).
Figure 2. ROC graph of prediction model for progression to severe disease, calculated by multivariate 
analysis.
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Factors strongly associated with progression to severe disease in the univariate 
analysis  were  GA,  non-Caucasian  ethnicity,  high  systolic  and  diastolic  blood 
pressure.  Of  the  laboratory  findings,  decrease  of  haemoglobin,  haematocrit 
and platelets, as well as increased proteinuria, uric acid and ALT were strongly 
associated with progression to severe disease (Table 3). Since more liberal p-values 
are advocated to increase the probability that real predictors are selected in the 
model, we selected all prognostic variables with a significance level of p <0.40 
to enter the model. Table 3 also shows this final model. The final model exists 
of the variables: nulliparity, maternal age, GA, previous abortion, ethnicity, blood 
pressures, dipstick, haemoglobin, platelets, uric acid and ALT. We averaged the 
5 predicted risks of each patient, which resulted in one performance estimate. 
The model showed good discrimination, with an area under the ROC curve of 
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1070.71 (95% CI, 0.67-0.74)), but the calibration was moderate (Hosmer-Lemeshow 
p-value=0.40 (varying for the 5 dataset between 0.16-0.74)). Figure 3 shows the 
rates of progression to severe disease ranged from 14% (lowest 10 percent) to 
60% (highest 10 percent). For the predicted deterioration between 30% and 45%, 
slight underestimation was seen. But the CIs of the group with low (<30%) risk of 
progression to severe disease and the group with high (>40%) risk did not overlap, 
indicating that distinction between these groups is possible. Bootstrapping showed 
little optimism (AUC varied from 0.66-0.67), indicating that the model holds for the 
overall population.
Table 3. Results of the univariate and multivariate analysis of predictors of progression to severe 
disease, pooled estimates based on imputed data.
Predictors Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Nulliparous 1.28 0.89 – 1.84 .18 1.87 1.09 – 2.76 .003
Maternal age (years) 1.03 0.99 – 1.07 .06 1.05 0.67 – 1.56 .02
Gestational age (weeks) 0.83 0.73 – 0.94 .004 0.88 0.97 – 1.05 .07
Previous abortion 1.36 0.95 – 1.94 .09 1.26 1.01 – 1.04 .25
Maternal smoking  1.07 0.65 – 1.76 .78
Body Mass Index  (kg/m2) 1.01 0.97 – 1.05 .54
Non-Caucasian ethnicity 1.74 1.09 – 2.76 .02 2.05 0.65 – 1.76 .09
Higher education level 1.03 0.67 – 1.56 .90
Blood Pressure (mmHg)
Systolic 1.03 1.01 – 1.04 <.001 1.02 0.59 – 0.93 .01
Diastolic 1.05 1.02 – 1.07 .001 1.04 0.31 – 0.89 .01
Laboratory findings
Dipstick (vs negative)
Trace 0.79 0.50 – 1.25 .32 0.81 0.99 – 1.00 .41
+ 1.17 0.72 – 1.90 .53 1.09 0.99 – 1.01 .92
++ 1.95 1.12 – 3.39 .02 1.71 1.04 – 1.64 .11
+++ 1.37 0.57 – 3.28 .48 1.17 1.67 – 1.56 .74
Haemoglobin (mmol/L) 0.74 0.59 – 0.93 .01 0.73 0.50 – 1.25 .02
Haematocrit (L/L x 10) 0.52 0.31 – 0.89 .02
Platelets (x109/L) 0.997 0.99 – 1.00 .05 0.99 0.72 – 1.90 .07
Uric acid (mmol/L x10) 1.30 1.04 – 1.64 .02 1.22 1.12 – 3.39 .12
Creatinine (μmol/L) 1.00 0.99 – 1.01 .41
Aspartate aminotransferase 
(U/L)
1.01 0.99 – 1.03 .22
Alanine aminotransferase (U/L) 1.02 1.00 – 1.03 .05 1.01 0.57 – 3.28 .12
Lactate dehydrogenase (U/L)  1.00 1.00 – 1.00 .51
* If the variable had a p value less than .40 in the univariable analysis, it was considered in the final 
(multivariable) model.
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Figure 3. Calibration plot demonstrating the association between the risks of progression to severe 
disease as predicted by the logistic model and the observed progression to severe disease.
Calibration Plot
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
predicted probability
o
b
s
e
r
v
e
d
 
p
r
o
b
a
b
i
l
i
t
y
DISCUSSION
In  this  study,  we  elaborate  on  the  recent  findings  of  the  HYPITAT  trial,  which 
revealed that labour should be induced in women with mild PE or GH at term.4 We 
investigated if patients at increased risk of developing severe maternal outcomes, 
could be identified from clinical characteristics. Hereby, we aimed to facilitate the 
correct management for the individual patient.
Our study is important in the clinical management of women with GH or mild PE. 
Early  prediction  and  identification  of  complications  and  progression  to  severe 
disease will benefit doctors and patients by guiding therapy. Moreover, increasing 
predictability  of  disease  progression  allows  clinicians  to  avoid  unnecessary 
interventions in low-risk groups.9 For instance, the HYPITAT trial found that fewer 
caesarean sections were performed in women allocated to induction of labour as 
compared to women allocated to expectant monitoring. This can be explained by 
the fact that more women progressed to severe disease and needed a caesarean 
section (26.6% versus 12.6% of the women without progression to severe disease 
P<0.01, Table 1).
The caesarean section rates found in other countries in women in whom labour 
is induced as well as in women with spontaneous labour are higher than in the 
Netherlands.  We  hypothesize  that  this  is  due  to  the  non-intervention  obstetric 
culture in the Netherlands. For example, Verhoeven et al. reported a caesarean 
section rate of only 11% in a series of women in whom labour was induced.14 We 
hypothesize that it is not the induction but rather the attending gynaecologist who 
is doing the induction who is the factor responsible for the high caesarean section 
rate. For example, delivery in hospital is associated with a higher risk of caesarean 
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labour the attending physician is longer alongside the woman than in spontaneous 
labour, with also an increased risk of caesarean section.
In this analysis nearly 35% of 703 women with GH or mild PE progressed to severe 
disease. Variables included in the prediction model are nulliparity, maternal age, 
GA,  previous  abortion,  ethnicity  (Caucasian  vs.  non-Caucasian),  systolic  and 
diastolic blood pressure, proteinuria, haemoglobin, platelets, uric acid and ALT. 
Thangaratinam et al. reported a prioritized list of tests to predict complications 
of PE. They identified blood pressure, proteinuria, liver function tests and medical 
history  as  the  most  important  predictors  of  maternal  complications  in  PE.9 
Serum uric acid, maternal age, parity and ethnicity scored poorly in the survey of 
Thangaratinam, even though in clinical practice these characteristics are regarded 
as  highly  important.  Several  studies  reported  a  positive  correlation  between 
elevated maternal serum uric acid levels and adverse maternal outcome but there 
are hardly any systematic reviews exploring the accuracy of uric acid to predict 
complications or progression to severe disease.16 Koopmans et al. found serum 
uric acid to be a useful test in the management of PE.17 Rinehart et al. tried to 
determine whether the rate of change of platelets count or LDH level in patients 
with severe PE could be used to determine which patients were more likely to 
develop the more dangerous forms of this disease.18 They concluded that the rate 
of change of platelets and LDH appeared to correlate well with eventual syndrome 
severity. In our study decrease in platelets was also determined as an independent 
predictor of progression to severe disease. 
Since  real  morbidity  such  as  HELLP  syndrome  was  very  rare,  and  some  true 
complications  such  as  eclampsia  or  even  maternal  death  did  not  occur  at  all, 
we  used  progression  to  severe  disease  as  the  primary  outcome.  We  included 
severe hypertension since this is directly related to severe complications such as 
eclampsia, pulmonary oedema and cerebral encephalopathy or haemorrhage. Sibai 
et al. stated that the development of severe GH (without proteinuria) at anytime 
during pregnancy, in labor or postpartum is associated with significant maternal 
morbidity and should therefore be considered as part of a primary outcome for 
future trials for prediction or prevention of PE.1 
The performance of our prediction model was assessed by evaluating discrimination 
and calibration. The ROC curve showed good discriminative capacity. However, in 
the assessment of performance of a prediction model, calibration is more important 
than discriminative capacity.19 In fact, patients and general practitioners are not 
concerned about how their chance is relative to other patients (discrimination); 
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instead, they want to know the likelihood that they progress to severe disease with 
a higher risk of maternal morbidity. Consequently, the clinical aim of the model is 
to differentiate between women with low and high risk of progression to severe 
disease. And even though the performance of our model was moderate, our data 
on calibration and internal validation do indicate that the model can distinguish 
these women at low risk and women at high risk of progression to severe disease. 
Obviously, progression to severe disease can be observed by serially measuring 
blood pressure, which shows progression to severe disease afterwards. However, 
the  clinical  situation  can  sometimes  deteriorate  very  quickly,  and  therefore 
prediction of progression to severe disease at baseline is of importance. The clinical 
utility of this model is that clinicians can differentiate between these groups, and 
for example immediately induce patients in the high risk group.
This distinction could especially be important for women with a prior caesarean 
section for instance, since induction of labour in women with a scarred uterus is 
associated with increased risk of uterine scar rupture.5 Although we did not study 
women with a previous caesarean section, the prediction could also hold in these 
women. As a consequence, induction of labour could be delayed in women at low 
risk of complications, whereas in women at high risk a repeat caesarean section 
could earlier be considered.
The fact that we had varying percentages of missing values can be considered a 
limitation of our study. The missing data of the predictive variables were imputed to 
prevent a loss of statistical power in the multivariable analysis and, more seriously, 
reduce the possibility of bias. Since vaginal examination was not done routinely in 
the non-randomised study group, the percentage of missing data was particularly 
high. Imputation of these data was not possible, with the consequence that we 
had to exclude these variables from the prediction model. In the sub analysis of the 
randomised group an unfavourable cervical examination (dilatation, consistency, 
position and length) are predictors of progression to severe disease as well (data 
not shown). So even though most clinicians would previously choose expectant 
management in this situation, our data indicates that women with an unfavourable 
cervix  are  good  candidates  for  induction  of  labour.  This  decreases  the  risk  of 
progression to severe disease without increasing the caesarean section rate.4 
In conclusion, in the prediction of progression to severe disease, in women with 
GH or mild PE at term, a distinction can be made between women with a low 
risk and women with high risk. After external validation, the identified predictors 
could therefore help doctors and patients in future clinical management in high 
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111risk groups and will allow clinicians to avoid unnecessary interventions in low-risk 
groups of mild PIH or PE at term.
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Risk indicators for eclampsia in 
women with gestational hypertension 
or mild pre-eclampsia at termABSTRACT
Objective  To  evaluate  whether  eclampsia  can  be  predicted  in  gestational 
hypertension or mild pre-eclampsia at term.
Methods For this case-control study we selected 76 cases with eclampsia from the 
LEMMoN study and 1149 controls with mild hypertensive disease of pregnancy, 
who  did  not  develop  eclampsia,  from  the  HYPITAT  study.  Risk  indicators  for 
eclampsia, identified in multivariable logistic regression, were used to assess the 
predictive capacity of our model with receiver-operating-characteristic (ROC)-curve 
analysis. Model optimism was assessed with bootstrapping.
Results  Maternal  age,  non-Caucasian  ethnicity,  systolic  blood  pressure  >155 
mmHg, ≥2+ protein on dipstick, elevated uric acid, creatinine >74 μmol/L, aspartate 
aminotransferase >30 U/L and lactate dehydrogenase >400 U/L were significantly 
associated with eclampsia. Other factors included in the model were previous fetal 
loss, previous miscarriage, gestational age and low platelet count. The area under 
the ROC-curve was 0.92. Bootstrapping showed minimal overfitting of the model. 
Conclusion In women with gestational hypertension or mild pre-eclampsia at term 
eclampsia can be predicted.
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INTRODUCTION
Hypertensive  disorders  of  pregnancy  are  predominant  causes  of  maternal  and 
neonatal mortality and morbidity worldwide.1,2 In the Netherlands, they are the 
largest single cause of maternal mortality.3 In many cases, clinical presentation 
is mild, though maternal and fetal complications can develop, of which eclampsia 
is most feared. The incidence of eclampsia in the Netherlands is 6.2 per 10,000 
deliveries, which is markedly increased as compared to other Western European 
countries.4
Recently we evaluated whether induction of labour in women with gestational 
hypertension (GH) or mild pre-eclampsia (PE) beyond 36 weeks of gestation was 
superior to expectant monitoring (HYpertension and Pre-eclampsia Intervention 
Trial At Term [HYPITAT trial]).5 We found that induction of labour was associated 
with a reduced risk of progression to severe maternal disease, without resulting 
in a higher caesarean delivery rate. Overall, induction of labour appeared to be the 
best treatment option for women diagnosed with GH or mild PE at term. 
Although we recommend a policy of induction of labour, identification of women 
at  increased  risk  for  complications,  most  seriously  eclampsia,  is  still  of  major 
importance. Early identification could be used as a guidance to start prophylactic 
treatment with magnesium sulphate6 and to induce labour immediately instead of 
the next morning.
After  a  systematic  review  of  the  medical  literature  we  found  no  studies  that 
quantify risk indicators for eclampsia in women with mild hypertensive disease 
beyond 36 weeks of gestation. In view of this lack of knowledge, we performed a 
case-control study to assess which patient characteristics may be associated with 
the occurrence of eclampsia among women with GH or mild PE beyond 36 weeks 
of gestation.
MATERIALS AND METHODS
This case-control study used data from two large studies that were published 
earlier.5,7  Cases  were  collected  from  the  LEMMoN  study,  a  nationwide  cohort 
study concerning severe maternal morbidity.7 In this study, women with severe 
maternal morbidity and mortality in the Netherlands were included between August 
2004 and August 2006. From this study we selected all women who developed 
eclampsia beyond 36 weeks of gestation. Women who already had experienced 
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119their first seizure upon referral to the obstetrician were excluded. Eclampsia was 
defined as the occurrence of convulsions, which could not be attributed to other 
causes.4
Controls were women who participated in the HYPITAT trial (clinical trial register 
number ISRCTN 08132825).5 This multicentre parallel randomised controlled, open 
label trial, was conducted in six academic and 32 non-academic hospitals in the 
Netherlands  between  October  2005  and  March  2008.  Induction  of  labour  was 
compared to expectant monitoring in women with GH or mild PE beyond 36 weeks 
of gestation. GH was defined as diastolic blood pressure ≥95 mmHg measured at 
two occasions, performed at least six hours apart. Mild PE was defined as diastolic 
blood pressure ≥90 mmHg measured at two occasions, performed at least six 
hours apart, combined with proteinuria (defined as ≥2+ protein on dipstick, >300 
mg total protein within a 24-hour urine collection or protein/creatinine ratio >30 
mg/mmol).8-10 In this trial eclampsia did not occur. Women from the randomised 
induction and expectant monitoring groups, as well as non-randomised women, 
were included in the current study, because at start of the HYPITAT trial all women 
had comparable baseline characteristics. 
Exclusion  criteria  for  the  current  study  were  multiple  pregnancy,  breech 
presentation, previous caesarean delivery, diabetes mellitus, renal disease, cardiac 
disease,  pre-existing  hypertension  treated  with  antihypertensive  medication, 
gestational diabetes requiring insulin therapy, haemolysis, elevated liver enzymes, 
and low platelets (HELLP) syndrome and severe hypertension defined as systolic 
blood pressure >170 mmHg, diastolic blood pressure >110 mmHg and severe 
proteinuria (>5 grams protein in a 24 hours urine collection). Data collection included 
maternal age, ethnic origin, parity, obstetrical history, general history, gestational 
age at time of admission to the hospital (LEMMoN) or at study entry (HYPITAT), 
body  mass  index  (BMI)  at  first  antenatal  appointment,  smoking  habits  during 
pregnancy and educational level. We also collected systolic and diastolic blood 
pressures, proteinuria, use of antihypertensive drugs prior to the first eclamptic 
seizure and laboratory measurements (haemoglobin, haematocrit, platelets, uric 
acid, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) 
and lactate dehydrogenase (LDH)) at time of admission to the hospital for cases 
and at study entry for controls. Furthermore, we collected information concerning 
the delivery, like gestational age at delivery, onset of labour and mode of delivery. 
Calculation of gestational age was based either on ultrasound, or on the first day of 
the last menstrual period.
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Development of adverse maternal and neonatal outcomes was reported for cases 
and controls. Adverse maternal outcome measures were maternal mortality, severe 
hypertension (diastolic blood pressure >110 mmHg or systolic blood pressure >170 
mmHg), severe proteinuria (>5 grams protein in a 24 hours urine collection), HELLP 
syndrome (decreased platelet count (<100 x109/L) and increased liver enzymes 
(AST >70 U/L or ALT >70 U/L)), obstetric haemorrhage (>1000 ml blood loss within 
24 hours after delivery), manual delivery of the placenta, admission to an intensive 
care unit and prolonged stay in the hospital. Adverse neonatal outcome measures 
were fetal or neonatal mortality, 5-minute apgar score <7, arterial pH <7.05 and 
admission to a neonatal intensive care unit.
The amount of missing data at admission or at study entry varied between 0% 
for the variables maternal age, parity, history of fetal loss and miscarriage versus 
40% for the variable educational level. Missing data of the predictive variables 
were imputed. In multivariable prognostic research complete case analysis should 
be avoided and multiple imputation methods are known to be superior to other 
imputation methods.11 Multiple imputation was performed using the mice (multiple 
imputation by chained equations) procedure.12 This procedure assumes that the 
distribution of each variable with missing values can be modeled on the basis of the 
other variables plus the clinical outcome of interest. Logistic regression was used 
for a categorical outcome variable and linear regression was used for continuous 
variables. The method estimates a distribution of the variable with missing values, 
taking all aspects of uncertainty in the imputation into account. We generated five 
imputed datasets.
The distribution of risk indicators among cases with and controls without eclampsia 
are expressed as median (5th–95th percentile) or number (%). The Kolmogorov–
Smirnov test was applied to assess normality of the data. Group differences were 
tested using the unpaired Student’s t-test in case of normal distribution and the 
nonparametric Mann–Whitney U test in case of skewed distribution. Categorical 
variables  were  compared  using  chi-square  statistics.  Maternal  and  neonatal 
outcomes and data concerning the delivery are presented as odds ratio (OR) with 
95% confidence interval (CI).
Spearman’s rank correlation test was used to find correlations between variables. 
Using the imputed multiple dataset, logistic regression was performed to identify 
risk indicators for eclampsia among clinical characteristics and laboratory findings. 
For  both  dichotomous  and  continuous  variables  univariable  pooled  ORs  with 
95% CI, as well as p-values, were calculated. Subsequently, multivariable logistic 
regression analysis with simultaneous inclusion of variables was performed to 
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all predicting variables reaching a p<0.50 in the univariable analysis. p=0.20 was 
used as a threshold for variables to stay in the model. The continuous variables 
that emerged as independent risk indicators in the multivariable analyses, were 
also categorized into quintiles and entered as categorical variables in the logistic 
regression  to  determine  the  cut-off  points  for  increased  risk  of  developing 
eclampsia.
To evaluate the discriminative performance of the logistic model, the area under 
the  Receiver  Operating  Characteristic  (ROC)  curve  was  calculated,  comparing 
the actual outcome to the predicted outcome. The ROC-curve was created after 
aggregating the five imputed datasets. Statistical analyses were conducted using 
PASW Statistics 17.0 (SPSS inc. Chicago, Illinois).
Extent of overfitting of the model, i.e. optimism, was assessed with bootstrapping 
in R.13 Two hundred bootstrap samples were drawn from each imputation set. In 
each bootstrap sample, the entire modelling process was repeated. The bootstrap 
procedure yields a ROC area corrected for optimism and a shrinkage factor to 
adjust the model for overfitting.
RESULTS
A total of 222 eclamptic women were included in the LEMMoN study. Of nine cases, 
we did not receive detailed information, leaving 213 cases available for analysis. Of 
these, 137 women (64%) were excluded from the current study for one or more of 
the following reasons: eclampsia occurring before 36 weeks of gestation (n=74), 
diabetes mellitus (n=4), pre-existing hypertension treated with antihypertensive 
medication (n=3), multiple pregnancy (n=21), previous caesarean delivery (n=15), 
a child in breech presentation (n=8) or first eclamptic seizure occurring prior to 
referral to the obstetrician (n=13). Subsequently, we excluded women who had 
HELLP  syndrome  (n=7),  severe  hypertension  (n=9)  or  severe  proteinuria  (n=9) 
at time of admission to the hospital. From the HYPITAT trial four patients were 
excluded,  because  they  had  severe  hypertension  at  time  of  randomisation. 
Ultimately, 76 cases from the LEMMoN study were compared to 1149 controls 
from the HYPITAT trial. 
 
Table  1  shows  the  distribution  of  potential  risk  indicators  between  cases  and 
controls at time of admission to the hospital (LEMMoN) or at study entry (HYPITAT). 
Cases were younger (29.0 [5th–95th percentile 20.0–36.5] vs 30.0 [22.0–38.0] years, 
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p=0.04) and at admission they had higher systolic blood pressures, more often a 
dipstick of 2+ or 3+, and more aberrant laboratory measurements as compared to 
controls at study entry. 
 
The  results  of  the  univariable  and  multivariable  regression  analysis  are  shown 
in Table 1. The clinical characteristics which appeared to be risk indicators for 
eclampsia in univariable analysis at admission or at study entry were maternal age, 
systolic blood pressure, 2+ and 3+ protein on dipstick. Laboratory measurements 
associated  with  eclampsia  were  platelet  count,  uric  acid,  creatinine,  AST,  ALT 
and LDH. In Spearman’s rank correlation haemoglobin and haematocrit (p<0.001) 
and AST and ALT (p<0.001) revealed to be correlated. Therefore haematocrit and 
ALT were not considered in multivariable analysis. Maternal age, non-Caucasian 
ethnicity, systolic blood pressure, 2+ and 3+ protein on dipstick, uric acid, creatinine, 
AST and LDH were statistically significant associated with the development of 
eclampsia in multivariable analysis. Other variables included in the model were 
previous fetal loss, previous miscarriage, gestational age and platelets. All these 
risk indicators contributed to the final prediction model. The corresponding ROC 
curve is shown in Figure 1 with an area under the curve of 0.92 (95% CI 0.89-0.95). 
Bootstrapping showed minimal optimism of the model (AUC varied from 0.88 to 
0.89), indicating that the model holds for the overall population.
Figure 1. Receiver operating characteristic (ROC) curve of prediction model for eclampsia
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in the multivariable analyses, were categorized into quintiles to determine cut-off 
points  for  increased  risk  of  developing  eclampsia.  In  case  of  systolic  blood 
pressure >155 mmHg, AST >30 U/L, creatinine >74 μmol/L and LDH >400 U/L an 
increased risk of eclampsia was shown. For the continuous variables maternal age, 
gestational age, platelets and uric acid the risk for developing eclampsia increased 
or decreased gradually.
Table 1. Risk indicators for eclampsia at admission (cases) and at study entry (controls): Univariable 
and multivariable analysis
Characteristics  Cases
(n=76)
Controls
(n=1149)
Univariable analysis Multivariable analysis
OR 95% CI p OR 95% CI p
Maternal age (years)* 29.0 (20.0-36.5) 30.0 (22.0-38.0) 0.95 (0.90-1.00) 0.032 0.93 (0.87-0.99) 0.047
Nulliparous 63 (83%) 838 (73%) 1.8 (0.98-3.31) 0.060
Non-Caucasian ethnicity 13 (17%) 124 (12%) 1.7 (0.90-3.09) 0.106 2.8 (1.09-7.23) 0.034
High education level 14 (26%) 243 (36%) 0.85 (0.40-1.80) 0.686
Fetal loss in history 3 (4%) 22 (2%) 2.1 (0.62-7.20) 0.235 4.5 (0.77-25.7) 0.097
Miscarriage in history 11 (15%) 269 (23%) 0.55 (0.29-1.06) 0.076 0.66 (0.29-1.50) 0.323
Body mass index at first antenatal appointment (kg/m2) 24.9 (19.0-37.7) 25.4 (19.8-36.6) 0.97 (0.92-1.02) 0.260
Smoking during pregnancy 7 (13%) 131 (12%) 1.10 (0.49-2.49) 0.817
Gestational age 38.7 (36.0-41.2) 38.4 (36.3-40.4) 1.10 (0.88-1.38) 0.416 1.3 (0.97-1.62) 0.097
Blood pressure (mmHg)
Systolic * 150 (123-170) 140 (125-160) 1.04 (1.02-1.06) <0.001 1.1 (1.02-1.07) 0.001
Diastolic  98 (80-110) 96 (89-105) 0.98 (0.95-1.02) 0.366
Dipstick *
Negative 9 (13%) 288 (31%)
Trace 8 (11%) 234 (25%) 1.1 (0.41-3.02) 0.837 1.0 (0.29-3.63) 0.977
+ 8 (11%) 246 (27%) 1.1 (0.42-3.08) 0.806 0.60 (0.16-2.24) 0.453
++ 25 (36%) 109 (12%) 6.1 (2.73-13.7) <0.001 3.4 (1.06-11.2) 0.050
+++ 20 (29%) 50 (5%) 9.7 (4.06-23.0) <0.001 6.2 (1.97-19.5) 0.003
Use of antihypertensive drugs 8 (11%) 151 (13%) 0.78 (0.37-1.65) 0.512
Laboratory measurements 
Haemoglobin (mmol/L) 7.65 (6.34-8.87) 7.50 (6.30-8.60) 1.2 (0.80-1.90) 0.356
Haematocrit (L/L)† 0.36 (0.30-0.43) 0.36 (0.30-0.41) 1.6 (0.56-4.29) 0.411
Platelets (x109/L) * 200 (105-319) 227 (138-346) 0.99 (0.99-1.00) 0.002 0.995 (0.99-1.00) 0.075
Uric acid (mmol/L) *† 0.37 (0.26-0.54) 0.31 (0.21-0.46) 1.8 (1.96-3.70) 0.004 1.8 (1.20-2.62) 0.004
Creatinine (μmol/L) * 77.0 (54.2-116) 61.0 (45.0-85.0) 1.05 (1.03-1.06) <0.001 1.02 (1.01-1.04) <0.001
Aspartate aminotransferase (U/L) * 30.0 (12.1-167) 20.0 (10.0-38.0) 1.05 (1.03-1.07) <0.001 1.03 (1.00-1.04) 0.012
Alanine aminotransferase (U/L) * 15.0 (5.00-127) 12.0 (6.00-31.5) 1.04 (1.02-1.05) <0.001
Lactate dehydrogenase (U/L) * 411 (207-708) 302 (157-475) 1.01 (1.01-1.01) <0.001 1.01 (1.00-1.01) <0.001
The distribution of risk indicators among cases with and controls without eclampsia are expressed 
as median (5th-95th percentile) or numbers (%). * Variables with a significant distribution between 
cases and controls (p< 0.05). OR = Odds Ratio; CI = confidence interval. If the variable had a p< 
0.50 in the univariable analysis, it was considered in the final (multivariable) model. A p= 0.20 was 
used as a threshold for variables to stay in the final model. † Scale adapted by multiplication with a 
factor 10 for regression analyses.
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Table 2 shows maternal outcome, data concerning delivery and neonatal outcome. 
Maternal mortality did neither occur in cases nor in controls. Women in the case 
group were more often diagnosed with severe hypertension, severe proteinuria, 
HELLP syndrome and obstetric haemorrhage as compared to the control group. 
Cases were admitted more often to an intensive care unit and their duration of stay 
in the hospital was significantly longer.
 
Table 1. Risk indicators for eclampsia at admission (cases) and at study entry (controls): Univariable 
and multivariable analysis
Characteristics  Cases
(n=76)
Controls
(n=1149)
Univariable analysis Multivariable analysis
OR 95% CI p OR 95% CI p
Maternal age (years)* 29.0 (20.0-36.5) 30.0 (22.0-38.0) 0.95 (0.90-1.00) 0.032 0.93 (0.87-0.99) 0.047
Nulliparous 63 (83%) 838 (73%) 1.8 (0.98-3.31) 0.060
Non-Caucasian ethnicity 13 (17%) 124 (12%) 1.7 (0.90-3.09) 0.106 2.8 (1.09-7.23) 0.034
High education level 14 (26%) 243 (36%) 0.85 (0.40-1.80) 0.686
Fetal loss in history 3 (4%) 22 (2%) 2.1 (0.62-7.20) 0.235 4.5 (0.77-25.7) 0.097
Miscarriage in history 11 (15%) 269 (23%) 0.55 (0.29-1.06) 0.076 0.66 (0.29-1.50) 0.323
Body mass index at first antenatal appointment (kg/m2) 24.9 (19.0-37.7) 25.4 (19.8-36.6) 0.97 (0.92-1.02) 0.260
Smoking during pregnancy 7 (13%) 131 (12%) 1.10 (0.49-2.49) 0.817
Gestational age 38.7 (36.0-41.2) 38.4 (36.3-40.4) 1.10 (0.88-1.38) 0.416 1.3 (0.97-1.62) 0.097
Blood pressure (mmHg)
Systolic * 150 (123-170) 140 (125-160) 1.04 (1.02-1.06) <0.001 1.1 (1.02-1.07) 0.001
Diastolic  98 (80-110) 96 (89-105) 0.98 (0.95-1.02) 0.366
Dipstick *
Negative 9 (13%) 288 (31%)
Trace 8 (11%) 234 (25%) 1.1 (0.41-3.02) 0.837 1.0 (0.29-3.63) 0.977
+ 8 (11%) 246 (27%) 1.1 (0.42-3.08) 0.806 0.60 (0.16-2.24) 0.453
++ 25 (36%) 109 (12%) 6.1 (2.73-13.7) <0.001 3.4 (1.06-11.2) 0.050
+++ 20 (29%) 50 (5%) 9.7 (4.06-23.0) <0.001 6.2 (1.97-19.5) 0.003
Use of antihypertensive drugs 8 (11%) 151 (13%) 0.78 (0.37-1.65) 0.512
Laboratory measurements 
Haemoglobin (mmol/L) 7.65 (6.34-8.87) 7.50 (6.30-8.60) 1.2 (0.80-1.90) 0.356
Haematocrit (L/L)† 0.36 (0.30-0.43) 0.36 (0.30-0.41) 1.6 (0.56-4.29) 0.411
Platelets (x109/L) * 200 (105-319) 227 (138-346) 0.99 (0.99-1.00) 0.002 0.995 (0.99-1.00) 0.075
Uric acid (mmol/L) *† 0.37 (0.26-0.54) 0.31 (0.21-0.46) 1.8 (1.96-3.70) 0.004 1.8 (1.20-2.62) 0.004
Creatinine (μmol/L) * 77.0 (54.2-116) 61.0 (45.0-85.0) 1.05 (1.03-1.06) <0.001 1.02 (1.01-1.04) <0.001
Aspartate aminotransferase (U/L) * 30.0 (12.1-167) 20.0 (10.0-38.0) 1.05 (1.03-1.07) <0.001 1.03 (1.00-1.04) 0.012
Alanine aminotransferase (U/L) * 15.0 (5.00-127) 12.0 (6.00-31.5) 1.04 (1.02-1.05) <0.001
Lactate dehydrogenase (U/L) * 411 (207-708) 302 (157-475) 1.01 (1.01-1.01) <0.001 1.01 (1.00-1.01) <0.001
The distribution of risk indicators among cases with and controls without eclampsia are expressed 
as median (5th-95th percentile) or numbers (%). * Variables with a significant distribution between 
cases and controls (p< 0.05). OR = Odds Ratio; CI = confidence interval. If the variable had a p< 
0.50 in the univariable analysis, it was considered in the final (multivariable) model. A p= 0.20 was 
used as a threshold for variables to stay in the final model. † Scale adapted by multiplication with a 
factor 10 for regression analyses.
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and  a  spontaneous  onset  of  labour  can  not  be  compared  between  cases  and 
controls,  because  controls  were  randomised  for  either  induction  or  expectant 
monitoring. Vaginal instrumental delivery rate and overall caesarean delivery rate 
were higher among cases.
Table 2. Maternal outcome, data concerning delivery and neonatal outcome
Characteristic Cases (n=76) Controls (n=1149) OR (95% CI) or p
Maternal outcome
Maternal mortality 0 0
Systolic blood pressure >170 mmHg 44 (58%) 210 (18%) 6.08 (3.77-9.82)
Diastolic blood pressure >110 mmHg 43 (57%) 248 (22%) 4.68 (2.91-7.53)
Severe proteinuria (>5 g/24 hrs) 3 (4%) 12 (1%) 3.89 (1.08-14.1)
HELLP syndrome 16 (21%) 24 (2%) 12.5 (6.31-24.8)
Postpartum haemorrhage 17 (22%) 118 (10%) 2.52 (1.42-4.46)
Admission to an intensive care unit 25 (33%) 28 (2%) 19.6 (10.7-36.0)
Duration of maternal stay in hospital (days) 8.00 (4.00-16.0) 2.00 (1.00-6.00) <0.001
Data concerning delivery
Gestational age at delivery (weeks)  39.5 (36.7-41.8) 39.6 (37.1-41.3) 0.847
Use of analgesics during delivery <0.001
None 21 (28%) 637 (56%)
Pethidine/ Phenergan/ Nubaine 18 (24%) 170 (15%)
Epidural 9 (12%) 255 (22%)
Spinal 17 (22%) 27 (2%)
Complete analgesia 11 (15%) 0
Other 0 59 (5%)
Onset of labour <0.001
Spontaneous 28 (37%) 392 (34%)
Induction  39 (51%) 749 (65%)
Planned caesarean delivery 9 (12%) 8 (1%)
Mode of delivery <0.001
Spontaneous 16 (21%) 792 (69%)
Vaginal instrumental delivery 28 (37%) 176 (15%)
Caesarean delivery 32 (42%) 181 (16%)
Delivery of the placenta <0.001
Spontaneous 42 (55%) 920 (80%)
Manual 2 (3%) 44 (4%)
During caesarean delivery 32 (42%) 181 (16%)
Neonatal outcome
Fetal or neonatal mortality 2 (3%) 0
Apgar Score after 5 minutes <7 5 (7%) 22 (2%) 3.69 (1.36-10.0)
Neonatal arterial pH <7.05 5 (14%) 36 (4%) 3.95 (1.45-10.8)
Admission to a neonatal intensive care unit 14 (19%) 26 (3%) 8.55 (4.24-17.2)
Gender (male) 48 (63%) 576 (50%) 1.71 (1.06-2.76)
Birth weight (g) 3185 (2430-4343) 3370 (2500-4210) 0.124
Data are median (5th-95th percentile) or numbers (%). OR = Odds Ratio; CI = confidence interval
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We observed more adverse neonatal outcome measures in cases as compared 
to controls. Among cases one fetus died with unknown reason and one neonate 
died because of asphyxia whereas among controls there were no fetal or neonatal 
deaths.
COMMENT
In this case-control study we evaluated risk indicators for eclampsia in women 
diagnosed  with  GH  or  mild  PE  beyond  36  weeks  of  gestation.  We  found  that 
maternal age, non-Caucasian ethnicity, systolic blood pressure >155 mmHg, ≥2+ 
protein on dipstick, elevated uric acid, creatinine >74 μmol/L, AST >30 U/L and LDH 
>400 U/L were statistically significant independent predictors for the occurrence 
of eclampsia. Other factors incorporated in the model were previous fetal loss, 
previous miscarriage, gestational age and low platelet count. The discriminative 
performance of the prediction model was excellent.
 
We think our study is of importance, because it is the first study in which risk 
indicators  for  eclampsia  are  identified  in  women  with  hypertensive  disorders 
beyond 36 weeks of gestation. However, limitations are also present. First, various 
prognostic  predictor  variables  had  varying  percentages  of  missing  values.  The 
missing data of the predictive variables were imputed, because deleting them 
would lead to a loss of statistical power in multivariable analysis and, more seriously, 
potentially biased results.11 Second, case-control studies are known to give more 
optimistic results on the predictive capacity of a model than cohort studies, as the 
latter better mimic clinical reality. In case-control studies, the controls are usually 
patients on the ‘healthy’ side of the disease spectrum, whereas cases are women 
with the most severe presentation of disease.14 Thus, the discriminative capacity of 
our model might appear to be overestimated when validated in another cohort. The 
third limitation of the study might be the fact that controls from the HYPITAT trial 
were collected from 38 hospitals in the Netherlands, whereas cases were collected 
from all 98 Dutch hospitals. However, we think that women in the case group are 
comparable to women in the control group, because local protocols are based on 
national guidelines of the Dutch Society for Obstetrics and Gynaecology.15 Finally, 
the inclusion period was slightly different for cases and controls. However, no large 
studies or new guidelines on the subject were presented in this period, so it is 
unlikely that management over the years has been changed.
Although predictive indicators for eclampsia have been suggested in literature, 
evidence on the accuracy of various tests to predict eclampsia in women with 
hypertensive  disorders  in  pregnancy  is  limited.  In  low-income  countries  the 
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18 In the Netherlands multiple pregnancy, nulliparity, young age, black ethnicity and 
overweight seem to be the most important risk factors for eclampsia as compared 
with healthy (non-preeclamptic) pregnant women.4
Only two case-control studies reported risk factors of eclampsia in women with 
hypertensive disorders in pregnancy.19,20 In multivariable analysis Ben Salem et 
al. indicated vivid deep tendon reflexes and uric acid concentration ≥0.35 mmol/l 
as risk factors.19 Witlin et al. found headache and deep tendon reflexes to be 
independent risk factors for eclampsia.20 The predictive indicators for eclampsia 
suggested in these studies might very well be different from the indicators we 
found, because women with severe PE were also included in these studies, whereas 
we only investigated risk indicators in women with mild hypertensive disease of 
pregnancy. Moreover, these studies also concerned preterm pregnancies whereas 
we only considered pregnancies beyond 36 weeks of gestation. To our knowledge, 
studies describing risk indicators for eclampsia in pregnancies beyond 36 weeks of 
gestation have never been published.
It  has  been  known  that  cerebral  haemorrhage  is  an  important  cause  of  death 
in  patients  with  eclampsia.  Martin  et  al.  found  that  a  systolic  blood  pressure 
threshold of approximately 155-160 mmHg, usually without developing a diastolic 
blood pressure more than 105 mmHg, preceded cerebral haemorrhage in a group 
of 28 women with severe PE and eclampsia.21 They concluded that women who 
have severe PE or eclampsia with severe systolic hypertension are especially at 
risk for cerebral haemorrhage. This finding is confirmed in our study, in which 
severe systolic blood pressure (>155 mmHg) is associated with the occurrence of 
eclampsia, in contrast to severe diastolic blood pressure. Thus, control of severe 
systolic hypertension is an important facet in the management of women with 
increased risk for eclampsia.21,22
Previously, the severity of proteinuria in PE has been considered a predictor of 
maternal complications, including eclampsia,23,24 whereas others have been less 
sanguine about the relationship.25,26 We identified that proteinuria of ≥2+ in a 
dipstick specimen strongly increased the risk of eclampsia. Therefore, although 
the results in literature are contrary, we think that the level or degree of proteinuria 
is extremely valuable for clinical decision making in preventing eclampsia.
Several studies reported a positive correlation between elevated maternal serum 
uric acid levels and adverse maternal outcomes but there are little data exploring 
the accuracy of uric acid to predict eclampsia.27 Thangaratinam et al. identified uric 
acid level as a poor predictor of eclampsia, although they found that a raised serum 
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uric acid was associated with an almost doubled risk of eclampsia.28 We repeated 
the meta-analysis with a bivariate meta-analytic model and a decision analysis to 
assess the value of serum uric acid in the management of women with PE and 
found that serum uric acid seems to be a useful test in predicting eclampsia.29 This 
finding was confirmed in our current study.
Accurate  prediction  of  eclampsia  still  constitutes  a  serious  clinical  challenge, 
and is necessary for successful management. The risk indicators found in this 
case-control study can be helpful in identifying women who are at highest risk for 
developing eclampsia and subsequently limiting mortality and morbidity caused 
by this life-threatening condition. In the HYPITAT trial, we already reported that 
in women without a previous caesarean delivery induction of labour should be 
the preferred strategy.5 The present study shows that in women with high risk 
for developing eclampsia labour should be induced immediately, without waiting 
until the next morning, and that prophylactic treatment with magnesium sulphate 
should be applied. Magnesium sulphate halves the risk of eclampsia with a number 
needed to treat of 91 (95% CI 63-143), and probably reduces the risk of maternal 
death.6
 
In  conclusion,  continuous  evaluation  of  maternal  condition,  complemented  by 
haematologic and biochemical parameters, should be standard management in 
women with GH or mild PE at term to identify women at increased risk of developing 
eclampsia. The identified predictors in this study may provide physicians guidance 
to induce labour immediately and to start prophylactic treatment with magnesium 
sulphate.
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Prediction of postpartum 
haemorrhage in women with 
gestational hypertension or mild 
pre-eclampsia at termABSTRACT
Objective To assess whether postpartum haemorrhage (PPH) can be predicted in 
women with gestational hypertension or mild pre-eclampsia at term.
Methods For this cohort study we used data from our multicentre randomised 
controlled trial (HYPITAT trial). PPH was defined as blood loss >1000 ml within 
24h after delivery. Two models were created to assess the predictive capacity 
of PPH. Model A included only antepartum variables, whereas model B included 
both antepartum and intrapartum variables. Logistic regression was performed to 
predict the occurrence of PPH. The predictive capacity of the models was assessed 
with receiver-operating-characteristic (ROC) analysis and calibration.
Results We included 1132 women, of whom 118 (10.4%) had PPH. Maternal age 
(OR 1.03), body mass index (OR 0.97), gestational age at randomisation (OR 1.19), 
proteinuria  (OR  3.06  for  +++  on  dipstick),  platelets  (OR  0.997)  and  aspartate 
aminotransferase  (OR  0.98)  were  independent  antepartum  predictors  of  PPH. 
Intrapartum variables incorporated in the model were gestational age at delivery 
(OR 1.21), birth weight (OR 1.36), mode of delivery (OR 1.06 and 1.67 for vaginal 
instrumental and caesarean delivery, respectively) and episiotomy (OR 2.1). Model 
A showed moderate discrimination, with an area under the ROC-curve of 0.63 (95% 
CI 0.57-0.69), whereas model B was slightly superior (AUC 0.69, 95% CI 0.63-0.74). 
Calibration was poor for model A (Hosmer-Lemeshow p-value=0.17) but better for 
model B (Hosmer-Lemeshow p-value=0.57). 
Conclusion In women with gestational hypertension or mild pre-eclampsia at term, 
PPH can be predicted from antepartum and intrapartum variables. The identified 
predictors should alert clinicians managing labour in these women.
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INTRODUCTION
Hypertensive  disorders  during  pregnancy  are  associated  with  considerable 
maternal morbidity and mortality.1-3 In literature it is described that women with 
hypertensive disorders are at increased risk of developing postpartum haemorrhage 
(PPH).4-8 Severe PPH can result in serious morbidity, such as adult respiratory 
distress syndrome, coagulopathy, shock, loss of fertility, Sheehan syndrome and 
ultimately maternal mortality.9,10
Until  recently,  worldwide  there  was  no  evidence  on  how  to  manage  women 
with mild hypertensive disease at term. In view of this dilemma, our study group 
performed a randomised controlled trial on the subject (HYPITAT trial), in which 
we found that induction of labour was associated with better maternal outcome 
as  compared  to  expectant  monitoring,  without  resulting  in  a  higher  caesarean 
delivery rate.11 This trial result was mainly based on a difference in progression 
to severe diseases (systolic blood pressure ≥170 mmHg, diastolic blood pressure 
≥110 mmHg or proteinuria ≥5 gram/ 24 hours) between induction of labour and 
expectant monitoring. Since PPH was found to be associated with hypertensive 
disorders of pregnancy, we included PPH  as primary outcome of this study as 
well.4-6 A positive effect of induction of labour on the incidence of PPH was not 
observed, but the overall 10% incidence of PPH found in our study was markedly 
higher than the 0.4-1.3% risk of PPH observed in low risk populations.4,12 The 
same phenomenon has been described in the LEMMoN study which revealed an 
incidence for PPH of 4.0 per 1.000 deliveries in the Netherlands, whereas in 11.2% 
of cases PPH is accompanied by pre-eclampsia (PE).13   
 
Because  of  this  high  incidence  of  PPH  in  women  with  a  pregnancy  related 
hypertensive disorder, identification of these women with increased risk of PPH is 
of major importance. We aimed at identification of women who are at increased 
risk of developing PPH to facilitate the best management for the individual patient. 
Prediction of PPH could be used as a guidance to pay particular attention to the 
woman during the early postpartum period and to supply effective prophylactic 
measures, obtaining a decrease in PPH incidence.
METHODS
For the present study we used data from the HYPITAT trial (clinical trial register 
number  ISRCTN  08132825).11  This  multicentre  parallel  randomised  controlled, 
open-label trial, was conducted in six academic and 32 non-academic hospitals in 
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137the Netherlands between October 2005 and March 2008. In short, patients with a 
singleton pregnancy with a child in cephalic position and a gestational age between 
36+0  and  41+0  weeks  whose  pregnancy  was  complicated  with  gestational 
hypertension (GH) or mild PE were randomly allocated to either induction of labour 
or expectant monitoring. Patients who did not give consent for randomisation, but 
who provided authorization for using their medical data, were treated according 
to local protocol. Patients allocated to induction of labour, were induced within 
24 hours after randomisation. Patients in the expectant group were monitored 
until the onset of spontaneous delivery or until there was a medical indication for 
delivery. Monitoring consisted of frequent maternal blood pressure measurements, 
assessments of proteinuria, laboratory tests and fetal condition.
In the present study we combined the randomised and non-randomised women 
in one cohort. The endpoint PPH considered in this study was defined as blood 
loss  >1000  ml  within  24  hours  after  delivery.9,14  Two  models  were  created  to 
assess whether this outcome could be predicted. First we created an antepartum 
model (model A) in which we evaluated whether PPH was predictable from clinical 
characteristics (parity, maternal age, smoking habits, prepregnancy body mass 
index (BMI), ethnicity, gestational age at randomisation, education level, previous 
abortion, diastolic and systolic blood pressure) or laboratory findings (haemoglobin, 
haematocrit,  platelets,  uric  acid,  creatinine,  aspartate  aminotransferase  (AST), 
alanine  aminotransferase  (ALT),  lactate  dehydrogenase  (LDH)  and  proteinuria). 
The  second  model  (model  B)  included  these  antepartum  variables,  as  well  as 
intrapartum variables, such as gestational age at delivery, epidural anaesthesia, 
duration of dilation stage or bearing down stage, use of oxytocine, onset of labour, 
mode of delivery, birthweight and perineal rupture. Calculation of gestational age 
was based either on ultrasound, or on the first day of the last menstrual period.
Several potentially prognostic variables had varying percentages of missing values. 
Exclusion of these variables would lead to a loss of statistical power in multivariable 
analysis and, more seriously, potentially biased results and therefore missing data 
of  the  predictive  variables  were  imputed.  In  multivariable  prognostic  research 
complete case analysis should be avoided and multiple imputation methods are 
known  to  be  superior  to  other  imputation  methods.15  Multiple  imputation  was 
performed using PASW Statistics 17.0 (SPSS inc. Chicago, Illinois), in which we 
generated five imputed datasets.
Data Analysis
The Kolmogorov-Smirnov test was applied to assess normality of the data. Group 
differences between women with and women without PPH were tested with the 
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unpaired Student’s t-test in case of normal distribution and with the nonparametric 
Mann-Whitney U test in case of skewed distribution. Categorical variables were 
compared by chi-square statistics.
Using the imputed multiple dataset, logistic regression was performed to predict 
the occurrence of PPH. For both dichotomous and continuous variables univariate 
pooled  odds  ratios,  and  95%  confidence  intervals  (CI),  as  well  as  p-values, 
were calculated. Subsequently, multivariable logistic regression analysis with a 
stepwise backward selection procedure of predictors was performed to construct 
the two prediction models for PPH. Spearman’s rank correlation test was used 
to find correlations between variables. In case of correlated variables, the least 
significant variable was excluded from multivariable analysis. Since the purpose of 
a prediction model is to reach optimal predictive power, our multivariable analysis 
was not limited to significant prognostic variables but considered all prognostic 
variables with a significance level of <0.40 in the univariate analysis.16
To evaluate the discriminative performance of the logistic model, the area under 
the  Receiver  Operating  Characteristic  (ROC)  curve  was  calculated,  comparing 
the actual outcome to the outcome predicted by the model. The ROC-curve was 
created using aggregated average predicted probabilities from the five imputed 
datasets.  We also evaluated the calibration of the prediction model by plotting 
observed and predicted event rates for 10 subgroups of patients on the basis 
of deciles of the predicted probability of PPH.17 Per group, the mean predicted 
probability,  aggregated  from  the  five  imputed  datasets,  as  well  as  the  mean 
observed PPH rate was calculated. In case of perfect calibration, all points would 
be situated on the line that describes X=Y, i.e. the predicted probability equals 
the  observed  probability.  The  reliability  of  the  model  was  estimated  with  the 
Hosmer and Lemeshow test for goodness-of-fit, where low p-values indicate poor 
calibration. Calculations were performed with the PASW Statistics 17.0 (SPSS inc. 
Chicago,  Illinois)  and  graphs  were  produced  using  GraphPad  Prism  (GraphPad 
Software, Inc. La Jolla, USA). Extent of overfitting of the model, i.e. optimism, was 
assessed with bootstrapping in R.18 Two hundred bootstrap samples were drawn 
from each imputation set. In each bootstrap sample, the entire modelling process 
was repeated. The bootstrap procedure yields a ROC area corrected for optimism 
and a shrinkage factor to adjust the model for overfitting.
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From  the  HYPITAT  trial  we  identified  1132  eligible  women  for  participation  in 
the present study. Among this cohort 118 women (10.4%) developed PPH, and 
consequently in 1014 women (89.6%) PPH did not occur.
The distribution of potential predictors between women with and women without 
PPH is shown in Table 1. During the antepartum period of pregnancy there were no 
differences in clinical characteristics and laboratory findings between both groups. 
Whereas intrapartum, women who developed PPH had a higher gestational age at 
delivery (p=0.007), a longer bearing down stage (p=0.019), a child with a higher 
birth weight (p=0.009), more episiotomies (p=0.024) and more often a retained 
placenta which was removed manually (p<0.001).
Table  1.  Distribution  of  predictors  among  patients  with  and  patients  without  postpartum 
haemorrhage at term.
Predictors Patients with postpartum 
haemorrhage
(n=118)
Patients without 
postpartum haemorrhage
(n=1014)
Clinical characteristics
Nulliparous 90 (76%) 734 (72%)
Maternal age (years) 30.0 (23.0-39.0) 30.0 (22.0-38.0)
Maternal smoking  15 (13%) 113 (12%)
Prepregnancy body mass index  (kg/m2) 24.5 (19.0-38.1) 25.4 (19.9-36.4)
Non-Caucasian ethnicity 15 (14%) 109 (12%)
Higher education level 24 (39%) 217 (36%)
Previous abortion 29 (25%) 238 (24%)
Gestational age at randomisation 38.7 (36.7-40.6) 38.3 (36.3-40.4)
Blood pressure (mmHg)
Systolic 140 (125-160) 140 (124-162)
Diastolic 96 (90-105) 96 (88-105)
Laboratory findings
Dipstick
Negative 27 (28%) 255 (31%)
Trace 26 (27%) 205 (25%)
+ 26 (27%) 217 (27%)
++ 11 (11%) 95 (12%)
+++ 8 (8%) 42 (5%)
Haemoglobin (mmol/L)  7.5 (6.1-8.6) 7.5 (6.4-8.6)
Haematocrit (L/L) 0.36 (0.30-0.40) 0.36 (0.30-0.41)
Platelets (x109/L)* 209 (137-345) 228 (139-345)
Uric acid (mmol/L) 0.31 (0.19-0.46) 0.31 (0.21-0.46)
Creatinine (μmol/L) 61 (45-92) 61 (45-85)
Aspartate aminotransferase (U/L) 19.5 (9.30-38.1) 20.0 (11.0-38.7)
1408
chapter
Factors significantly associated with PPH in the univariate analysis were platelet 
count (OR 0.997 per unit, p=0.05), gestational age at delivery (OR 1.3 per week, 
p=0.003), mode of delivery (OR 1.7 for vaginal instrumental delivery and OR 1.4 for 
caesarean delivery versus spontaneous delivery, p=0.04 and p=0.19), birth weight 
(OR  1.6  per  kg,  p=0.008)  and  episiotomy  (OR  1.6,  p=0.03)  (Table  2).  Placenta 
delivery  was  in  univariate  analysis  strongly  associated  with  PPH  (OR  25.0  for 
retained placenta versus spontaneous placental delivery, p<0.001). This variable 
was excluded from multivariable analysis, as it is obvious that retained placenta is 
already a strong alert for PPH.
Since  more  liberal  p-values  are  advocated  to  increase  the  probability  that  real 
predictors are selected in the model, we selected all prognostic variables with a 
significance level of p<0.40 in the univariate analysis to enter the model. The criterion 
for removal from the model was a p-value >0.50. Haematocrit was excluced from 
Table 1. (cont.)
Predictors Patients with postpartum 
haemorrhage
(n=118)
Patients without 
postpartum haemorrhage
(n=1014)
Alanine aminotransferase (U/L) 13.0 (5.0-34.0) 12.0 (6.0-31.0)
Lactate dehydrogenase (U/L) 334 (161-472) 298 (156-476)
Data concerning delivery
Gestational age delivery (weeks)* 39.8 (37.7-41.4) 39.6 (37.1-41.3)
Epidural anaesthesia 35 (30%) 241 (24%)
Duration of dilation stage (min) 435 (104-2044) 405 (60-2508)
Duration of bearing down stage (min)* 51 (4-167) 34 (4-156)
Use of oxytocine 70 (60%) 596 (59%)
Induction of labour  78 (66%) 668 (66%)
Mode of delivery
Spontaneous 71 (60%) 709 (70%)
Vaginal instrumental delivery 25 (21%) 149 (15%)
Caesarean delivery 22 (19%) 156 (15%)
Birthweight (kg)* 3.50 (2.72-4.39) 3.35 (2.48-4.19)
Perineal rupture (vs none)*
No rupture 35 (30%) 341 (34%)
1st -2nd  27 (23%) 330 (33%)
3rd-4th 2 (2%) 19 (2%)
Episiotomy 53 (45%) 320 (32%)
Placenta delivery*
Spontaneous 66 (57%) 841 (83%)
Manual removal/ retained placenta 28 (24%) 15 (2%)
After caesarean section 22 (19%) 156 (15%)
The distribution of predictors is expressed as median (5th-95th percentile) or numbers (%). *Variables 
with a significant distribution between groups (p < 0.05). 
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141Table  2.  Predictors  of  postpartum  haemorrhage  in  women  with  mild  hypertensive  disease  of 
pregnancy at term: univariable and multivariable analysis of the antepartum model (model A) and 
intrapartum model (model B). 
Predictors Univariable analysis Multivariable analysis  
Model A
Multivariable analysis  
Model B  
OR P 95% CI OR P 95% CI OR P 95% CI
Clinical characteristics
Nulliparous 1.2 .37 (0.79-1.9) 1.4 .15 (0.88-2.3)
Multiparity (para4+) 0.78 .81 (0.10-6.1)
Maternal age (years) 1.03 .16 (0.99-1.1) 1.04 .05 (1.0-1.1) 1.03 .11 (0.99-1.1)
Maternal smoking  1.2 .58 (0.65-2.1)
Prepregnancy body mass index  (kg/m2) 0.97 .12 (0.93-1.01) 0.97 .17 (0.93-1.01) 0.97 .15 (0.93-1.01)
Non-Caucasian ethnicity 1.2 .47 (0.70-2.2)
Higher education level 1.3 .31 (0.78-2.2)
Previous abortion 1.1 .79 (0.68-1.7)
Gestational age at randomisation (weeks) 1.2 .06 (0.99-1.4) 1.2 .03 (1.02-1.4)
Blood Pressure (mmHg)
Systolic 1.003 .67 (0.99-1.02)
Diastolic 1.01 .54 (0.98-1.04)
Laboratory findings
Dipstick (vs negative)
Negative
Trace 1.2 .53 (0.65-2.3) 1.2 .56 (0.64-2.3) 1.2 .56 (0.64-2.3)
+ 1.3 .42 (0.72-2.2) 1.2 .54 (0.67-2.2) 1.3 .36 (0.74-2.3)
++ 1.1 .73 (0.55-2.3) 1.1 .83 (0.52-2.3) 1.2 .59 (0.59-2.5)
+++ 2.2 .08 (0.94-5.3) 2.1 .08 (0.93-4.8) 3.1 .01 (1.3-7.2)
Haemoglobin (mmol/L)  0.85 .25 (0.65-1.1) 0.82 .19 (0.61-1.1)
Haematocrit (L/L x 10)* 0.67 .23 (0.35-1.3)
Platelets (x109/L) 0.997 .05 (0.99-1.00) 0.997 .07 (0.99-1.00) 0.997 .07 (0.99-1.00)
Uric acid (mmol/L x10)* 1.01 .94 (0.76-1.4)
Creatinine (μmol/L) 1.004 .46 (0.99-1.01)
Aspartate aminotransferase (U/L) 0.99 .27 (0.96-1.01) 0.98 .12 (0.96-1.00) 0.98 .19 (0.96-1.01)
Alanine aminotransferase (U/L) 1.00 .94 (0.98-1.02)
Lactate dehydrogenase (U/L) 1.00 .70 (1.00-1.00)
Intrapartum data
Gestational age at delivery (weeks) 1.3 .003 (1.1-1.5) 1.2 .04 (1.01-1.5)
Epidural anaesthesia 1.4 .16 (0.91-2.0)
Duration of dilation stage (min) 1.00 .75 (1.00-1.00)
Duration of bearing down stage (min) 1.00 .28 (0.99-1.00)
Use of oxytocine 1.04 .84 (0.70-1.5)
Induction of labour (vs spontaneous)  1.01 .96 (0.68-1.5)
Mode of delivery (vs spontaneous)
Spontaneous
Vaginal instrumental delivery 1.7 .04 (1.03-2.7) 1.1 .84 (0.61-1.9)
Caesarean delivery 1.4 .19 (0.85-2.3) 1.7 .16 (0.82-3.4)
Birthweight (kg) 1.6 .008 (1.1-2.3) 1.4 .15 (0.90-2.1)
Perineal rupture (vs none)
No rupture
1st -2nd  0.80 .39 (0.47-1.3) 1.1 .74 (0.57-2.2)
3rd-4th 1.1 .92 (0.25-4.6) 1.5 .61 (0.31-7.2)
Episiotomy 1.6 .03 (1.04-2.6) 2.1 .03 (1.07-4.0)
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Table  2.  Predictors  of  postpartum  haemorrhage  in  women  with  mild  hypertensive  disease  of 
pregnancy at term: univariable and multivariable analysis of the antepartum model (model A) and 
intrapartum model (model B). 
Predictors Univariable analysis Multivariable analysis  
Model A
Multivariable analysis  
Model B  
OR P 95% CI OR P 95% CI OR P 95% CI
Clinical characteristics
Nulliparous 1.2 .37 (0.79-1.9) 1.4 .15 (0.88-2.3)
Multiparity (para4+) 0.78 .81 (0.10-6.1)
Maternal age (years) 1.03 .16 (0.99-1.1) 1.04 .05 (1.0-1.1) 1.03 .11 (0.99-1.1)
Maternal smoking  1.2 .58 (0.65-2.1)
Prepregnancy body mass index  (kg/m2) 0.97 .12 (0.93-1.01) 0.97 .17 (0.93-1.01) 0.97 .15 (0.93-1.01)
Non-Caucasian ethnicity 1.2 .47 (0.70-2.2)
Higher education level 1.3 .31 (0.78-2.2)
Previous abortion 1.1 .79 (0.68-1.7)
Gestational age at randomisation (weeks) 1.2 .06 (0.99-1.4) 1.2 .03 (1.02-1.4)
Blood Pressure (mmHg)
Systolic 1.003 .67 (0.99-1.02)
Diastolic 1.01 .54 (0.98-1.04)
Laboratory findings
Dipstick (vs negative)
Negative
Trace 1.2 .53 (0.65-2.3) 1.2 .56 (0.64-2.3) 1.2 .56 (0.64-2.3)
+ 1.3 .42 (0.72-2.2) 1.2 .54 (0.67-2.2) 1.3 .36 (0.74-2.3)
++ 1.1 .73 (0.55-2.3) 1.1 .83 (0.52-2.3) 1.2 .59 (0.59-2.5)
+++ 2.2 .08 (0.94-5.3) 2.1 .08 (0.93-4.8) 3.1 .01 (1.3-7.2)
Haemoglobin (mmol/L)  0.85 .25 (0.65-1.1) 0.82 .19 (0.61-1.1)
Haematocrit (L/L x 10)* 0.67 .23 (0.35-1.3)
Platelets (x109/L) 0.997 .05 (0.99-1.00) 0.997 .07 (0.99-1.00) 0.997 .07 (0.99-1.00)
Uric acid (mmol/L x10)* 1.01 .94 (0.76-1.4)
Creatinine (μmol/L) 1.004 .46 (0.99-1.01)
Aspartate aminotransferase (U/L) 0.99 .27 (0.96-1.01) 0.98 .12 (0.96-1.00) 0.98 .19 (0.96-1.01)
Alanine aminotransferase (U/L) 1.00 .94 (0.98-1.02)
Lactate dehydrogenase (U/L) 1.00 .70 (1.00-1.00)
Intrapartum data
Gestational age at delivery (weeks) 1.3 .003 (1.1-1.5) 1.2 .04 (1.01-1.5)
Epidural anaesthesia 1.4 .16 (0.91-2.0)
Duration of dilation stage (min) 1.00 .75 (1.00-1.00)
Duration of bearing down stage (min) 1.00 .28 (0.99-1.00)
Use of oxytocine 1.04 .84 (0.70-1.5)
Induction of labour (vs spontaneous)  1.01 .96 (0.68-1.5)
Mode of delivery (vs spontaneous)
Spontaneous
Vaginal instrumental delivery 1.7 .04 (1.03-2.7) 1.1 .84 (0.61-1.9)
Caesarean delivery 1.4 .19 (0.85-2.3) 1.7 .16 (0.82-3.4)
Birthweight (kg) 1.6 .008 (1.1-2.3) 1.4 .15 (0.90-2.1)
Perineal rupture (vs none)
No rupture
1st -2nd  0.80 .39 (0.47-1.3) 1.1 .74 (0.57-2.2)
3rd-4th 1.1 .92 (0.25-4.6) 1.5 .61 (0.31-7.2)
Episiotomy 1.6 .03 (1.04-2.6) 2.1 .03 (1.07-4.0)
OR = Odds Ratio; CI = confidence 
interval.  If  the  variable  had  a  p 
less  than  .40  in  the  univariable 
analysis, it was considered in the 
final (multivariable) model. A p of 
.50  was  used  as  a  threshold  for 
variables to stay in the final model. 
*Scale  adapted  by  multiplication 
with  a  factor  10  for  regression 
analyses.
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143the multivariable analysis, because haemoglobin and haematocrit were found to 
be strongly correlated (R=0.921, p<0.001). Results of the multivariable analysis of 
prediction model A, including only antepartum prognostic variables, and model B, 
including besides these antepartum prognostic variables also variables concerning 
the delivery, are shown in Table 2.
For both prediction models, we averaged the five imputed predicted risks of each 
patient, which resulted in one performance estimate. Model A showed moderate 
discrimination,  with  an  area  under  the  ROC  curve  of  0.63  (95%  CI,  0.57-0.69), 
Figure 1a. ROC curve model A (antepartum 
variables).
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Figure 1b. ROC curve model B (antepartum and 
intrapartum variables).
Figure 2a. Calibration plot model A 
(antepartum variables).
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Figure 2b. Calibration plot model B 
(antepartum and intrapartum variables)
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whereas model B showed better discrimination, with an area under the ROC curve 
of 0.69 (95% CI, 0.63-0.74) (figure 1a and 1b). In addition, calibration was poor 
for model A (Hosmer-Lemeshow p-value=0.17) and good for model B (Hosmer-
Lemeshow p-value=0.57) (figure 2a and 2b). Figure 2b shows the rates of PPH 
ranged from 3% (lowest 10 percent) to 23% (highest 10 percent). Almost all points 
are situated on the line X=Y, indicating that the predicted probability equals the 
observed probability, except for the sixth point which shows a slight overestimation 
of  the  predicted  probability.  Bootstrapping  indicated  some  overfitting  with 
corrected ROC areas under the curve ranging from 0.57 to 0.59 for model A and 
from 0.61 to 0.63 for model B.
DISCUSSION
In this cohort study we evaluated predictors for PPH in women diagnosed with 
gestational  hypertension  (GH)  or  mild  pre-eclampsia  (PE)  beyond  36  weeks  of 
gestation. Prediction of PPH in these women is possible when prognostic variables 
in the antepartum period are combined with variables concerning delivery. Included 
variables in this model during antepartum period were maternal age, prepregnancy 
BMI, proteinuria, platelets count and AST. Variables incorporated in this model 
intrapartum were gestational age at delivery, mode of delivery, birth weight and 
perineal rupture or episiotomy.
Obstetric haemorrhage is worldwide a leading cause of maternal mortality and 
severe  maternal  morbidity,  accounting  for  25%  of  all  maternal  deaths.19,20  In 
the Netherlands in the period 1993-2005, the most frequent cause of maternal 
mortality was (pre) eclampsia with a Maternal Mortality Ratio (MMR, maternal 
mortality per 100,000 live-born children) of 3.5. The second cause was shared by 
thromboembolism and cardiovascular diseases (MMR 1.6). The fourth cause was 
sudden death in pregnancy (MMR 0.8), followed by obstetric haemorrhage and 
obstetric sepsis (MMR 0.7).3 Severe maternal morbidity caused by PPH includes 
adult  respiratory  distress  syndrome,  coagulopathy,  shock,  loss  of  fertility,  and 
Sheehan  syndrome.9,10  So  hypertensive  disease  of  pregnancy  as  well  as  PPH 
contributes significantly to maternal mortality and severe morbidity. Thereby, the 
HYPITAT trial shows that PPH is more frequently found in women with hypertensive 
disease of pregnancy at term (10% vs 0.4-1.3% for a low risk population). Vice 
versa Zwart et al found that a major obstetric haemorrhage, defined as the need 
for transfusion of four or more units of red blood cells, or hysterectomy or arterial 
embolisation, was accompanied by PE in 11.2% of cases.13 Other studies have   
also found a significant association between PE and PPH.4-8 In a study on vaginal 
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other studies, which were restricted to caesarean deliveries, PE was associated 
with about two-fold higher risk of PPH.6,8 We suggest that angiogenic factors in 
maternal circulation can explain the association between women with hypertensive 
disease of pregnancy and PPH.
Because  of  the  high  incidence  of  PPH  in  women  with  pregnancy  related 
hypertensive disorders, we think prediction of PPH in women with GH of PE is of 
major importance. Moreover, studies describing predictors for PPH in such women 
are scarce. But, limitations are also present. First, various prognostic predictor 
variables  had  varying  percentages  of  missing  values.  The  missing  data  of  the 
predictive variables were imputed, because deleting them would lead to a loss of 
statistical power in multivariable analysis and, more seriously, potentially biased 
results.15 Second, different options for the definition of PPH can be considered. 
We defined PPH as blood loss >1000 ml within 24 hours after delivery.9,14 Other 
options to define PPH are transfusion need or drop of haemoglobin level. The latter 
was considered to be the most objective, but obviously depends on standardised 
assessment of pre- and post haemorrhage haemoglobin levels, which were not 
available for all patients. Probably the need of blood transfusion was the best 
option, however this management based criterion is depending on local transfusion 
policies.  Although  blood  loss  is  known  to  be  largely  underestimated21,22  we 
decided that blood loss >1000 ml within 24 hours after delivery was the best 
option, because this definition is internationally accepted.
Risk factors for PPH in the overall population include high maternal age, maternal 
obesity, prolonged labour, induced and augmented labour, overdistended uterus 
(high  birth  weight  or  macrosomia,  multiple  pregnancy,  hydramnios),  abruptio 
placentae, placenta praevia, PE, HELLP syndrome, previous caesarean delivery, 
previous  postpartum  haemorrhage,  episiotomy,  operative  delivery  (especially 
emergency  caesarean  delivery)  and  anaemia.4,6,9,12,23  Many  of  the  above 
mentioned variables were also found to be independent predictors of PPH in our 
study,  such  as  increased  maternal  age,  decreased  haemoglobin  rate  (only  for 
model  A),  decreased  platelets  count,  decreased  AST,  caesarean  delivery,  high 
birth  weight  and  episiotomy.  However,  prolonged  labour,  labour  induction  and 
augmentation with oxytocine were not included in our final model. Furthermore, 
multiple  pregnancy,  placentae  praevia  and  previous  caesarean  delivery  were 
exclusion criteria in the HYPITAT trial, and for that reason not assessed in the current 
study. Abruptio placenta did not occur in the HYPITAT trial and so this could not be 
investigated either. Noteworthy, severe PE, manifested as severe proteinuria (3+ 
on dipstick) was significantly related to the occurrence of PPH. Contrary to popular 
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belief, multiparity (para 4+) was not associated with PPH, while the risk of PPH is 
slightly elevated in nulliparous women, as confirmed in other studies.12,23
Recent studies demonstrate an increase of severe maternal morbidity related to 
major obstetrical haemorrhage in Western countries.24-28 Possible explanations 
from these results include the increasing age of women at birth, the increasing 
caesarean  delivery  rate  and  a  high  birth  weight  (macrosomia),  which  are  all 
confirmed in our study. Macrosomia is more and more a common lifestyle problem 
needing public health intervention, and is linked to maternal obesity, older age and 
diabetes mellitus.29 In our study a high BMI was not associated with PPH, but in 
contrast a non significant trend towards a higher risk of PPH in case of smaller BMI 
was observed. This counter-intuitive outcome might be explained from the fact 
that we only included women with hypertensive disease of pregnancy, for which 
obesity itself is a risk factor.
Most cases of PPH are due to uterine atony and retained placenta.9 We decided 
not  to  include  uterine  atony  or  retained  placenta  as  variable  in  our  prediction 
model, because they are already known as a strong alert for PPH and the stage 
of performing an active prophylactic postpartum management is already expired. 
Moreover, uterine atony has to be recognized clinically and is a subjective variable.
While  maternal  deaths  are  extremely  rare  in  the  Netherlands,  the  morbidities 
associated with PPH remain a major problem. The results of this study indicate that 
PPH can be used as a complimentary indicator to assess the quality of obstetric 
care.  Most  of  the  identified  predictors  were  related  to  obstetric  management 
and interventions, and are thus preventable. Including these factors in the flow 
charts of local protocols, could help identification of PPH and consequently lead 
to an optimal and quick treatment. In case of an increased risk of PPH particular 
attention  is  needed  during  early  postpartum  period  and  active  prophylactic  or 
therapeutic  techniques  can  be  used.  So,  the  identified  predictors  should  alert 
clinicians managing labour in women with GH and PE.
ACKNOWLEDGEMENTS
We  thank  research  nurses  and  midwives  of  our  consortium  as  well  as 
gynaecologists, residents and midwives from the participating centres for their 
help in the recruitment of patients and data collection for the HYPITAT trial. We 
also thank all members of the HYpertension and Pre-eclampsia Intervention Trial At 
Term (HYPITAT) study group.
Prediction of postpartum haemorrhage in pregnancy hypertension at term
147REFERENCES
  1.  Sibai  BM.  Diagnosis  and  management  of  gestational  hypertension  and  preeclampsia. 
Obstet Gynecol 2003;102:181–92. 
  2.  Khan KS, Wojdyla D, Say L, Gülmezogly AM, Van Look PF. WHO analysis of causes of 
maternal death: a systematic review. Lancet 2006;367:1066–74.
  3.  Schutte JM, Steegers EA, Schuitemaker NW, Santema JG, de Boer K, Pel M, et al.; the 
Netherlands Maternal Mortality Committee. Rise in maternal mortality in the Netherlands. 
BJOG 2010;117:399–406.
  4.  Sheiner E, Sarid L, Levy A, Seidman SD, Hallak M. Obstetric risk factors and outcome of 
pregnancies complicated with early postpartum hemorrhage: a population-based study. J 
Matern Fetal Neonatal Med 2005;18:149–54.
  5.  Combs CA, Murphy EL, Laros RK Jr. Factors associated with postpartum hemorrhage with 
vaginal birth. Obstet Gynecol 1991;77:69–76.
  6.  Combs CA, Murphy EL, Laros RK Jr. Factors associated with postpartum hemorrhage with 
cesarean deliveries. Obstet Gynecol 1991;77:77–82.
  7.  Eskild A, Vatten LJ. Abnormal bleeding associated with preeclampsia: A population study 
of 315,085 pregnancies. Acta Obstet Gynecol Scand 2009;88:154–8.
  8.  Naef RW, Chauhan SP , Chevalier SP , Roberts WE, Meydrech EF, Morrison JC. Prediction of 
hemorrhage at caesarean delivery. Obstet Gynecol 1994;83:923–6.
  9.  Bonnar J. Massive obstetric haemorrhage. Baillieres Best Pract Res Clin Obstet Gynaecol 
2000;14:1–18.
  10.  American College of Obsteticians and Gynecologists. Practice bulletin. Clinical Management 
Guidelines for Obstetrician-Gynecologists. Number 76. Postpartum Hemorrhage. Obstet 
Gynecol 2006;108:1039–47.
  11.  Koopmans  CM,  Bijlenga  D,  Groen  H,  Vijgen  SMC,  Aarnoudse  JG,  Bekedam  DJ,  et 
al.  Induction  of  labor  versus  expectant  monitoring  for  gestational  hypertension  and 
preeclampsia after 36 weeks (the HYPITAT trial): a multicenter randomised controlled trial. 
Lancet 2009;374:979–88.
  12.  Stones RW, Paterson CM, Saunders NJ. Risk factors for major obstetric haemorrhage. Eur 
J Obstet Gynecol Reprod Biol 1993;48:15–8.
  13.  Zwart JJ, Richters JM, Öry F, de Vries JIP , Bloemenkamp KWM, van Roosmalen J. Severe 
maternal morbidity in the Netherlands: a nationwide population based cohort study of 
371000 pregnancies. BJOG 2008;115:842–50.
  14.  Mousa H, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database 
Syst Rev 2007;1:CD003249.
  15.  Van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is 
superior  to  complete  case  analysis  and  the  missing-indicator  method  in  multivariable 
diagnostic research: a clinical example. J Clin Epidemiol 2006;59:1102–9.
  16.  Steyerberg EW, Eijkemans MJ, Habbema JD. Stepwise selection in small data sets: a 
simulation study of bias in logistic regression analysis. J Clin Epidemiol 1999;52:935–42.
  17.  Altman DG, Royston P . What do we mean by validating a prognostic model? Stat Med 
2000;19:453–73.
1488
chapter
  18.  R  Development  Core  Team.  R:  A  language  and  environment  for  statistical  computing. 
Vienna: R Foundation for Statistical Computing, 2008. ISBN 3-900051-07-0. Available at: 
http://www.R-project.org. Retrieved November 28, 2008.
  19.  AbouZahr C. Global burden of maternal death and disability. Br Med Bull 2003;67:1–11.
  20.  World Health Organization. Maternal Mortality in 2000: Estimates Developed by WHO, 
UNICEF, and UNFPA. Geneva, World Health Organization, 2004. 
  21.  Patel A, Goudar SS, Geller SE, Kodkany BS, Edlavitch SA, Wagh K, et al. Drape estimation 
vs.  visual  assessment  for  estimating  postpartum  hemorrhage.  Int  J  Gynaecol  Obstet 
2006;93:220–4.
  22.  Zwart JJ, Yazdani ST, Harvey MS, de Vries RRP , van Roosmalen J. Underreporting of major 
obstetric haemorrhage in the Netherlands. Transfus Med 2009;20:118–22.
  23.  Al-Zirqi  I,  Forsen  L,  Stray-Pedersen  B.  Prevalence  and  risk  factors  of  severe  obstetric 
haemorrhage. BJOG 2008;115:1265–72.
  24.  Lewis GG (ed) 2007. The Confidential Enquiry into Maternal and Child Health (CEMACH). 
Saving mother’s lives: reviewing maternal deaths to make motherhood safer – 2003-2005. 
The Seventh Report on Confidential Enquiries into Maternity Deaths in the United Kingdom. 
London, CEMACH, 2007.
  25.  Wen SW, Huang L, Liston R, Heaman M, Baskett T, Rusen ID, et al. Severe maternal 
morbidity in Canada, 1991-2001. CMAJ 2005;173:759–64.
  26.  Joseph KS, Rouleau J, Kramer MS, Young DC, Liston RM, Baskett TF. Investigation of an 
increase in postpartum haemorrhage in Canada. BJOG 2007;114:751–9.
  27.  Roberts CL, Ford JB, Algert CS, Bell JC, Simpson JM, Morris JM. Trends in adverse maternal 
outcomes during childbirth: a population-based study of severe maternal morbidity. BMC 
Pregnancy Childbirth 2009;9:7.
  28.  Kuklina EV, Meikle SF, Jamieson DJ, Whiteman MK, Barfield WD, Hillis SD, et al. Severe 
obstetric morbidity in the United States: 1998-2005. Obstet Gynecol 2009;113:293–9.
  29.  Jolly MC, Sebire NJ, Harris JP , Regan L, Robinson S. Risk factors for macrosomia and its 
clinical consequences: a study of 350,311 pregnancies. Eur J Obstet Gynecol Reprod Biol 
2003;111:9–14.
Prediction of postpartum haemorrhage in pregnancy hypertension at term
149Corine M. Koopmans
Maria G. van Pampus
Henk Groen
Jan G. Aarnoudse
Paul P. van den Berg
Ben W.J. MolEurpean Journal of Obstetrics, Gynecology and Reproductive Biology.   
2009; 146: 8–14
9
C
h
a
p
t
e
r
Accuracy of serum uric acid as 
a predictive test for maternal 
complications in pre-eclampsia: 
Bivariate meta-analysis and decision 
analysisABSTRACT
Objective The aim of this study is to determine the accuracy and clinical value of 
serum uric acid in predicting maternal complications in women with pre-eclampsia.
Methods An existing meta-analysis on the subject was updated. The accuracy of 
serum uric acid for the prediction of maternal complications was assessed with a 
bivariate model estimating a summary Receiver Operating Characteristic (sROC) 
curve. Subsequently, a clinical decision analysis was performed, in which three 
alternative strategies were modelled: (I) expectant management with monitoring 
until spontaneous labour; (II) induction of labour; (III) serum uric acid as test for 
predicting maternal complications. In the latter strategy, accuracy data of serum 
uric acid derived from the sROC curve were used to assess the value of serum 
uric  acid  in  the  management  of  women  with  pre-eclampsia.  In  this  strategy, 
women with an increased serum uric acid were supposed to have labour induced, 
whereas women with serum uric acid levels below the threshold were managed 
expectantly. The decision whether to use the policy expectant management, to 
induce labour or to test serum uric acid levels, is based on the expected utility of 
each strategy. The expected utility depends on the probability of occurrence of 
severe maternal complications (i.e. severe hypertension, haemolysis, elevated liver 
enzymes and low platelet count (HELLP syndrome) or eclampsia) and the mode of 
delivery (caesarean section versus vaginal delivery). Valuation of the outcomes was 
performed using a distress ratio, which expresses how much worse a complication 
of pre-eclampsia is valued as compared to a caesarean section.
Results Eight studies, testing 1565 women with pre-eclampsia, met the inclusion 
criteria. If the distress ratio was 10, the strategy regarding serum uric acid would 
be the preferred strategy when the probability of complications was between 2.9% 
and 6.3%. At higher complication rates induction of labour would be preferred, 
whereas at lower complication rates expectant management would be the best 
treatment option. These findings were stable in sensitivity analyses, using different 
distress ratios.
Conclusion Based on the decision analysis, serum uric acid seems to be a useful 
test in the management of pre-eclampsia under realistic assumptions.
152INTRODUCTION
Pre-eclampsia  (PE)  is  a  leading  cause  of  maternal  and  perinatal  mortality  and 
morbidity. The incidence of PE in nulliparous women is estimated between 3 and 
14 percent.1 PE is a multisystem disorder characterized by gestational hypertension 
(GH) after the 20th week of gestation and proteinuria.2 It can result in maternal 
complications as severe hypertension, eclampsia and haemolysis, elevated liver 
enzymes and low platelet count (HELLP syndrome), or fetal complications such 
as  growth  restriction,  fetal  distress  and  even  perinatal  death.  In  view  of  the 
severe consequences of these complications, their prediction is of pre-eminent 
importance and might help to decide whether termination of pregnancy might be a 
better option than expectant monitoring.
Uric acid is a marker of oxidative stress, tissue injury and renal dysfunction, and 
therefore might be helpful in the prediction of complications of PE.3 Uric acid is 
the end product of purine metabolism and is synthesized by the enzyme xanthine 
oxidase. Hypoxia and ischemia of the placenta and cytokines such as interferon 
induce the expression of xanthine oxidase and therefore increase the production 
of  uric  acid  and  also  reactive  oxygen  species.4  In  uncomplicated  pregnancies, 
serum uric acid concentration fall in early pregnancy 25–35% due to an elevation 
in  renal  clearance  secondary  to  increased  glomerular  filtration  rate  or  reduced 
proximal tubular reabsorption and due to changes in its production rate.5–7 Later 
in  pregnancy  the  serum  uric  acid  levels  increase,  possibly  due  to  raised  fetal 
production, decreased binding to albumin and a decline in uric acid clearance until 
toward the end of pregnancy when they approach non-pregnant values.3,8–10 The 
most commonly accepted explanation for the hyperuricemia in PE is increased 
reabsorption and decreased excretion of uric acid in the proximal tubules, although 
others suggest that increased uric acid is a marker of raised xanthine oxidase 
activity.4
Literature on serum uric acid as a predictor of complications of PE is conflicting. 
Several  studies  have  demonstrated  a  correlation  between  elevated  maternal 
serum uric acid levels and adverse maternal and neonatal outcome11–16, whereas 
other studies showed that serum uric acid is a poor predictor of PE.17–19 In a recent 
systematic  review  on  the  subject20,  a  raised  serum  uric  acid  was  associated 
with an almost doubled risk of severe complications, such as eclampsia, severe 
hypertension, and perinatal death. Despite this doubled risk, the authors of the 
review concluded that the uric acid test was not clinically useful in the management 
of women with PE. They stated that there was little evidence to justify the use 
of  therapeutic  measures  like  magnesium  sulphate  or  early  delivery  aimed  at 
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conclusion was based on the fact that the likelihood ratio of raised serum uric acid 
for a pre-eclamptic patient to develop complications was two. Several concerns 
can be voiced on this review. First, the authors pooled likelihood ratios, which 
is a debatable statistical procedure.21 Moreover, the authors only looked at one 
cut-off value, thereby overlooking the possibility that in patients with serum uric 
acid values far above this cut-off value the risk of pregnancy complications is much 
higher. Finally, a decision analysis, in which clinical consequences of strategies 
with and strategies without uric acid measurements were modelled, has never 
been performed.
In  view  of  these  limitations,  we  repeated  the  meta-analysis  with  a  bivariate 
meta-analytic model, allowing us to assess test accuracy of serum uric acid in a 
more quantitative way. Subsequently, we performed decision analysis to assess 
the value of serum uric acid in the management of women with PE.
MATERIALS AND METHODS
Study identification and selection
For this review we reassessed the articles which were previously included in a 
systemic review written by Thangaratinam et al.20 As these authors performed 
a search until 2004, we updated their search for the period 2004–2007, using a 
similar search strategy.
We also used similar methods as Thangaratinam et al. to assess study quality. 
In  short,  two  authors  (C.K.  and  H.G.)  extracted  data  on  study  quality  and  test 
accuracy. Subsequently, accuracy data were used to construct 2 x 2 tables relating 
serum uric acid levels to maternal complications (severe hypertension, eclampsia 
and HELLP syndrome). In contrast to Thangaratinam et al., we only focused on the 
maternal complications.
Data synthesis
From  the  2  x  2  tables,  cross-classifying  serum  uric  acid  test  results  and  the 
complications  in  pregnant  women  with  PE,  sensitivities  and  specificities  were 
calculated  and  plotted  in  a  Receiver  Operating  Characteristic  (ROC)  curve  to 
visualise  data.  We  used  a  bivariate  meta-analysis  model  to  calculate  pooled 
estimates of sensitivity and specificity for several serum uric acid cut-off values 
and to fit a summary ROC (sROC) curve. This model incorporates the correlation 
154that may exist between sensitivity and specificity within studies due to possible 
differences in thresholds between studies. The bivariate model uses a random 
effects approach for both sensitivity and specificity, allowing for heterogeneity 
beyond chance due to clinical or methodological differences between studies.22,23
Clinical decision analysis
Subsequently, we used the data from the estimated sROC curve to model the use 
of serum uric acid measurements in the management of severe complications 
in pre-eclamptic pregnancies. We considered a hypothetical case of a pregnant 
woman with mild PE at 37 weeks of gestation. The woman had a blood pressure of 
160/95 mmHg, proteinuria of 700 mg in 24 h and normal laboratory tests. The fetus 
was in good clinical condition, with fetal growth at the 50th percentile, normal 
amniotic fluid, normal fetal movements and a normal non-stress test.
A decision tree was constructed in which we modelled three alternative strategies 
for women with mild PE at term (Fig. 1). Strategy I is expectant management with 
monitoring until spontaneous labour occurs. Expectant management bears the risk 
of the development of severe maternal and fetal complications by deterioration 
of the PE. In strategy II, labour is induced immediately. This strategy is thought to 
prevent maternal and fetal complications, but at the expense of an increased risk 
of failed induction of labour and subsequent caesarean section.24–27 In strategy III, 
serum uric acid is used to assess the risk of the occurrence of complications. In 
women with an increased serum uric acid, labour is induced whereas women with 
normal serum uric acid levels are managed expectantly.
Figure 1. Decision tree for women with gestational hypertension or mild pre-eclampsia representing 
the three strategies for management to reduce maternal complications. The different outcomes are 
presented.
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or to test serum uric acid levels and to induce labour in case of an increased blood 
value, is based on the expected utility of each strategy. The expected utility of 
a strategy depends on the probability of possible outcomes and the subjective 
values attached to the outcomes.
Outcomes and data
We  considered  two  possible  outcomes,  i.e.  the  occurrence  of  a  complication 
and the mode of delivery. The occurrence of a complication of PE was defined as 
severe hypertension, eclampsia and HELLP syndrome. For the mode of delivery, 
a caesarean section was considered as a negative outcome. For each strategy, 
four combinations of outcomes were possible: (I) a patient without a complication 
who delivered vaginally, (II) a patient with a complication who delivered vaginally, 
(III) a patient without a complication who delivered by caesarean section, and (IV) 
a patient who experienced both negative outcomes, i.e. a complication of PE and 
a caesarean section.
In order to compare the three different strategies, the relative valuations of the 
adverse pregnancy outcomes, i.e. complicated pregnancy and caesarean section, 
have to be taken into account. To compare the disutility caused by these two 
events, we used the amount of distress caused by these issues as a measure to 
compare the negative impact of these two outcomes. The amount of distress can 
be expressed on a distress scale. For an uncomplicated pregnancy resulting in 
a vaginal delivery the distress is considered to be zero, whereas the three other 
combinations of possible outcomes will generate distress. The overall valuation 
of the outcome of a pregnancy is determined by the distress of severe maternal 
complications relative to distress caused by caesarean section. In other words, 
how much worse is a severe maternal complication of PE valued as compared to 
a caesarean section? We propose the use of a distress ratio as an instrument to 
compare the strength of the negative impact of these two events. This ratio of the 
distress of ‘a complication’ and the distress of ‘a caesarean section’ is referred to 
as the ‘distress ratio’. For example, a distress ratio of 10 for a severe complication 
implies that a severe complication is valued 10 times worse than a caesarean 
section. Understandably, this measure is subjective.28
Data  from  the  Dutch  National  Obstetric  Registration  from  January  2000  until 
January 2005 showed that the non-elective caesarean section rate among women 
with GH or PE in whom labour started spontaneously was 14% versus 22% in 
whom labour was induced (OR 1.7, 95% CI 1.6–1.8).27 The prevalence of several 
complications in the expectant group was provided by the Dutch Perinatal Registry 
156(PRN).29 The expected complication rate after expectant management for women 
with a singleton pregnancy in cephalic presentation at term (>36 weeks) and a 
diastolic blood pressure ≥90 mmHg was 6.2% for severe hypertension (diastolic 
blood pressure >110 mmHg at two occasions 6 h apart), 0.07% for eclampsia 
and 0.03% for HELLP syndrome, resulting in an overall complication rate of 6.3%. 
When labour was induced this risk was considered to be zero.
Calculation formulas
In strategy I, i.e. expectant management, the expected distress can be calculated 
from 
(I)  (Pcomp _ Exp x DIScomp) + (Psc _ Exp x DISsc) + (P(comp+sc) _ Exp x 
DIS(comp+sc))
The  probability  of  a  complication  after  expectant  management  (Pcomp _ Exp) 
was initially set at 5.0% and the probability of a caesarean section after expectant 
management and spontaneous onset of labour (Psc _ Exp) was set at 14%. We 
selected different distress ratios between 2 and 25 for a complication (DIScomp) 
and for caesarean section the distress was set at 1 (DISsc). For the expected 
distress of a complication and a caesarean section after expectant management 
we added the probabilities of these two outcomes (P(comp+sc) _ Exp) and the 
distress ratios (DIS(comp+sc)). A spontaneous delivery is assumed to bring no 
distress, and so is set at zero (not shown in the calculation).
In strategy II, i.e. induction of labour, the expected distress can be calculated from 
(II)  (Pcomp _ Ind  x  DIScomp)  +  (Psc _ Ind  x  DISsc)  +  (P(comp+sc) _ Ind  x 
DIS(comp+sc))
 
The probability of a complication after induction of labour (Pcomp _ Ind)  was set at 
0% and the probability of a caesarean section after induction of labour (Psc _ Ind) at 
22%. The expected distress of the combination of a complication and a caesarean 
section after induction of labour was calculated by adding the probabilities of these 
two outcomes (P(comp+sc) _ Ind ) and the distress ratios (DIS(comp+sc)).
In strategy III, i.e. testing with serum uric acid, the expected distress is the addition 
of four calculations:
(IIIa)  Distress for a situation with positive test and true risk of complication
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DISsc + P(comp+sc) _ Ind x DIS(comp+sc))
(IIIb)  Distress for a situation with negative test and true risk of complication
  (1 - Sensitivity uric acid) x Pcomp x (Pcomp _ Exp x DIScomp + Psc _ Exp x 
DISsc + P(comp+sc) _ Exp x DIS(comp+sc))
(IIIc)  Distress for a situation with negative test and absence of risk of complication
  (Specificity uric acid) x (1 – Pcomp) x (Pcomp _ Exp x DIScomp + Psc _ Exp 
x DISsc + P(comp+sc) _ Exp x DIS(comp+sc))
(IIId)  Distress for a situation with positive test and absence of risk of complication
  (1 – Specificity uric acid) x (1- Pcomp) x (Pcomp _ Ind x DIScomp + Psc _ Ind 
x DISsc + P(comp+sc) _ Ind x DIS(comp+sc))
For this strategy, sensitivity and specificity were used to calculate the probability 
of a complication and/ or a caesarean section in case of increased or normal values 
of uric acid, which were derived from the estimated sROC curve.
According to the principles of decision theory, the best choice is the one with 
the lowest expected distress. The decision whether to use the policy expectant 
management, to induce labour, or to test serum uric acid levels and to induce 
labour in case of an increased blood value, thus depends on the expected distress 
of each strategy.
In subsequent sensitivity analyses, several decision models with different distress 
ratios were constructed to show which management should be the best option in 
women with mild preeclampsia. We performed multiple sensitivity analyses for the 
variables.
RESULTS
Study identification and eligibility
Thangaratinam et al.20 had detected seven articles on the subject. Our search for 
the period 2004–2007 revealed three additional articles reporting on the association 
between serum uric acid and maternal complications of which we excluded two 
because of insufficient data to construct 2 x 2 tables. Finally, eight primary articles 
met the selection criteria.
158Study characteristics, inclusion and exclusion criteria and the outcome measures 
of the included studies are listed in Table 1. In total, 1565 pregnant women with PE 
were included in these eight studies. The test thresholds of serum uric acid varied 
from 270 to 540 μmol/l in individual studies. The most common was 350 μmol/l. 
The commonest maternal complication assessed was severity of hypertension. 
Analyses of clinical characteristics suffered from unclear reporting in the studies.
Sensitivity and specificity
Table  1  also  summarizes  the  sensitivities  and  specificities  of  serum  uric  acid 
levels in predicting severe maternal complications of PE for each study. There 
were six studies that reported on the capacity of serum uric acid to predict severe 
hypertension, two studies that reported on the prediction of eclampsia and one 
study that reported on the prediction of HELLP syndrome. Williams and Galerneau19 
described two complications, i.e. severe hypertension and HELLP syndrome, and 
used two different cut-off values of serum uric acid.
A plot of sensitivity-specificity points in ROC curve for these three severe maternal 
complications is shown in Fig. 2, which also contains a sROC curve constructed 
with the bivariate method.
Figure 2. Summary Receiver-operating characteristic (sROC) of several studies for the prediction of 
maternal complications in pre-eclampsia.
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The probability of severe maternal complications, i.e. severe hypertension, HELLP 
syndrome and eclampsia, in pre-eclamptic women was set at 5.0%. In the initial 
analysis, we presume that the distress ratio was 10, i.e. the expected distress of 
severe complications was valued ten times worse than the expected distress of a 
caesarean section. The expected distress was 2.7 for expectant management, 2.6 
for induction of labour and 2.5 for the strategy in which serum uric acid was used 
to decide for induction of labour or expectant management. Thus, under these 
assumptions, strategy III regarding serum uric acid would be the procedure of first 
choice, because of its lowest expected distress. However the difference with the 
two other strategies is small.
Table  1.  Clinical  characteristics  for  individual  studies  on  the  predictive  accuracy  of  uric  acid  in 
predicting maternal complications of pre-eclampsia
1st Author  Year Country Inclusion criteria Number of 
patients (n)
Outcome Cut off value 
(μmol/l)
TP FN FP TN Sensitivity Specificity
Peralta Pedrero30 2004 Mexico IN: BP ≥ 140/90 mmHg after 20 weeks and 
proteinuria ≥ 1+ and 300 mg/24 hours
EX: liver and renal insufficiency and 
diabetes 
216 Severe hypertension (BP ≥ 
160/110 mmHg)
270 119 34 43 20 0.78 0.32
Williams19 2002 United States IN: BP ≥ 140/90 mmHg after 20 weeks and 
proteinuria ≥ 1+ or 300 mg/24 hours
EX: diabetes, chronic hypertension and 
multiple gestations
194 Severe hypertension (systolic 
BP ≥ 160 and/or diastolic 
BP ≥ 110 mmHg on two 
occasions)  
450
540
17
10
50
56
18
11
109
116
0.25
0.15
0.86
0.91
HELLP-syndrome (SGOT 
> 40 IU/L, LDH >600 IU/L, 
haemolysis on film and 
platelet count ≤ 150 x 109 /L)
450
540
13
9
42
46
21
12
118
127
0.24
0.16
0.85
0.91
Brown31 1996 Australia IN: Australian Society for the Study of 
Hypertension in Pregnancy (ASSHP) criteria 
for preeclampsia32
EX: essential hypertension, secondary 
hypertension (predominantly renal disease)
825 Severe hypertension (systolic 
BP ≥ 170 and/or diastolic BP 
≥ 110 mmHg)
350 130 41 351 303 0.76 0.46
Voto33  1988 Argentina IN: BP ≥ 140/90 mmHg
EX: essential hypertension
125 Severe hypertension (BP ≥ 
160/100 mmHg)
350 15 10 18 82 0.60 0.82
Liedholm11 1984 Sweden IN: BP ≥ 140/90 mmHg during or after the 
first 20 gestational weeks and proteinuria ≥ 
1+ on at least two occasions
EX: diabetes mellitus
26 Severe hypertension (use of a 
combination therapy of beta-
blocker and hydralazine)
350 12 3 3 8 0.80 0.73
Seitchik9 1953 United States IN: BP ≥ 140/90  mmHg 14 Severe hypertension 350 2 .5 1 11 0.80 0.92
Yassaee34 2003 Iran IN: severe preeclampsia 103 Eclampsia 350 12 1 41 49 0.92 0.54
Fadel35 1969 Egypt IN: BP > 140/ 90 mmHg and/or proteinuria  
in latter half of pregnancy
62 Eclampsia 350 8 14 2 38 0.36 0.95
BP: blood pressure; IN: included; EX: excluded; HELLP: haemolysis, elevated liver enzymes, and 
low platelet count; SGOT: serum glutamic oxaloacetic transaminase; LDH: lactate dehydrogenase; 
TP: true positive; FN: false negative; FP: false positive; TN: true negative.
160In subsequent sensitivity analyses we varied the prevalence of severe complications 
between 0 and 10%. Fig. 3A shows the expected distress for the three strategies, 
when the distress ratio is presumed to be 10. When the prevalence of severe 
complications was between 2.9 and 6.3%, the third strategy, looking at serum uric 
acid, had the lowest distress. In case of a prevalence equal or more than 6.3%, 
induction of labour was expected to have the lowest expected distress, whereas 
equal to or below a prevalence of 2.9%, expectant management would give the 
lowest expected distress, and so be the best treatment option.
Fig. 3B–D depicts the situation for distress ratios of 2, 5 and 25 respectively; 
showing that treatment concerning serum uric acid levels becomes less attractive 
with increasing distress ratios compared to the other two strategies. The prevalence 
for severe complications brings less distress regarding serum uric acid between 
4.1 and 8.7% for a distress ratio of 2; between 3.2 and 7.0% for a distress ratio of 
Table  1.  Clinical  characteristics  for  individual  studies  on  the  predictive  accuracy  of  uric  acid  in 
predicting maternal complications of pre-eclampsia
1st Author  Year Country Inclusion criteria Number of 
patients (n)
Outcome Cut off value 
(μmol/l)
TP FN FP TN Sensitivity Specificity
Peralta Pedrero30 2004 Mexico IN: BP ≥ 140/90 mmHg after 20 weeks and 
proteinuria ≥ 1+ and 300 mg/24 hours
EX: liver and renal insufficiency and 
diabetes 
216 Severe hypertension (BP ≥ 
160/110 mmHg)
270 119 34 43 20 0.78 0.32
Williams19 2002 United States IN: BP ≥ 140/90 mmHg after 20 weeks and 
proteinuria ≥ 1+ or 300 mg/24 hours
EX: diabetes, chronic hypertension and 
multiple gestations
194 Severe hypertension (systolic 
BP ≥ 160 and/or diastolic 
BP ≥ 110 mmHg on two 
occasions)  
450
540
17
10
50
56
18
11
109
116
0.25
0.15
0.86
0.91
HELLP-syndrome (SGOT 
> 40 IU/L, LDH >600 IU/L, 
haemolysis on film and 
platelet count ≤ 150 x 109 /L)
450
540
13
9
42
46
21
12
118
127
0.24
0.16
0.85
0.91
Brown31 1996 Australia IN: Australian Society for the Study of 
Hypertension in Pregnancy (ASSHP) criteria 
for preeclampsia32
EX: essential hypertension, secondary 
hypertension (predominantly renal disease)
825 Severe hypertension (systolic 
BP ≥ 170 and/or diastolic BP 
≥ 110 mmHg)
350 130 41 351 303 0.76 0.46
Voto33  1988 Argentina IN: BP ≥ 140/90 mmHg
EX: essential hypertension
125 Severe hypertension (BP ≥ 
160/100 mmHg)
350 15 10 18 82 0.60 0.82
Liedholm11 1984 Sweden IN: BP ≥ 140/90 mmHg during or after the 
first 20 gestational weeks and proteinuria ≥ 
1+ on at least two occasions
EX: diabetes mellitus
26 Severe hypertension (use of a 
combination therapy of beta-
blocker and hydralazine)
350 12 3 3 8 0.80 0.73
Seitchik9 1953 United States IN: BP ≥ 140/90  mmHg 14 Severe hypertension 350 2 .5 1 11 0.80 0.92
Yassaee34 2003 Iran IN: severe preeclampsia 103 Eclampsia 350 12 1 41 49 0.92 0.54
Fadel35 1969 Egypt IN: BP > 140/ 90 mmHg and/or proteinuria  
in latter half of pregnancy
62 Eclampsia 350 8 14 2 38 0.36 0.95
BP: blood pressure; IN: included; EX: excluded; HELLP: haemolysis, elevated liver enzymes, and 
low platelet count; SGOT: serum glutamic oxaloacetic transaminase; LDH: lactate dehydrogenase; 
TP: true positive; FN: false negative; FP: false positive; TN: true negative.
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and specificity values were both set to 68%. If we chose a lower sensitivity and a 
higher specificity combination from the sROC curve, i.e. a sensitivity of 43% and a 
specificity of 80%, the expected distress for serum uric acid is less advantageous 
however almost comparable to the situation which is shown in Fig. 3A–D. Extensive 
sensitivity analyses with sensitivity and specificity combinations between 40 and 
80% and distress ratios varying between 2 and 25, showed that the use of serum 
uric acid remained of value at prevalence of complications between 3 and 9%. At 
higher distress ratios, the amount of distress reduced by the test was higher.
Figure 3 (A-D). Expected distress for three strategies: (I) expectant management, (II) induction of 
labour and (III) treatment depending on serum uric acid levels. In each figure, the prevalence of 
severe complications in pre-eclamptic women varies between 0 and 10% and the expected distress 
is calculated for the distress ratios between 2 and 25. The distress ratio represents the distress 
caused by severe complications as compared to the distress caused by a caesarean section. For 
example, a distress of 25 implies that severe complications are valued 25 times worse than a 
caesarean section. Sensitivity is 68% and specificity is 68%.
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162COMMENT
This meta-analysis summarizes the available evidence on the accuracy of serum 
uric acid in the prediction of severe maternal complications in pre-eclampsia (PE). 
The decision analysis was performed to evaluate whether the use of serum uric 
acid is useful in the management of women with PE. We found that under realistic 
assumptions,  the  use  of  serum  uric  acid  improves  the  maternal  outcome  and 
should therefore be applied in patients with hypertensive disorders at term.
Evidence on the accuracy of serum uric acid in the prediction of eclampsia and 
HELLP syndrome is limited, since our search revealed only three studies. For this 
reason we added severe hypertension, which itself is not a complication, but rather 
a risk situation, together with eclampsia and HELLP syndrome as a composite 
adverse  maternal  outcome  in  the  decision  analysis.  Progression  to  severe 
hypertension could be associated with severe maternal morbidity, as eclampsia, 
pulmonary edema and cerebral encephalopathy or haemorrhage.36–38
Inclusion of the study of Yassaee in the meta-analysis was questionable since only 
women with severe hypertension were included, whereas in the other studies 
women with mild hypertension were also included. Because of this discrepancy 
we repeated the meta-analysis also without the study of Yassaee. In subsequent 
sensitivity analyses, the clinical utility of serum uric acid measurements appeared 
to be comparable to our initial analysis.
The  overall  complication  rate  we  used  in  the  decision  analysis  was  6.3%,  of 
which 6.2% was the complication rate of severe hypertension. Besides the much 
lower complication rate of eclampsia and HELLP syndrome, the distress due to 
eclampsia and HELLP syndrome might be much higher as compared to severe 
hypertension. However, as stated above, severe hypertension is also associated 
with poor maternal outcome. Moreover, increase of the distress ratio did not alter 
the conclusion of our analysis (Fig. 3A–D).
A  significant  limitation  of  this  review  is  the  heterogeneity  noticed  between 
individual studies with regard to population, test thresholds, frequency of testing, 
gestational age at development of PE and at delivery, interval between the test 
and outcome, and reference standards. Awareness is important about variations 
in methods for measuring uric acid levels and different therapeutic interventions 
such as use of antenatal steroids in reducing respiratory distress syndrome39 and 
antihypertensives that might help to reduce fetal and maternal complications40, 
because it could influence the outcomes.
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chapterThangaratinam et al.20 concluded that serum uric acid measurement was not a 
clinically useful test to predict maternal complications in women with PE. They based 
their conclusion on a likelihood ratio of two, which they found to be insufficient for 
clinical use. However, they based their conclusion only on test accuracy. Based on 
our decision analysis, in which we combined test accuracy both with the prevalence 
of disease and with the impact of clinical outcomes, we draw a different conclusion. 
Apparently, the limited accuracy of the test is still enough to make it a useful test in 
its clinical context.
In conclusion, measurement of serum uric acid seems to be a useful test to predict 
maternal complications in the management of women with PE. In patients with 
increased serum uric acid values labour should be induced, due to their increased 
risk of complications.
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Accuracy of liver function tests for 
predicting adverse maternal and fetal 
outcomes in pre-eclamptic women: A 
systematic reviewABSTRACT
Introduction Pre-eclampsia is one of the single largest causes of maternal and 
fetal mortality and morbidity. Liver function tests (LFTs) are routinely performed in 
women with pre-eclampsia as part of a battery of investigations to assess severity 
at admission and later to guide appropriate management.
Methods A systematic review of test accuracy studies to determine the accuracy 
with  which  liver  function  tests  predict  maternal  and  fetal  complications  in 
women with pre-eclampsia. We conducted electronic searches without language 
restrictions in Medline (1951-2010), Embase (1980-2010) and the Cochrane Library 
(2009).  Primary  articles  that  evaluated  the  accuracy  of  liver  function  tests  in 
predicting complications in women with pre-eclampsia were chosen. Data was 
extracted by two reviewers independently. A bivariate model estimated area under 
summary Receiver Operating Characteristic curve (AUC), sensitivity and specificity.
Results There were 13 primary articles including a total of 3507 women assessing 
maternal (30 2 x 2 tables) and fetal (19 2 x 2 tables) outcomes. For predicting 
adverse maternal outcome, the point estimates of specificity were > 70% in 18 
tables with AUC of 0.79 (95% CI 0.51–0.93). For predicting adverse fetal outcomes 
the AUC was 0.65 (95% CI 0.26–0.9) and the specificity of the test was >70% in 9 
2 x 2 tables. Sensitivity of the test was poor for both maternal and fetal outcomes.
Conclusion  LFTs  performed  better  in  predicting  adverse  maternal  than  fetal 
outcomes in women with pre-eclampsia. Presence of raised liver enzymes were 
associated with an increased probability of maternal and fetal complications, but 
normal liver enzymes did not rule out disease.
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INTRODUCTION
Pre-eclampsia (PE) affects approximately 2–8% of all pregnancies and is associated 
with several complications.1 It remains one of the single largest causes of maternal 
and fetal mortality and morbidity.1-4 PE accounts for about one-fifth of antenatal 
admissions,  two-thirds  of  referrals  to  day  assessment  units  and  a  quarter  of 
obstetric admissions to intensive care units.5 Although the rate of complications 
is relatively low in PE, when present they result in adverse maternal and fetal 
outcomes. Clinicians need to identify the women at risk of severe complications 
who  need  effective  interventions  like  magnesium  sulphate,  anti  hypertensives, 
corticosteroids or delivery to reduce or prevent complications to the mother or 
baby.
Liver function tests (LFTs) are currently routinely performed in most obstetric units 
as part of the battery of tests in women with PE. A Delphi survey of international 
experts considered LFTs to be the third important predictor of maternal and fetal 
complications  after  blood  pressure  and  proteinuria.6  Liver  enzymes,  aspartate 
aminotransferase (AST) or serum glutamic oxalocetic transaminase (SGOT) and 
alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT) 
are often raised in PE. The clinical manifestations of liver involvement are right 
upper quadrant or epigastric pain, elevated liver enzymes, and in severe cases, 
subcapsular haemorrhage or hepatic rupture. Haemolysis, Elevated Liver functions, 
and Low Platelets (HELLP) syndrome is diagnosed in 10 – 20% of women with 
severe PE.
Prediction of PE and its complications are poor and when the condition is diagnosed 
there is a need to establish its severity.7 A scientific strategy based on systematic 
literature  review  methodology  help  to  elucidate  current  uncertainties  and  to 
identify gaps in the research evidence.8 Several studies have reported a positive 
correlation  between  elevated  maternal  serum  liver  enzyme  levels  and  adverse 
maternal and fetal outcomes.9-11 However, these studies have not generally been 
conducted with large enough sample size to provide precise accuracy estimates 
and they vary widely in their definition of PE and maternal and fetal outcomes. 
There are no systematic reviews exploring the accuracy of liver enzymes to predict 
complications of PE. We therefore conducted a comprehensive systematic review 
to  obtain  precise  estimates  of  maternal  serum  liver  enzyme  levels  to  predict 
maternal and fetal complications in women with PE.
Liver function tests for predicting pre-eclampsia complications
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The review was carried out with a prospective protocol12 using widely recommended 
methods.13-16
Identification of studies
We  searched  MEDLINE  (1951-2010),  EMBASE  (1974-2010)  and  the  Cochrane 
Library (2009) for relevant citations. We developed a broad and sensitive search 
strategy consisting of MeSH, key terms related words and word variants capturing 
population  of  PE,  tests  including  liver  function  tests  and  maternal  and  fetal 
outcomes were employed. From this comprehensive database, the citations on 
liver function as a test were identified.17 Initial generic searches were regularly 
updated and supplemented by specific search strategies to capture liver function 
tests.  This  was  done  to  ensure  that  all  relevant  studies  were  identified.  The 
reference lists of all known primary and review articles were hand searched to 
identify cited articles not captured by electronic searches. Details of the search 
strategy are available from the authors. We contacted corresponding authors for 
missing data. Language restrictions were not applied. A comprehensive database 
of relevant articles, published and unpublished was constructed.
Study selection and data extraction procedures
Studies which evaluated the accuracy of maternal LFTs in women with PE for 
the prediction of maternal or fetal complications were selected in a two-stage 
process. First, the electronic searches were scrutinised and full manuscripts of all 
citations that were likely to meet the predefined selection criteria were obtained 
by two independent reviewers (CMK and SI). Secondly, final inclusion or exclusion 
decisions were made by the reviewers (ST and CMK) after examination of these 
manuscripts.  Studies  which  met  the  predefined  and  explicit  criteria  regarding 
population, tests, outcomes and study design were selected for inclusion in the 
review as shown below.
Population: Women with pre-eclampsia. 
Index test: LFTs including AST, ALT, Lactate dehydrogenase (LDH), Gamma glutamyl 
transferase (GGT), Alkaline Phosphatase (ALP) and Bilirubin.
Composite  adverse  outcome:  Maternal  outcome  included  one  of  the  following; 
eclampsia, pulmonary oedema, maternal death, abruption, disseminated intravascular 
coagulation (DIC), renal failure, intra cerebral haemorrhage, adult respiratory distress 
syndrome, retinal detachment.12,18 Fetal outcome that included one of the following; 
intra uterine death, neonatal deaths, fetal distress, intra uterine growth restriction, 
intraventricular haemorrhage, respiratory distress syndrome, mechanical ventilation, 
necrotising enterocolitis, bronchopulmonary dysplasia, preterm birth.12
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Study design: Test accuracy study allowing generation of 2 x 2 tables.
Information  was  extracted  from  each  selected  article  on  study  characteristics, 
quality and accuracy results. Accuracy data were used to construct 2 x 2 tables of 
liver enzyme results and outcomes. The index test was considered positive if liver 
function test levels for any of the analyses were above a threshold defined in the 
primary study, and index test negative if these were below the threshold. When 
disagreements occurred, they were resolved by consensus or arbitration.
Methodological quality assessment
All manuscripts meeting the selection criteria were assessed for their method-
ological quality, defined as the confidence that the study design, conduct and 
analysis  minimised  bias  in  the  estimation  of  test  accuracy.  Based  on  existing 
checklists,14-16,19,20  quality  assessment  involved  scrutinising  study  design  and 
relevant features of the population, test and outcomes of the study. A study was 
considered  to  be  of  good  quality  if  it  used  a  prospective  design,  consecutive 
enrolment,  full  verification  of  the  test  result  with  reference  standard,  and  had 
adequate test and outcome description.15,16,19,20
Data synthesis
For each study, we constructed a 2 x 2 table cross-classifying the LFT results 
and the occurrence of complications. To visualise data we plotted sensitivity and 
specificity in receiver operating characteristic (ROC) plots.21 In a ROC plot the 
upper left corner is the ideal position because it reflects the highest sensitivity and 
the lowest false positive rate (highest specificity). A bivariate random effects model 
was used to fit a summary sROC curve.22-25 Briefly, the bivariate model preserves 
the two-dimensional nature of diagnostic data in a single model incorporating the 
correlation that may exist between sensitivity and specificity within studies due to 
possible differences in threshold between studies. When more than one adverse 
maternal or fetal outcome was reported, we selected the test accuracy study (2 x 
2 table) with the worst outcome to avoid multiple inclusions of the same patients 
in the meta analysis as this gives erroneous precision to the summary estimates. 
We refrained from pooling sensitivity and specificity or likelihood ratios separately 
due to differences in liver enzymes and thresholds included in the selected studies 
which led to heterogeneity. Area under sROC curve (AUC) presented the most 
suitable  summary  of  these  data.  All  statistical  analyses  were  performed  using 
MetaDisc and Stata 10.0 statistical package.
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Literature identification and study quality
Fig. 1 summarises the process of literature identification and selection. There were 
13 primary articles that met the selection criteria, consisting of 49 2 x 2 tables 
including a total of 3507 women.11,26-37 Each study’s salient features are provided 
in Table 1. Methodological quality of included studies (Fig. 2) showed that the index 
tests was adequately described in 5 out of 13 studies (38 %)11,29,33,34,37 and reference 
standard (maternal and fetal outcomes) was adequate in all the studies.11,26,28-37 
Figure  1.  Study  selection  process  for  systematic  review  of  accuracy  of  liver  function  tests  in 
predicting maternal and fetal complications in preeclamptic women.
Five of the 13 (38%) studies were prospectively conducted26,29-31,37 and none of 
the studies were blinded for outcome measurement (Fig. 2).
Study characteristics
Five of the 13 studies consisted of women with severe PE.27,28,32-34 The gestational 
age  of  the  women  with  PE  was  specified  in  7  studies.27,29,32-34,37  The  liver 
function tests evaluated in the primary studies were mainly liver enzymes (AST, 
Total citations identified from electronic searches: n=147
Citations excluded after screening titles and/or abstracts: n=43
Articles of accuracy of liver function tests in predicting maternal and fetal complicationsin 
women with pre-eclampsia retrieved for detailed evaluation: n= 104
Articles excluded with reasons:
inappropriate population =  26
LFT not used as a test to predict complications of pre-eclampsia  =  22
2 x 2 table not possible =  33
Articles not retrieved =  10
Total 91
Primary articles included in systematic review: n=13
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ALT, LDH) as reported in all studies. One study reported the accuracy of GGT and 
serum bilirubin.31 The accuracy of LDH was reported with cut offs ranging from 
350 to 1400 IU/l.9,27,32-35,37 AST and ALT threshold levels were not specified in 
3 studies.29,34,36 The cut off levels of AST was reported as 2 standard deviation 
higher than normal in 1 study11 and in the rest levels of AST and ALT ranged from 
43 to 500 IU/l and 32 to 300 IU/l respectively. The tests were performed more than 
once in most studies but no data was provided on the time between the test and 
occurrence of outcome.
Prediction of maternal outcomes
Thirteen primary studies evaluated accuracy of LFTs to predict adverse maternal 
outcomes  in  30  2  x  2  tables  (Table  2a).11,26-36  Eclampsia  was  the  commonest 
adverse outcome that was reported. The prediction of eclampsia was evaluated 
through  10  2  x  2  tables  in  8  studies.  Prediction  of  eclampsia  had  the  highest 
specificity of 0.97 as observed in 2 studies (95% CI 0.93–0.99; 95% CI 0.92–0.99). 
The cut off levels of LFTs were AST/ALT (500/300 U/l)26 and ALT more than 60 U/
l35 for the two studies respectively. Both evaluated the role of ALT in women with 
broad spectrum PE. The highest predicted positive and negative likelihood ratios, 
LR+ 9.1 (95% CI 3.3–25.5)26 and LR- 0.12 (95% CI 0.01–1.8)30 were observed for 
eclampsia. The highest sensitivity of 0.95 (95% CI 0.63–1) was observed for LDH/
AST/ALT (600/70/70 U/l) in the prediction of DIC.28
Figure 2. Quality of the included studies in the systematic review of accuracy of liver function tests 
in predicting maternal and fetal complications.
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175Table  1.  Characteristics  of  studies  included  in  the  review  of  accuracy  of  liver  function  tests  in 
predicting maternal and fetal complications in women with pre-eclampsia.
Study Population Test Outcome
Study (year)
Language
Quality Number  Inclusion and exclusion criteria Intervention Gestation of 
testing
Frequency 
of testing
Cut off level
Odendaal 
(2000)
English
Case control
Retrospective
Not consecutive patient 
enrolment
Blinded
Follow up complete
340 Early severe pre-eclampsia
with a blood pressure control to around 140/90 to 
150/100 mmHg, Singleton pregnancy
Nil known >28/40 liver 
function 
tests twice 
weekly
LDH 350  Abruption 
Diagnosis of abruption placenta: 
≥ 15% of the maternal surface 
of the placenta is covered with 
blood clots
Audibert 
(1996)
English
Cohort study
Retrospective
Consecutive enrolment
Blinding not known
Follow up complete
327 Severe pre-eclampsia or HELLP syndrome as 
defined by criteria of The American College of 
Obstetricians and Gynecologists (ACOG).
Exclusion: Laboratory abnormalities from other 
disorders
Magnesium sulphate 
to all women with 
severe pre-eclampsia, 
glucocorticoids  <34/40
Not specified Not known LDH 600
AST 70
ALT 70
Eclampsia
Caesarean section
Blood transfusion
Disseminated intravascular 
coagulation
Pleural effusion
Wound Haematoma/infection
Acute renal failure
Abruption
Pulmonary oedema
Intracerebral haemorrhage
Maternal death
Abramovici 
(1999)
English
Cross sectional
Retrospective
Consecutive
Blinding not known
Follow up complete
269 Severe pre-eclampsia as defined by ACOG, 
Singleton pregnancy
Exclusion: History of renal, liver or haematological 
abnormalities, multiple pregnancies
Nil known 24/40-36/40 Not known LDH 600
AST 70
Intrauterine growth retardation
Neonatal death
Respiratory distress syndrome
Intraventricular haemorrhage 
grade 3-4
Necrotising enterocolitis grade 
2-3
Bronchopulmonary dysplasia
Mechanical ventilation
Caesarean section
Haddad  
(2000)
English
Case control
Retrospective
Can’t tell enrolment
Not blinded
Follow up complete
64 Severe pre-eclampsia  criteria of ACOG 
Exclusion: History of haematological or liver 
diseases. Gestation >28 weeks at admission
Intravenous magnesium 
sulphate routinely to all 
severe pre-eclamptics
< 28/40 Not known LDH 600
AST 70
Eclampsia
Abruptio placentae
Disseminated intravascular 
coagulation
Ascites
Pulmonary oedema
Pleural effusion
Acute renal failure
Transfusion of blood products
Caesarean section
Neonatal death
Intraventricular Haemorrhage
Respiratory Distress Syndrome
Martin Jr 
(1999)
English
Retrospective
Cohort
Consecutive enrolment
No blinding
Follow up complete
568 Severe Pre-eclampsia with or without  HELLP 
syndrome
Exclusion: Eclampsia
Not specified Not specified Admission 
data
LDH 1000-
1400
AST 50-150
ALT 30-100
Combined maternal adverse 
outcome
Aali (2004)
English
Cross sectional
Prospective
Consecutive
No blinding
Follow up complete
200 Pre-eclampsia according to ACOG
Eclampsia: occurrence of generalized convulsion 
in patients with preeclampsia
Magnesium sulphate to 
all patients to prevent or 
control convulsions,i.v. 
hydralazine given when 
diastolic BP>110 mmHg,
Betamethasone given 
from 24-34 weeks 
gestation to accelerate 
lung maturity
No  specified Multiple AST 500
ALT 300
Eclampsia
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Ascites
Pulmonary oedema
Pleural effusion
Acute renal failure
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Caesarean section
Neonatal death
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syndrome
Exclusion: Eclampsia
Not specified Not specified Admission 
data
LDH 1000-
1400
AST 50-150
ALT 30-100
Combined maternal adverse 
outcome
Aali (2004)
English
Cross sectional
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No blinding
Follow up complete
200 Pre-eclampsia according to ACOG
Eclampsia: occurrence of generalized convulsion 
in patients with preeclampsia
Magnesium sulphate to 
all patients to prevent or 
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Study Population Test Outcome
Study (year)
Language
Quality Number  Inclusion and exclusion criteria Intervention Gestation of 
testing
Frequency 
of testing
Cut off level
Crisp (1959)
English
Cohort
Prospective
Consecutive
Follow up complete
64 Pre-eclampsia definition not specified  Nil known No  specified Multiple AST 70 Eclampsia
Borglin (1958)
English
Cohort
Prospective
Not blinded
Follow up complete
53 Symptoms of toxaemia (defined as proteinuria and 
increased blood pressure or pronounce edema in 
the last trimester)or liver damage
Exclusion: Evidence of chronic nephropathy
Nil known Last trimester Multiple, 
weekly
Raised AST 
and ALT
Eclampsia
Romero (1988)
English
Cohort
Retrospective
Consecutive enrolment
Not blinded
Follow up complete
355 Pregnancy induced hypertension
Exclusion: Mean Arterial Pressure<105 in 
3rd trimester, chronic hypertension without 
superimposed PIH, multiple gestation, 
cholelithiasis and liver diseases causing raised 
SGOT
Nil known >26/40 Multiple AST 2SD Pulmonary oedema
Preterm delivery
Respiratory distress syndrome
Intrauterine growth retardation
Fetal distress
Neonatal death
Apgar<7 @1 min
Apgar<7 @5 min
Yucesoy 
(2005)
English
Cross sectional
Retrospective
Consecutive enrolment
Not blinded
Follow up complete
255 Mild and severe pre-eclampsia defined 
by  National High Blood Pressure Education 
Programme Working Group on High Blood 
Pressure in Pregnancy. 
mild preeclampsia, defined as blood pressure 
≥140/90 mmHg with albuminuria of at least 300 
mg/24 h after 20 weeks of gestation. 
severe preeclampsia, involving eclampsia and 
HELLP syndrome.
Magnesium sulphate 
infusion in severe pre-
eclampsia to prevent 
convulsions, 
Nifedipine to control high 
blood pressure,
2 doses of betamethasone 
for foetal lung maturity in 
28-34 weeks gestation.
>20/40 Multiple Increase in 
AST or ALT or 
LDH
Placental abruption
Acute renal failure
Disseminated intravascular 
coagulation
Pulmonary edema
Adult respiratory distress 
syndrome
Retinal detachment
Intracranial bleeding
Maternal death
Woldeselassie 
(2005)
English
Retrospective Cross 
sectional
Consecutive enrolment
Not blinded
Follow up complete
230 Pre-eclampsia 
Exclusion: Only symptomatic with no confirmed 
diagnosis
Anti-hypertensives and 
magnesium sulphate
Not specified Multiple ALT 60
AST 43
LDH 181
Eclampsia
Severe pre-eclampsia (HELLP)
Girling (1997)
English
Prospective
Cross sectional
Consecutive enrolment
Not blinded
Follow up complete
45 Pre-eclampsia
2 consecutive measurements of diastolic BP 
>=90 mm Hg 4 or more hours apart or a single 
reading >=110 mmHg, with proteinuria >0.3g/24h 
or >=2+ on dipstick testing
Exclusion: Liver pathology, hypertension, multiple 
pregnancy
Not specified Not specified Multiple Gestation 
specific 95% 
reference 
range
Third trimester
ALT 32
AST 30
Bilirubin 14
GGT 41
Maternal complications (medical 
complication due to pre 
eclampsia)
Caesarean section
Neonatal death
Pre term delivery
Menzies 
(2007) 
English
Cohort
Prospective
Consecutive enrolment
No blinding
Adequate population, 
test and outcome 
description
Follow up complete
737 Pre-eclampsia of any severity
Inclusion criteria: BP ≥140/90mmHg (twice  
≥ 4 hours apart, after 20 weeks ) and either 
proteinuria ( ≥2+by dipstick,  ≥ 0.3g/24h or  ≥ 
30 mg/mmol by spot protein:creatinine ratio) or 
hyperuricemia
HELLP syndrome
Superimposed pre eclampsia, defined as 
pre existing hypertension with accelerated 
hypertension, new proteinuria or new 
hyperuricemia.
Exclusion criteria: Women who have already 
achieved any component of the adverse maternal 
outcome
Anti hypertensives, 
magnesium sulphate
After 20 
weeks
Multiple LDH 600
ALT/AST 40/55
Adverse maternal outcome 
(death or complication involving 
hepatic or central nervous 
system or renal or respiratory or 
haematological systems)
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with pre-eclampsia
Study Year Test Cut off Sensitivity (95% CI) Specificity (95% CI) LR+ (95% CI) LR- (95% CI)
Eclampsia
Borglin 1958 AST/ ALT Increased 0.67 (0.02-1.0) 0.74 (0.54-0.89) 2.6 (0.70-9.4) 0.45 (0.05-4.4)
Crisp 1959 AST 70 0.93 (0.52-1.0) 0.55 (0.41-0.69) 2.1 (1.5-3.0) 0.12 (0.01-1.8)
Romero 1988 AST 2SD 0.71 (0.29-0.96) 0.80 (0.75-0.85) 3.6 (2.1-6.1) 0.36 (0.11-1.2)
Aali 2004 AST/ ALT 500/ 300 0.27 (0.13-0.46) 0.97 (0.93-0.99) 9.1 (3.3-25.5) 0.75 (0.61-0.93)
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.27 (0.11-0.50) 0.73 (0.66-0.78) 1.0 (0.49-2.0) 1.0 (0.77-1.31)
Abramovici 1999* AST 70 0.34 (0.15-0.65) 0.86 (0.76-0.93) 0.94 (0.37-2.4) 1.0 (0.87-1.2)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.56 (0.21-0.86) 0.51 (0.37-0.65) 1.1 (0.59-2.2) 0.87 (0.40-1.90)
Woldesellasie 2005  AST 43 0.82 (0.48-0.98) 0.16 (0.14-0.20) 0.97 (0.73-1.3) 1.2 (0.31-4.3)
Woldesellasie 2005 ALT 60 0.04 (0.00-0.34) 0.97 (0.92-0.99) 1.3 (0.07-23.4) 0.99 (0.87-1.1)
Woldesellasie 2005 LDH 180 0.70 (0.35-0.93) 0.84 (0.77-0.90) 4.5 (2.5-8.0) 0.36 (0.14-0.92)
Pulmonary oedema
Romero 1988 AST 2SD 0.67 (0.09-0.99) 0.79 (0.74-0.84) 3.2 (1.4-7.5) 0.42 (0.08-2.1)
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.50 (0.19-0.81) 0.73 (0.67-0.79) 1.9 (0.97-3.6) 0.68 (0.37-1.3)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.67 (0.22-0.96) 0.52 (0.38-0.65) 1.4 (0.74-2.6) 0.64 (0.2-2.1)
Adverse maternal outcome
Martin Jr 1999* AST 150 0.70 (0.63-0.77) 0.48 (0.43-0.53) 1.4 (1.2-1.5) 0.62 (0.48-0.8)
Martin Jr 1999* LDH 1400 0.72 (0.65-0.79) 0.49 (0.44-0.54) 1.4 (1.2-1.6) 0.57 (0.44-0.74)
Martin Jr 1999* ALT 100 0.66 (0.59-0.73) 0.47 (0.42-0.52) 1.2 (1.1-1.4) 0.72 (0.57-0.91)
Girling 1997 AST/ ALT/ Bil/ GGT 30/ 32/ 14/ 41 0.93 (0.52-1.0) 0.57 (0.37-0.76) 2.2 (1.4-3.5) 0.12 (0.01-1.7)
Menzies 2007 ALT/ AST 40/55 0.33 (0.22-0.45) 0.80 (0.77-0.84) 1.7 (1.2-2.4) 0.83 (0.71-0.99)
Menzies 2007 LDH 600 0.62 (0.49-0.74) 0.60 (0.56-0.64) 1.6 (1.3-1.9) 0.63 (0.46-0.86)
Abruption
Odendaal 2000* LDH 350 0.07 (0.02-0.16) 0.96 (0.88-0.99) 1.7 (0.41-6.7) 0.97 (0.89-1.1)
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.40 (0.16-0.68) 0.73 (0.67-0.79) 1.5 (0.78-2.9) 0.82 (0.54-1.2)
Haddad 2005* LDH/ AST/ ALT 600/ 70/ 70 0.40 (0.05-0.85) 0.49 (0.36-0.63) 0.79 (0.26-2.4) 1.2 (0.57-2.6)
Maternal death
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.67(0.02-1.0) 0.73 (0.67-0.78) 2.5 (0.78-7.8) 0.46 (0.05-4.4)
Abramovici 1999* AST 70 0.80(0.12-1.0) 0.83 (0.71-0.92) 4.8 (2.1.11.1) 0.24 (0.02-2.8)
Yucesoy 2005 AST/ ALT/ LDH Increased 0.86(0.23-1.0) 0.85 (0.78-0.90) 5.6 (3.2-9.7) 0.17 (0.01-2.2)
Disseminated intravascular coagulation
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.95 (0.63-1.0) 0.76 (0.70-0.81) 3.9 (3.0-5.1) 0.06 (0.00-0.94)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.89 (0.33-1.0) 0.62 (0.47-0.75) 2.3 (1.4-3.7) 0.18 (0.01-2.5)
Intra cerebral haemorrhage
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.67 (0.02-1.0) 0.73 (0.67-0.78) 2.3 (1.4-3.7) 0.46 (0.05-4.4)
Acute renal failure
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.80 (0.12-1.0) 0.73 (0.67-0.79) 3.0 (1.6-5.8) 0.27 (0.02-3.3)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 1.0 (0.03-1.0) 0.51 (0.38-0.64) 1.5 (0.66-3.5) 0.49 (0.04-5.5)
*severe  pre-eclampsia;  ALT:  Alanine  transaminase;  AST:  Aspartate  transaminase;  LDH:  Lactate 
dehydrogenase; GGT: Gamma glutamyltransferase; Bi:Bilirubin; SD: Standard Deviation.
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Table 2a. Accuracy of liver function tests in the prediction of adverse maternal outcomes in women 
with pre-eclampsia
Study Year Test Cut off Sensitivity (95% CI) Specificity (95% CI) LR+ (95% CI) LR- (95% CI)
Eclampsia
Borglin 1958 AST/ ALT Increased 0.67 (0.02-1.0) 0.74 (0.54-0.89) 2.6 (0.70-9.4) 0.45 (0.05-4.4)
Crisp 1959 AST 70 0.93 (0.52-1.0) 0.55 (0.41-0.69) 2.1 (1.5-3.0) 0.12 (0.01-1.8)
Romero 1988 AST 2SD 0.71 (0.29-0.96) 0.80 (0.75-0.85) 3.6 (2.1-6.1) 0.36 (0.11-1.2)
Aali 2004 AST/ ALT 500/ 300 0.27 (0.13-0.46) 0.97 (0.93-0.99) 9.1 (3.3-25.5) 0.75 (0.61-0.93)
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.27 (0.11-0.50) 0.73 (0.66-0.78) 1.0 (0.49-2.0) 1.0 (0.77-1.31)
Abramovici 1999* AST 70 0.34 (0.15-0.65) 0.86 (0.76-0.93) 0.94 (0.37-2.4) 1.0 (0.87-1.2)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.56 (0.21-0.86) 0.51 (0.37-0.65) 1.1 (0.59-2.2) 0.87 (0.40-1.90)
Woldesellasie 2005  AST 43 0.82 (0.48-0.98) 0.16 (0.14-0.20) 0.97 (0.73-1.3) 1.2 (0.31-4.3)
Woldesellasie 2005 ALT 60 0.04 (0.00-0.34) 0.97 (0.92-0.99) 1.3 (0.07-23.4) 0.99 (0.87-1.1)
Woldesellasie 2005 LDH 180 0.70 (0.35-0.93) 0.84 (0.77-0.90) 4.5 (2.5-8.0) 0.36 (0.14-0.92)
Pulmonary oedema
Romero 1988 AST 2SD 0.67 (0.09-0.99) 0.79 (0.74-0.84) 3.2 (1.4-7.5) 0.42 (0.08-2.1)
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.50 (0.19-0.81) 0.73 (0.67-0.79) 1.9 (0.97-3.6) 0.68 (0.37-1.3)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.67 (0.22-0.96) 0.52 (0.38-0.65) 1.4 (0.74-2.6) 0.64 (0.2-2.1)
Adverse maternal outcome
Martin Jr 1999* AST 150 0.70 (0.63-0.77) 0.48 (0.43-0.53) 1.4 (1.2-1.5) 0.62 (0.48-0.8)
Martin Jr 1999* LDH 1400 0.72 (0.65-0.79) 0.49 (0.44-0.54) 1.4 (1.2-1.6) 0.57 (0.44-0.74)
Martin Jr 1999* ALT 100 0.66 (0.59-0.73) 0.47 (0.42-0.52) 1.2 (1.1-1.4) 0.72 (0.57-0.91)
Girling 1997 AST/ ALT/ Bil/ GGT 30/ 32/ 14/ 41 0.93 (0.52-1.0) 0.57 (0.37-0.76) 2.2 (1.4-3.5) 0.12 (0.01-1.7)
Menzies 2007 ALT/ AST 40/55 0.33 (0.22-0.45) 0.80 (0.77-0.84) 1.7 (1.2-2.4) 0.83 (0.71-0.99)
Menzies 2007 LDH 600 0.62 (0.49-0.74) 0.60 (0.56-0.64) 1.6 (1.3-1.9) 0.63 (0.46-0.86)
Abruption
Odendaal 2000* LDH 350 0.07 (0.02-0.16) 0.96 (0.88-0.99) 1.7 (0.41-6.7) 0.97 (0.89-1.1)
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.40 (0.16-0.68) 0.73 (0.67-0.79) 1.5 (0.78-2.9) 0.82 (0.54-1.2)
Haddad 2005* LDH/ AST/ ALT 600/ 70/ 70 0.40 (0.05-0.85) 0.49 (0.36-0.63) 0.79 (0.26-2.4) 1.2 (0.57-2.6)
Maternal death
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.67(0.02-1.0) 0.73 (0.67-0.78) 2.5 (0.78-7.8) 0.46 (0.05-4.4)
Abramovici 1999* AST 70 0.80(0.12-1.0) 0.83 (0.71-0.92) 4.8 (2.1.11.1) 0.24 (0.02-2.8)
Yucesoy 2005 AST/ ALT/ LDH Increased 0.86(0.23-1.0) 0.85 (0.78-0.90) 5.6 (3.2-9.7) 0.17 (0.01-2.2)
Disseminated intravascular coagulation
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.95 (0.63-1.0) 0.76 (0.70-0.81) 3.9 (3.0-5.1) 0.06 (0.00-0.94)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.89 (0.33-1.0) 0.62 (0.47-0.75) 2.3 (1.4-3.7) 0.18 (0.01-2.5)
Intra cerebral haemorrhage
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.67 (0.02-1.0) 0.73 (0.67-0.78) 2.3 (1.4-3.7) 0.46 (0.05-4.4)
Acute renal failure
Audibert 1996* LDH/ AST/ ALT 600/ 70/ 70 0.80 (0.12-1.0) 0.73 (0.67-0.79) 3.0 (1.6-5.8) 0.27 (0.02-3.3)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 1.0 (0.03-1.0) 0.51 (0.38-0.64) 1.5 (0.66-3.5) 0.49 (0.04-5.5)
*severe  pre-eclampsia;  ALT:  Alanine  transaminase;  AST:  Aspartate  transaminase;  LDH:  Lactate 
dehydrogenase; GGT: Gamma glutamyltransferase; Bi:Bilirubin; SD: Standard Deviation.
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pre-eclampsia
Study Year Test Cut off Sensitivity (95% CI) Specificity (95% CI) LR+ (95% CI) LR- (95% CI)
Intra uterine death
Yucesoy 2005 AST/ ALT/ LDH Inc 0.71 (0.29-0.96) 0.86 (0.79-0.91) 4.9 (2.7-9.0) 0.33 (0.1-1.1)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.63 (0.24-0.91) 0.52 (0.38-0.65) 1.3 (0.71-2.4) 0.72 (0.29-1.8)
Neonatal death
Romero 1988 AST 2SD 0.50 (0.16-0.84) 0.80 (0.75-0.84) 2.5 (1.2-5.1) 0.63 (0.31-1.3)
Abramovici 1999* AST 70 0.50 (0.19-0.81) 0.68 (0.60-0.74) 1.5 (0.80-3.0) 0.74 (0.4-1.4)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.38 (0.09-0.76) 0.50 (0.35-0.65) 0.75 (0.29-1.9) 1.3 (0.68-2.3)
Intra uterine growth restriction
Abramovici 1999* AST 70 0.39 (0.25-0.54) 0.68 (0.60-0.74) 1.2 (0.8-1.9) 0.90 (0.70-1.1)
Romero 1988 AST 2SD 0.48 (0.34-0.63) 0.85 (0.80-0.89) 3.2 (2.0-4.9) 0.61 (0.47-0.80)
Respiratory distress syndrome
Abramovici 1999* AST 70 0.51 (0.38-0.64) 0.74 (0.66-0.81) 1.9 (1.3-2.8) 0.67 (0.51-0.88)
Romero 1988 AST 2SD 0.82 (0.60-0.95) 0.84 (0.79-0.89) 5.2 (3.6-7.3) 0.22 (0.09-0.52)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.46 (0.31-0.61) 0.40 (0.12-0.74) 0.76 (0.42-1.4) 1.4 (0.60-3.0)
Intra ventricular haemorrhage
Romero 1988 AST 2SD 0.60 (0.15-0.90) 0.80 (0.74-0.84) 3.0 (1.4-6.3) 0.50 (0.17-1.5)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.33 (0.01-0.91) 0.51 (0.37-0.65) 0.68 (0.13-3.5) 1.3 (0.56-3.0)
Abramovici 1999* AST 70 0.11 (0.00-0.67) 0.66 (0.59-0.73) 0.33 (0.02-4.5) 1.3 (0.96-1.9)
Necrotising enterocolitis
Abramovici 1999* AST 70 0.20 (0.00-0.88) 0.66 (0.59-0.73) 0.59 (0.05-7.1) 1.2 (0.64-2.3)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.50 (0.07-0.93) 0.52 (0.38-0.66) 1.0 (0.38-2.9) 0.96 (0.35-2.6)
Bronchopulmo-nary dysplasia
Abramovici 1999* AST 70 0.68 (0.43-0.87) 0.70 (0.63-0.77) 2.3 (1.6-3.4) 0.45 (0.23-0.88)
Mechanical ventilation
Abramovici 1999* AST 70 0.47 (0.35-0.59) 0.74 (0.66-0.82) 1.8 (1.3-2.7) 0.71 (0.56-0.90)
Preterm birth
Romero 1988 AST 2SD 0.50 (0.37-0.63) 0.88 (0.83-0.92) 4.2 (2.7-6.5) 0.57 (0.44-0.73)
Adverse outcome
Girling 1997 AST/ ALT/ Bil/ GGT 30/ 32/ 14/ 41 0.86 (0.23-1.0) 0.50 (0.32-0.68) 1.7 (0.99-3.0) 0.27 (0.02-3.8)
*severe  pre-eclampsia;  ALT:  Alanine  transaminase;  AST:  Aspartate  transaminase;  LDH:  Lactate 
dehydrogenase; GGT: Gamma glutamyltransferase; Bi:Bilirubin; SD: Standard Deviation
The  sensitivity  of  the  LFT  to  predict  any  maternal  complication  ranged  from 
0.04 (95% CI 0–0.34) to 0.95 (95% CI 0.63–1) and specificity from 0.16 (95% CI 
0.14–0.20) to 0.97 (95% CI 0.92–0.99) respectively. Fig. 3a provides estimates of 
sensitivity and specificity for various maternal outcomes. The AUC for predicting 
any adverse maternal outcome was 0.79 (95% CI 0.51–0.93) (Fig. 4a).
Prediction of fetal outcomes
Five primary studies evaluated accuracy of LFT to predict adverse fetal outcomes 
in 19 2 x 2 tables (Table 2b).11,27,31,32,36 The commonest reported adverse fetal 
outcomes were neonatal death, respiratory distress syndrome and intraventricular 
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Table 2b. Accuracy of liver function tests in the prediction of adverse fetal outcomes in women with 
pre-eclampsia
Study Year Test Cut off Sensitivity (95% CI) Specificity (95% CI) LR+ (95% CI) LR- (95% CI)
Intra uterine death
Yucesoy 2005 AST/ ALT/ LDH Inc 0.71 (0.29-0.96) 0.86 (0.79-0.91) 4.9 (2.7-9.0) 0.33 (0.1-1.1)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.63 (0.24-0.91) 0.52 (0.38-0.65) 1.3 (0.71-2.4) 0.72 (0.29-1.8)
Neonatal death
Romero 1988 AST 2SD 0.50 (0.16-0.84) 0.80 (0.75-0.84) 2.5 (1.2-5.1) 0.63 (0.31-1.3)
Abramovici 1999* AST 70 0.50 (0.19-0.81) 0.68 (0.60-0.74) 1.5 (0.80-3.0) 0.74 (0.4-1.4)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.38 (0.09-0.76) 0.50 (0.35-0.65) 0.75 (0.29-1.9) 1.3 (0.68-2.3)
Intra uterine growth restriction
Abramovici 1999* AST 70 0.39 (0.25-0.54) 0.68 (0.60-0.74) 1.2 (0.8-1.9) 0.90 (0.70-1.1)
Romero 1988 AST 2SD 0.48 (0.34-0.63) 0.85 (0.80-0.89) 3.2 (2.0-4.9) 0.61 (0.47-0.80)
Respiratory distress syndrome
Abramovici 1999* AST 70 0.51 (0.38-0.64) 0.74 (0.66-0.81) 1.9 (1.3-2.8) 0.67 (0.51-0.88)
Romero 1988 AST 2SD 0.82 (0.60-0.95) 0.84 (0.79-0.89) 5.2 (3.6-7.3) 0.22 (0.09-0.52)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.46 (0.31-0.61) 0.40 (0.12-0.74) 0.76 (0.42-1.4) 1.4 (0.60-3.0)
Intra ventricular haemorrhage
Romero 1988 AST 2SD 0.60 (0.15-0.90) 0.80 (0.74-0.84) 3.0 (1.4-6.3) 0.50 (0.17-1.5)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.33 (0.01-0.91) 0.51 (0.37-0.65) 0.68 (0.13-3.5) 1.3 (0.56-3.0)
Abramovici 1999* AST 70 0.11 (0.00-0.67) 0.66 (0.59-0.73) 0.33 (0.02-4.5) 1.3 (0.96-1.9)
Necrotising enterocolitis
Abramovici 1999* AST 70 0.20 (0.00-0.88) 0.66 (0.59-0.73) 0.59 (0.05-7.1) 1.2 (0.64-2.3)
Haddad 2000* LDH/ AST/ ALT 600/ 70/ 70 0.50 (0.07-0.93) 0.52 (0.38-0.66) 1.0 (0.38-2.9) 0.96 (0.35-2.6)
Bronchopulmo-nary dysplasia
Abramovici 1999* AST 70 0.68 (0.43-0.87) 0.70 (0.63-0.77) 2.3 (1.6-3.4) 0.45 (0.23-0.88)
Mechanical ventilation
Abramovici 1999* AST 70 0.47 (0.35-0.59) 0.74 (0.66-0.82) 1.8 (1.3-2.7) 0.71 (0.56-0.90)
Preterm birth
Romero 1988 AST 2SD 0.50 (0.37-0.63) 0.88 (0.83-0.92) 4.2 (2.7-6.5) 0.57 (0.44-0.73)
Adverse outcome
Girling 1997 AST/ ALT/ Bil/ GGT 30/ 32/ 14/ 41 0.86 (0.23-1.0) 0.50 (0.32-0.68) 1.7 (0.99-3.0) 0.27 (0.02-3.8)
*severe  pre-eclampsia;  ALT:  Alanine  transaminase;  AST:  Aspartate  transaminase;  LDH:  Lactate 
dehydrogenase; GGT: Gamma glutamyltransferase; Bi:Bilirubin; SD: Standard Deviation
haemorrhage  as  reported  in  3  studies.11,27,32  The  sensitivity  and  specificity  of 
LFT to predict any adverse fetal outcome ranged from 0.11 (95% CI 0–0.67) to 
0.86 (95% CI 0.23–1) and from 0.40 (95% CI 0.12–0.74) to 0.88 (95% CI 0.83–0.92) 
respectively. The highest sensitivity  and specificity were observed for raised ALT/
AST/GGT/Bilirubin (32/30/41/14) in predicting a composite adverse fetal outcome31 
and  for  levels  of  AST  (≥  2  SD  standard  deviation)  in  predicting  preterm  birth 
respectively.11 Fig. 3b provides estimates of sensitivity and specificity for various 
fetal outcomes. The best likelihood ratios of positive and negative tests for adverse 
fetal outcome were 5.2 (95% CI 3.6–7.3) and 0.22 (95% CI 0.09–0.52) for levels of 
Liver function tests for predicting pre-eclampsia complications
183Figure 3. Receiver Operating  Characteristic (ROC) plane. 
3a. Adverse maternal outcomes. 
3b. Adverse fetal outcomes
Figure 4. Summary Receiver Operating Characteristic (sROC) curve
4a. Maternal adverse outcome, 
4b. Fetal adverse outcome
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AST (≥ 2 SD) in predicting respiratory distress syndrome11. The AUC for predicting 
any adverse fetal outcome was 0.65 (95% CI 0.26–0.90) (Fig. 4b).
DISCUSSION
In  women  with  pre-eclampsia  (PE),  LFTs  were  at  best  moderate  predictors  of 
maternal and fetal complications. The test specificity, however, was better than 
sensitivity. This meant that with a positive test result one could be more confident 
about predicting poor outcome than one could about ruling out complications with 
a negative result.
Current national and international classifications on severity of PE are hampered 
by  the  unknown  disease  aetiology.  However,  uteroplacental  ischemia  causing 
activation of the endothelium seems to play a major role. Endothelial dysfunction 
is considered to underlie many of the clinical symptoms of PE like hypertension, 
increased vascular permeability resulting in edema and proteinuria, and expression 
of  inflammatory  parameters  leading  to  coagulopathy.38-40  These  changes  also 
cause ischemia of target organs, such as brain, liver, kidney and placenta. Fibrin 
deposition,  periportal  haemorrhage,  ischemic  lesions  and  microvesicular  fat 
deposition are histological findings observed in the livers of preeclamptic women.41 
Our published reviews have evaluated the accuracy of uric acid and proteinuria 
in predicting maternal and fetal complications in women with PE.42,43 This paper 
adds further evidence to inform on this subject.
Amongst  all  maternal  outcomes,  studies  that  predicted  eclampsia  performed 
better than others with some showing significant LRs26,30 and high specificity26 
and  sensitivity.30  The  specificity  was  higher  than  70%  in  6  of  the  8  studies 
predicting eclampsia with LFT. On further examination of these studies, Aali et 
al’s patients were women with severe PE and a considerable number of patients 
had poor access to care.26 The largest study to evaluate the role of LFTs in PE 
was the prospective cohort study by Menzies et al.37 The results of this study 
were from unpublished data provided by the authors. The sensitivity of the LFT 
was better for LDH levels of 600 IU/L when compared to ALT/AST of 40/55 IU/l in 
predicting a composite adverse maternal outcome. The converse was true for the 
test specificity.
For  women  with  raised  liver  enzymes,  the  specificity  of  the  test  for  maternal 
outcomes  was  better  than  sensitivity  with  point  estimates  more  than  70%  in 
two-thirds of the 2 x 2 evaluations. Less than half the included 2 x 2 tables had 
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comparison to sensitivity for maternal complication, the study by Crisp et al was 
conducted in late 50s prior with a difference in the quality of healthcare.30 The 
other 2 studies consisted of  women with severe PE and with large proportion of 
patients with HELLP syndrome in comparison to other studies.32,33 It is likely that 
the test performance differs in the subgroup of women with severe PE especially 
those with other factors contributing to maternal complications.
The test performance in predicting adverse fetal outcomes performed similarly 
with the test specificity better than sensitivity. Very few studies evaluating fetal 
outcome had sensitivity more than 50% (Fig. 3). The low specificity observed in 
the studies by Haddad et al, and Abramovici et al could be attributed to the very 
narrow spectrum of the included patients.27,32 The relatively low cut offs chosen 
in the study by Girling et al may have contributed to the low specificity but high 
sensitivity.31 The overall performance of the test was marginally better in predicting 
adverse maternal outcomes than fetal outcomes. The difference however was not 
statistically significant with overlapping confidence intervals.
Our review is the first to systematically collate and appraise the existing evidence 
on the predictive accuracy of LFTs in women with PE. The validity of our findings 
depends on the methodological quality of the systematic review and the quality 
of the included studies. We conducted an extensive search of literature with no 
language restrictions to minimise the risk of missing studies and used contemporary 
statistical  methods.  There  were  limitations  in  the  included  studies.  Firstly,  the 
definition of PE differed between different studies. Secondly, very few studies 
provided details of the test methods and the gestation of testing. The test cut offs 
differed considerably between studies and often with no rationale for the chosen 
threshold values. Information on gestational age may help in better interpretation 
of the predictive role of the test as women with early onset PE with increased risk 
of maternal and fetal complications, where decision making often involves complex 
balancing of maternal benefits against fetal risks. Thirdly, although the tests were 
performed prior to the outcome, no details were available on the time elapsed 
between the test results and the final maternal or fetal outcome. It is possible 
that the outcome could have been modified by time or any interventions like anti 
hypertensives, magnesium sulphate, corticosteroids (treatment paradox).44 Lack 
of information on the predictor variables and treatment. Fourthly, the definition 
of adverse outcome measures differed between the studies. Fifthly, systematic 
reviews and meta analyses are by their very design dependent on the primary 
studies for the data necessary to answer the question. The significant heterogeneity 
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between the studies and paucity of data on predictor variables has constrained us 
from performing multi regression analysis of the effect of these variables on the 
outcome. Although every effort had been made to obtain unpublished data, we 
faced limited success in this endeavour. Despite these provisos this is the best 
available summary of the available studies.
Through this review we have highlighted the moderate ability of abnormal LFT in 
correctly identifying women at increased risk of maternal and fetal complications.   
However, given the uncertainties in the data, making clinical recommendations 
or developing prediction rules for using LFTs is not possible without good quality 
large prospective studies. These studies should especially focus on the sub group 
of women with early onset PE where monitoring has a critical role in prolonging 
gestation.
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General discussion and future perspectives
This  thesis  focused  on  the  choice  between  induction  of  labour  and  expectant 
monitoring in women with pregnancies complicated by hypertensive disease at 
term. The HYpertension and Pre-eclampsia Intervention Trial at Term (HYPITAT) 
aimed to provide clarity on the best treatment for women with a term pregnancy 
complicated  by  gestational  hypertension  (GH)  or  mild  pre-eclampsia  (PE).  We 
found that induction of labour reduced the probability of progression to severe 
disease without increasing (and probably decreasing) the caesarean section rate. 
Induction of labour was also less expensive with the same maternal quality of life. 
The following paragraphs describe the impact of implementation of the HYPITAT 
study results and discuss other clinical decisions in obstetrics which arise from the 
HYPITAT trial. 
Situation prior to HYPITAT
The Dutch Maternal Mortality Committee (1993 – 2005) and the LEMMoN study 
(national study into ethnicity determinants of maternal morbidity in the Netherlands; 
August 2004 – August 2006), describe substantially higher incidences of maternal 
mortality and severe morbidity due to hypertensive disorders in the Netherlands 
than  in  other  Western  countries.1,2  Maternal  deaths  caused  by  hypertensive 
disorders were three times higher than in the UK1,3, and the incidence of eclampsia 
was clearly increased as compared to other neighbouring European countries.2 
Substandard  care  of  hypertensive  disease  of  pregnancy  was  found  in  91%  of 
women with maternal death and in 60% of women with eclampsia.1,2,4 Substandard 
care consisted mainly of failure to check proteinuria in case of an increased blood 
pressure resulting in a delay in detection of PE and suboptimal prophylactic or 
therapeutic treatment with anticonvulsive and antihypertensive medication. 
At the start of the HYPITAT study in 2005, the optimal policy for women with 
pregnancies complicated by hypertensive disease (nearly) at term was not clear, 
due to which in the Netherlands a strong practice variation existed for the treatment 
of women with GH or mild PE beyond 36 weeks’ gestation. This was shown by the 
prior beliefs of Dutch gynaecologists and residents, as stated in the introduction 
of this thesis. Obviously, the attending obstetricians had discordant views in this 
situation and management was individualized to the patient without a proper body 
of knowledge to rely on. In the Netherlands a conservative management was not 
uncommon, whereas in other developed countries a more aggressive management, 
namely delivery after stabilization, was the management of choice. The tendency 
of Dutch obstetricians of being expectant to deliver pre-eclamptic women is also 
reflected by the fact that gestational age at delivery in women with hypertensive 
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197disorders is three weeks higher in the Netherlands as compared to the UK.2,5 This 
discrepancy between the Netherlands and other developed countries regarding 
the treatment of women with hypertensive disease of pregnancy, gave us the 
opportunity to set up a randomised clinical trial, in which induction of labour was 
compared with expectant monitoring. Some hospitals in the Netherlands decided 
not to participate in the HYPITAT trial because they believed that the effect of an 
expectant  management  could  disadvantage  women’s  health.  Their  belief  was 
based on experience, as evidence did not yet exist. In total 38 of the 93 hospitals 
(41%) across the Netherlands participated in the HYPITAT trial. 
Impact of HYPITAT study results on doctors’ behaviour and eclampsia 
rates in the Netherlands
The results of the HYPITAT trial showed that in women with GH or mild PE at term 
induction of labour improved maternal outcome, decreased the caesarean section 
rate and was a costs saving strategy, and should therefore be the treatment of 
choice in these women. We wondered whether the HYPITAT trial had impact on 
doctors’  behaviour  and  provoked  an  increased  number  of  inductions  of  labour 
among women with hypertensive disease of pregnancy at term. Therefore, we 
investigated  whether  participation  of  hospitals  in  the  trial  had  impact  on  the 
implementation of its results and subsequent consequences for maternal health 
in the Netherlands. 
We studied data from the Perinatal Registry of the Netherlands (PRN) from 2001 
until 2009.6 The HYPITAT trial was performed between October 2005 and March 
2008. We identified women with GH or PE with a singleton pregnancy and a fetus 
in cephalic position beyond 36 weeks’ gestation from the PRN, and distinguished 
the period before the trial (January 2001 – October 2005), the period during the trial 
(October 2005 – March 2008) and the period after the trial (April 2008 – December 
2009). We studied trends in onset of labour and the occurrence of eclampsia, both 
in 38 hospitals that participated in the HYPITAT trial, and in 55 hospitals that did not.
Table 1 shows the distribution of spontaneous labour, induced labour and primary 
caesarean section in 22,830, 11,298 and 9,513 patients treated before, during and 
after the trial. The number of women in whom labour was induced increased after 
the HYPITAT trial (58.3% prior versus 67.1% after the trial, p<0.01). This change 
in management was mainly due to hospitals that participated in the trial (12.1% 
increase  in  inductions  in  participating  hospitals  versus  5.1%  increase  in  non 
participating  hospitals).  Similarly,  in  patients  with  a  gestational  age  beyond  36 
weeks, there was a decrease in the risk of suffering from eclampsia: .85% prior 
versus .19% after the trial (p=<0.01). This decrease was specifically observed in 
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the hospitals that participated in the HYPITAT trial, where the decrease was from 
0.95% to .13%. In hospitals not participating in the HYPITAT study this decrease 
was .72% prior versus .28% after the trial.
Several remarks can be made on these apparent consequences of the trial. First, the 
number of patients who were randomised in the HYPITAT trial (n=756) or were asked 
for the study but refused (n=397) was only 18% of the potentially eligible patients 
in the participating hospitals. Second, prior to the trial, the number of inductions of 
labour due to hypertensive disease at term was higher in the hospitals that did not 
participate in the HYPITAT trial. Apparently, those hospitals that had a conservative 
approach prior to the study were more often willing to participate in the trial than 
hospitals that had a priori a more aggressive approach. Third, implementation of 
induction of labour after the trial was better in hospitals that had participated in 
the HYPITAT trial. This was associated with a stronger decrease of cases with 
eclampsia, and a decrease of number of planned caesarean section rates.
In conclusion, participation in this multicentre trial improved doctors’ awareness 
of disease severity due to the best management in women with GH or mild PE at 
term, and had immediate consequences for maternal health.
Impact of the results of the HYPITAT trial in the United Kingdom
The UK National Institute of Clinical Excellence (NICE) has adapted their guidelines 
on ‘Hypertension in Pregnancy’. They mainly mentioned that the overall maternal 
benefits seen in the HYPITAT trial were maintained in the subgroup of women with 
Table 1. Onset of delivery in patients with a singleton pregnancy in cephalic position after 36 weeks’ 
gestation with gestational hypertension or mild preeclampsia.
Onset of labour Eclampsia
Spontaneous 
n (%)
Induction 
n (%)
Planned CS 
n (%)
Missing 
n (%)
All patients
Before the trial (n=22830) 9002 (39.4%) 13313 (58.3%) 474 (2.1%) 41 (0.2%) 193 (.85%)
During the trial (n=11298) 4712 (41.7%) 6345 (56.2%) 208 (1.8%) 33 (0.3%) 34 (.30%)
After the trial (n=9513) 2976 (31.3%) 6385 (67.1%) 134 (1.4%) 18 (0.2%) 18 (.19%)
Patients who delivered in hospitals that did participate in HYPITAT
Before the trial (n=12663) 5608 (44.3%) 6772 (53.5%) 249 (2.0%) 34 (0.3%) 120 (0.95%)
During the trial (n=6571) 3048 (46.4%) 3406 (51.8%) 90 (1.4%) 27 (0.4%) 14 (.21%)
After the trial (n=5475) 1797 (33.2%) 3593 (65.6%) 67 (1.2%) 18 (0.3%) 7 (.13%)
Patients who delivered in hospitals that did not participate in HYPITAT
Before the trial (n=10167) 3394 (33.4%) 6541 (64.3%) 225 (2.2%) 7 (0.1%) 73 (.72%)
During the trial (n=4727) 1664 (35.2%) 2939 (62.2%) 118 (2.5%) 6 (0.1%) 20 (.42%)
After the trial (n=3945) 1143 (29.0%) 2738 (69.4%) 64 (1.6%) 0 11 (.28%)
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women with GH. The Guideline Development Group recommends now induction 
of labour in women with GH whose diastolic blood pressure is greater than 95 
mmHg with or without antihypertensive treatment after 37 weeks’ gestation, and 
advices induction of labour within 24–48 hours after onset of mild or moderate PE 
beyond 37 weeks’ gestation.7
Prediction of maternal complications in hypertensive disease of pregnancy
Over  the  years,  relatively  little  progress  has  been  made  in  predicting  which 
patients will progress to severe disease, how rapid progression might occur, or 
how progression might be impeded once the diagnosis has been made. In this 
thesis several variables are identified in women with mild hypertensive disease 
of  pregnancy  with  an  increased  risk  for  severe  maternal  morbidity,  as  severe 
hypertension, HELLP syndrome, eclampsia and postpartum haemorrhage (Chapter 
6, 7 and 8).  We  identified  clinical characteristics and  specific biochemical  and 
haematological parameters as moderate or good predictors of adverse maternal 
outcome, which may serve to provide guidance for the clinical management of 
these patients. Obesity is one of these predictors which is already known before 
pregnancy. In case of obesity, women should receive appropriate preconceptional 
advice to change their lifestyle and to loose weight prior to conception. We found 
that  systolic  blood  pressure  above  155  mm  Hg  and  proteinuria  equal  or  more 
than  2+  in  a  dipstick  specimen  were  important  predictors  for  severe  disease 
and eclampsia (Chapter 6 and 7). Especially treatment of elevated systolic blood 
pressure has been a neglected topic. Control of severe systolic hypertension is 
an important aspect of the management of women with hypertensive disease of 
pregnancy and it would be obedient to start antihypertensive treatment in women 
with a systolic blood pressure of 155 mm Hg or higher. Worth mentioning are also 
the raised serum uric acid and liver enzymes rates, which seems to be useful 
predictors in the management of PE too (Chapter 10 and 11). We think it is essential 
to ensure that for each individual case a care plan is developed that includes the 
acceptable thresholds of all monitored variables we found for pregnancies. If one 
or more thresholds are exceeded a patient needs to be monitored frequently and 
after 37 weeks’ of gestation an induction of labour has to be considered, particularly 
in women with a low Bishop Score (Chapter 3 and 6).
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Future perspectives
Prediction models
GH and PE are the most common medical disorders during pregnancy and are 
associated  with  maternal  and  perinatal  morbidity  and  mortality.  The  large 
majority of these cases develop at or near term and we know now that induction 
of  labour  prevents  further  maternal  complications.  Moreover  new  insights  into 
the  predictability  of  maternal  complications  in  women  with  pregnancy  related 
hypertension are described in this thesis. Knowledge on the predictors contributing 
to increased neonatal morbidity in women with GH or PE at term is scarce and 
therefore we will aim to assess whether neonatal complications can be predicted 
from clinical data. The identified predictors from this study may guide physicians in 
neonatal care. Although this is an interesting clinical issue during term pregnancies, 
it will be all the more important for preterm pregnancies when the risk of neonatal 
morbidity and mortality is much higher. Late preterm birth has been associated 
with significant increases in respiratory morbidity, neonatal infections, prolonged 
hospital  stays,  and  neonatal  mortality.8,9  Therefore  we  intend  to  perform  this 
investigation not only in women with hypertensive disease of pregnancy beyond 36 
weeks’ of gestation (HYPITAT I) but also in women with a gestational age between 
34 and 37 weeks (HYPITAT II).
Furthermore, we are assessing the predictability of the caesarean section risk in 
women with GH or mild PE at term from clinical data during induction of labour or 
expectant monitoring. The HYPITAT trial showed that induction of labour was likely 
to reduce the risk of caesarean section in pregnant women with mild hypertensive 
disease at term. However, it was not clear whether this observation holds for the 
whole spectrum of patients, including patients with an unripe cervix. Although, the 
subgroup analysis already showed that in the induction group, the rate of caesarean 
section was lower in nulliparous women and in those with cervical Bishop score 
<2, refuting the belief that induction of labour especially in these women increases 
the rate of caesarean section. Additionally, identification of women at increased 
risk of developing severe maternal outcomes is especially important for women 
with a prior caesarean section. Induction of labour in women with a scarred uterus 
may be associated with increased risk of uterine scar rupture, especially when 
prostaglandins are used.10 Hence, identification of women with an increased or 
decreased risk for caesarean section, would result in an overall reduced caesarean 
section  rate  which  subsequently  will  diminish  the  incidence  of  women  with  a 
scarred uterus in a next pregnancy.
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pregnancy complicated by hypertensive disease to identify those women with 
an increased risk of severe maternal or neonatal morbidity. Before such models 
might lead to appropriate management, however, they first have to be subjected to 
internal and external validation. Our study group has already assessed the internal 
validity and extent of overfitting of some models with bootstrapping, providing 
preliminary information on whether the models will hold in the general population. 
However, external validation is needed to verify this and to improve the models for 
use in the general population. A valid, final decision model may make it possible 
to distinguish between pregnant women at high risk and at low risk of developing 
severe complications and to improve future management of these patients, which 
may result in better health care and avoidance of unnecessary interventions in 
low-risk groups. However, this goal is probably far ahead of us and may require a 
lot of additional research.
Two obstetric issues following HYPITAT: 
HYPITAT II and HyRAS
HYpertension and Preeclampsia Intervention Trial At near Term (HYPITAT II)
Until the HYPITAT trial, all guidelines were based on expert opinions rather than 
randomised trials. The HYPITAT trial is the first multicentre trial designed to compare 
the risks and benefits of induction of labour versus expectant monitoring for women 
at ≥36 weeks’ gestation. A ‘grey’ zone still exists for GH or mild PE between 34 and 
37 weeks’ gestation concerning the best timing of birth. Nevertheless, there is 
general agreement that women with stable hypertensive disease at <37 weeks’ 
gestation can benefit from expectant monitoring11-16, however there is no clinical 
evidence. Women with mild PE may progress to severe disease with its risks, 
but it is not clear whether these risks outweigh the risks of planned late preterm 
birth  for  the  baby.  On  the  one  hand,  several  retrospective  and  observational 
studies have reported that 15–30% of women during expectant monitoring will 
progress to severe hypertension or severe PE, with a predisposition of maternal 
multi-organ system involvement which is substantially associated with maternal 
and fetal morbidity and mortality.17-20 On the other hand, termination of pregnancy 
before 37 weeks’ gestation bears a risk for the neonate. In a recent cohort study, 
late preterm neonatal mortality rates per 1,000 live births were 1.1, 1.5, and 0.5 
at 34, 35, and 36 weeks’ gestation, respectively, compared with 0.2 at 39 weeks’ 
gestation (P<.001). Neonatal morbidity was significantly increased at 34, 35, and 
36  weeks’  gestation,  including  ventilator-treated  respiratory  distress,  transient 
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tachypnea, grades 1 or 2 intraventricular haemorrhage, sepsis work-ups, culture-
proven sepsis, phototherapy for hyperbilirubinemia, and intubation in the delivery 
room.  Approximately  80%  of  late  preterm  births  were  attributed  to  idiopathic 
preterm labour or ruptured membranes and 20% to obstetric complications. The 
complication rates vary from 15% at 34 weeks to below 2% at 37 weeks.21
There is an urgent need for randomised trials to investigate the effectiveness and 
efficiency of induction of labour in women with GH or mild PE with a gestational 
age of 34–37 weeks of pregnancy, as compared to expectant monitoring. In view 
of this clinical dilemma, we currently perform a randomised clinical trial in which 
induction of labour is compared to expectant monitoring in those women. The 
primary  outcome  will  be  maternal  morbidity  and  neonatal  respiratory  distress 
syndrome. Also neonatal complications, maternal quality of life and recovery, as 
well as costs are compared. The study is performed in eight perinatal centres and 
more than 40 non-academic hospitals that already collaborate in the Obstetric 
Consortium in which the HYPITAT-I trial was performed.
Hypertension Risk Assessment Study (HyRAS): A 2-year follow-up on the 
HYPITAT study
The  aim  of  this  cohort  study22  is  to  provide  more  insight  into  an  individuals’ 
cardiovascular risk profile following a pregnancy complicated by GH or mild PE, so 
prevention against cardiovascular disease can be started at a relatively young age. 
Cardiovascular disease is the cause of death in 31% of women in the Netherlands.23 
Hypertensive disorders in pregnancy and cardiovascular disease in later life both 
show features of ‘the metabolic syndrome’ and atherosclerosis, so they might 
develop by common pathophysiologic pathways with similar vascular risk factors 
involved.  Vascular  damage  occurring  during  GH  or  PE  may  contribute  to  the 
development of future cardiovascular disease, which has been studied in women 
with severe early-onset PE.24,25 However, data concerning long term effects on 
cardiovascular risk of pregnancies complicated by a hypertensive disorder at term, 
which is more common, is lacking. Therefore, this prospective cohort study is 
performed to establish whether women with GH or PE at term are at increased 
risk  for  cardiovascular  disease  in  later  life.  A  calculated  10-year  cardiovascular 
event risk will allow identification of those women who may benefit from primary 
prevention by tailored interventions, at a relatively young age.
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In clinical practice it is for an obstetrician always important to be aware of the 
risk that serious obstetric complications can develop, because obstetrics can be 
unpredictable and complications may have major impact. Overall, always keep in 
mind: the only course of action that would reliably prevent disease progression 
is to proceed to delivery in those patients presenting with GH or mild PE once a 
reasonable gestational age has been achieved. 
The  relatively  high  incidences  of  maternal  mortality  and  morbidity  due  to 
hypertensive  disorders  of  pregnancy,  the  evidence  of  substandard  treatment 
of these disorders and the results of the HYPITAT trial, should be an alert that 
improvement of the Dutch care system is needed. This accumulation of evidence 
indeed evoked growing awareness among Dutch obstetric caregivers and they 
intended  to  be  more  aggressive  in  their  practical  approach.  We  advocate  a 
reduction in delay of diagnosing PE and assessing and managing disease severity, 
which might be attained by frequent blood pressure measurements, screening 
of  proteinuria  in  case  of  increased  blood  pressures  and  lowering  thresholds 
for  treatment  with  anticonvulsive  and  antihypertensive  medication.  Further 
improvement of obstetric care can be achieved by educating all pregnant women 
about  the  danger  signs  associated  with  serious  complications  of  pregnancy. 
Development  of  a  multi-language  patient  leaflet  with  warning  signs  for  these 
complications may help to reduce delay in treating these women and to decrease 
severe maternal morbidity. Audits of maternal deaths and severe maternal morbidity 
due to hypertensive disorders may lead to better cooperation between midwives, 
nurses and doctors and also improve the obstetrical health care on local, regional 
and national level.26 New guidelines based on good research together with more 
awareness of the public and adequate training of health workers will lead to better 
perinatal outcome for the mother and her baby in the Netherlands.
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Summary
This thesis has been subdivided into two main parts. Part I describes the results of 
a randomised controlled trial, the HYPITAT trial (Hypertension and Pre-eclampsia 
Intervention Trial At Term). Part II addresses prediction of severe maternal morbidity 
in women with a pregnancy complicated with gestational hypertension or (mild) 
pre-eclampsia.
PART I
The randomised trial: HYpertension and Pre-eclampsia Intervention Trial 
At Term (HYPITAT)
Hypertensive  disorders  complicate  about  6-8%  of  pregnancies  and  these 
disorders make a substantial contribution to maternal and neonatal morbidity and 
mortality  worldwide.  Termination  of  pregnancy  is  the  only  definitive  treatment 
in  this  situation,  but  timing  of  delivery  is  debated  in  preterm  as  well  as  term 
gestation. Induction of labour is likely to improve maternal outcome, but possibly 
at the expense of increased probability of caesarean section and adverse neonatal 
outcome. In view of this dilemma, obstetricians are confronted with difficult clinical 
management decisions. In the Netherlands a strong practice variation existed for 
the treatment of women with gestational hypertension (GH) or mild pre-eclampsia 
(PE)  beyond  36  weeks’  gestation.  Obviously,  the  attending  obstetricians  were 
either in doubt or had discordant views in these situations. In most Dutch centres, 
the protocol recommended expectant monitoring, whereas in the USA and other 
developed countries, induction of labour was more general practice in women with 
gestational hypertension or mild PE at term, although these recommendations 
were not based on the results of randomised clinical trials.
The practice variation and uncertainty on the issue in the Netherlands, gave us 
the opportunity to set up a nationwide multicentre randomised clinical trial, in 
which  the  effectiveness  of  induction  of  labour  was  compared  with  expectant 
monitoring. This trial was called the HYPITAT trial, ‘HYpertension and Pre-eclampsia 
Intervention Trial At Term’. The trial started in October 2005 and was part of the 
Dutch Obstetric Consortium, which is a collaboration of obstetric clinics in the 
Netherlands (www.studies-obsgyn.nl/hypitat). Six academic and 32 non-academic 
hospitals participated. The trial was approved by the Institutional Review Board 
of  the  University  of  Leiden  and  was  registered  in  the  clinical  trial  register  as 
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randomisation. The trial was funded by ZonMw (grant number 945-06-553).
Chapter 2 provides a detailed description of the study protocol. Women with a 
singleton pregnancy with a child in cephalic presentation and a gestational age 
between 36+0 and 41+0 weeks whose pregnancy was complicated by GH or 
mild PE were eligible. GH was defined as diastolic blood pressure ≥95 mmHg 
measured  at  two  occasions,  performed  at  least  six  hours  apart.  Mild  PE  was 
defined  as  diastolic  blood  pressure  ≥90  mmHg  measured  at  two  occasions, 
performed at least six hours apart, combined with proteinuria (defined as ≥2+ 
protein on dipstick, >300 mg total protein within a 24-hour urine collection and/or 
protein/creatinine ratio >30 mg/mmol). Exclusion criteria were severe GH or severe 
PE, defined as diastolic blood pressure ≥110 mmHg, systolic blood pressure ≥170 
mmHg and/ or proteinuria ≥5 gram within 24 hours, pre-existing hypertension, 
diabetes  mellitus,  gestational  diabetes  requiring  insulin  therapy,  renal  disease, 
heart disease, previous caesarean section, haemolysis, elevated liver enzymes, 
and low platelets (HELLP) syndrome, oliguria <500 ml within 24-hours, pulmonary 
oedema  or  cyanosis,  HIV  seropositivity,  use  of  intravenous  antihypertensive 
medication, fetal anomalies, intra-uterine growth restriction and abnormalities at 
fetal heart rate (FHR)–monitoring.
The study was staffed by research nurses and midwives, who counselled patients, 
asked informed consent and monitored the study protocol in each centre. Before 
randomisation, cervical length and vaginal digital examination were performed. 
Women  were  randomly  allocated  to  either  induction  of  labour  or  expectant 
monitoring.  Patients  allocated  to  induction  of  labour  were  induced  within  24 
hours  after  randomisation  with  amniotomy  and,  if  needed,  augmentation  with 
oxytocine (Bishop score >6) or with intracervical or intravaginal prostaglandins or 
a balloon catheter (Bishop score ≤6). Patients allocated to expectant monitoring 
were monitored until the onset of spontaneous delivery, except when there was 
a medical indication for delivery. Monitoring consisted of frequent maternal blood 
pressure measurements, assessments of proteinuria, laboratory tests and regular 
assessment of fetal condition. Patients who did not give informed consent for 
randomisation, but who gave authorisation for the use of their medical data, were 
treated according to one of the two protocols at the discretion of the attending 
obstetrician.
The  primary  outcome  of  this  trial  was  a  composite  measure  of  poor  maternal 
outcome, defined as maternal mortality, maternal morbidity (eclampsia, HELLP 
syndrome,  pulmonary  oedema,  thrombo-embolic  disease  and/  or  placental 
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abruption), progression to severe disease (at least one measurement of diastolic 
blood pressure ≥110 mmHg, systolic blood pressure ≥170 mmHg and proteinuria 
≥5  gram/  24  hours)  and  major  postpartum  haemorrhage.  Secondary  outcome 
measures  were  neonatal  mortality,  neonatal  morbidity,  caesarean  and  vaginal 
instrumental delivery rates, quality of life (QoL) and costs. Neonatal morbidity was 
defined as 5-minute Apgar score <7, umbilical artery pH <7.05 or admission to a 
neonatal intensive care unit.
In total 720 women had to be randomised to reduce the risk of poor maternal 
outcome from 12 to 6% (two-sided, α: 0.05; β: 0.80). Assuming a 5% loss to 
follow up, we anticipated randomisation of 750 women. Analyses were performed 
by intention-to-treat. Treatment effect is presented as relative risk (RR) with 95% 
confidence  intervals  (CI),  adjusted  for  the  stratified  randomisation  by  centre, 
parity and underlying disease (i.e. GH or PE). After primary analysis, women were 
classified into subgroups based on their characteristics at trial entry: gestational 
age (36-37, 37-38, 38-39, 39-40 and 40-41 weeks of gestation), parity (nulli- and 
multiparous women), hypertensive related diseases (GH and PE), Bishop score and 
cervical length.
Clinical results of the trial are presented in Chapter 3. Between October 2005 
and March 2008, we identified 1153 eligible women, of whom 756 (66%) gave 
informed  consent  for  randomisation.  We  randomly  assigned  377  women  to 
induction  of  labour  and  379  to  expectant  monitoring.  Baseline  characteristics 
of  the  two  randomised  groups  were  comparable.  Outcome  data  for  all  756 
women were analysed. Women within the expectant monitoring group delivered 
approximately one week later as compared with induction of labour (0.83 [range 
0.04-9.6] vs 6.4 [range 0.08-28.5] days, p<0.001). In 10 (3%) of the 377 women 
allocated to the induction group, labour started spontaneously. In 173 (46%) of the 
379 women allocated to expectant monitoring, labour was induced. Among these 
173 inductions, 125 women (72%) had at least one medical reason for induction, 
whereas induction was elective for 48 women (28%). The composite maternal 
outcome rates were significantly lower in women who were allocated to induction 
of labour as compared to women allocated to expectant monitoring (31% vs 44%, 
RR 0.71 [95% CI 0.59-0.86], p<0.001). Neither maternal death nor eclampsia or 
placental abruption occurred. Four women allocated to induction of labour and 11 
women allocated to expectant monitoring developed HELLP syndrome (1% vs 3%, 
RR 0.37 [95% CI 0.12-1.14]).
Caesarean  sections  were  performed  less  frequently  in  the  induction  group  as 
compared  to  the  expectant  monitoring  group  (14%  vs  19%,  RR  0.75  [95%  CI 
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caesarean section rate was higher among women in whom the composite poor 
maternal outcome occurred. Vaginal instrumental delivery rates were comparable 
between both groups (13% vs 14%, RR 0.93 [95% CI 0.65-1.33]). There were no 
fetal or neonatal deaths in either group. The composite neonatal morbidity rate 
was not statistically significant (6% vs 8%, RR 0.75 [95% CI 0.45-1.26]).
In  almost  all  subgroups  a  trend  toward  a  better  maternal  outcome  was  found 
after induction of labour as compared to expectant monitoring. Only in women 
randomised at a gestational age between 36 and 37 weeks and in women with 
a cervical dilatation >2 cm the point estimate of the RR was above 1. Although 
expected otherwise, induction of labour seems to be the best policy in women 
with an unfavourable cervix.
In  conclusion,  in  pregnant  women  with  mild  hypertensive  disease  beyond  a 
gestational age of 37 weeks, induction of labour is associated with better maternal 
outcome  as  compared  to  expectant  monitoring,  without  resulting  in  a  higher 
caesarean section rate.
In Chapter 4, the maternal health-related quality of life (HR-QoL) of the HYPITAT 
trial is reported. As well as randomised as non-randomised women participated in 
the HR-QoL study. Patients were asked to fill out written validated questionnaires, 
covering background characteristics, condition-specific issues and the Short Form 
(SF-36), European Quality of Life (EuroQoL 6D3L), Hospital Anxiety and Depression 
scale (HADS), and Symptom Check List (SCL-90) at baseline, 6 weeks postpartum 
and  6  months  postpartum.  The  SF-36  was  subdivided  into  the  standardized 
summary scores Physical (PCS) and Mental Component Score (MCS). We analysed 
data of 491 randomised and 220 non-randomised women. We did not find any 
HR-QoL differences between the intervention groups, e.g. the PCS and MCS were 
comparable after 6 weeks (p= 0.37 and p= 0.55) and after 6 months (p= 0.70 and 
p=0.67). We conclude that, despite the clinical benefit of induction of labour, the 
HR-QoL is equal after induction of labour and expectant management in women 
who had GH or PE beyond 36 weeks of gestation.
Besides the clinical effectiveness, it is also important to assess the economic 
consequences of the recommendation to induce labour in hypertensive pregnancies. 
In Chapter 5 we describe the results of the short-term cost-effectiveness analysis, 
which was performed alongside the HYPITAT trial. We used a societal perspective. 
Costs and effects were compared from the moment of randomisation to one year 
postpartum.  The  process  of  care  was  differentiated  into  three  cost  categories 
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(direct medical, non-medical and indirect costs) and provided details on utilisation 
of healthcare resources. Maternal admissions were distinguished into three phases 
(antenatal, delivery and postpartum phase) and into three levels of care (intensive, 
medium, or ward). Estimated unit costs were based on several sources: top-down 
calculations provided by one academic and one general hospital (for maternal and 
neonatal admissions), bottom-up calculation (one hour use of the labour room and 
operating theatre), Dutch standardized prices (visits to primary and paramedical 
health care providers, outpatient visits and non-medical costs), and market prices 
medication).  All  unit  costs  were  expressed  in  2007  Euros  using  the  consumer 
pricing index. Total costs per patient were calculated by multiplying resource use 
per patient by unit costs. The average costs of induction of labour (n= 377) were 
€7.077 versus €7.908 for expectant monitoring (n= 379), with an average difference 
of -€831 (95% CI - €1.561 to - €144). This 11% difference predominantly originated 
from the antepartum period, due to longer admission during expectant monitoring 
(difference - €1.441). During delivery costs in the induction group were higher than 
in the expectant monitoring group, due to longer time in the labour room (difference 
€980).  Until  one  year  postpartum,  women  in  the  expectant  monitoring  group 
generated slightly more costs (difference - €398), because of longer maternal and 
neonatal stays and more specialist visits. No substantial differences were found in 
follow-up and non-medical costs. So, induction of labour is a cost saving strategy 
compared to expectant monitoring in women with GH or mild PE at term.
Main conclusions of the HYPITAT trial
In pregnancies complicated with gestational hypertension or mild pre-eclampsia 
at term:
•  Induction of labour is associated with better maternal outcome as compared to 
expectant monitoring (31% vs 44%, RR 0.71 [95% CI 0.59-0.86]).
•  Induction of labour does not increase the caesarean section rate (14% vs 19%, 
RR 0.75 [95% CI 0.55-1.04]). The higher caesarean section rate in the expectant 
monitoring group is mainly ascribed to deterioration of the maternal condition 
in this group.
•  Induction of labour is also the best treatment option in case of an unfavourable 
cervix.
•  Maternal  quality  of  life  is  equal  after  induction  of  labour  and  expectant 
monitoring.
•  Induction of labour is a cost saving strategy compared to expectant monitoring.
Overall,  induction  of  labour  should  be  advised  in  women  with  gestational 
hypertension and a diastolic blood pressure ≥95 mmHg or mild pre-eclampsia at a 
gestational age beyond 37 weeks.
215
SummaryPART II
Prediction of severe maternal morbidity in gestational hypertension or
(mild) pre-eclampsia
From the HYPITAT trial we learned that the best treatment option in women with 
mild hypertensive disease of pregnancy at term is induction of labour. The goal of 
the second part of this thesis was to formulate more specific recommendations 
to  improve  quality  of  care  and  subsequently  limiting  maternal  mortality  and 
morbidity.  For  the  correct  choice  of  management  for  the  individual  patient, 
identification of women at increased risk of developing severe maternal outcomes 
is of major importance. Early identification will benefit doctors and patients by 
helping to monitor disease severity, guide therapy and will allow clinicians to avoid 
unnecessary interventions in low-risk groups.
In  Chapter  6  a  cohort  study  is  presented,  which  aimed  to  assess  whether 
deterioration of the clinical situation can be predicted in women with GH or mild PE 
at term. Women with a singleton pregnancy, a fetus in cephalic position, between 
36 and 41 weeks of gestation, complicated by GH or mild PE that were managed 
expectantly, were selected from the HYPITAT trial. The outcome of interest was a 
composite outcome of progression to severe disease, defined as eclampsia, HELLP 
syndrome, maternal mortality, diastolic blood pressure ≥110 mmHg, systolic blood 
pressure ≥170 mmHg and/or proteinuria ≥5 gram in 24 hours. We used multiple 
imputation techniques for missing data. Logistic regression was used to determine 
the predictive value of clinical characteristics or laboratory findings and to generate 
a prediction model for clinical deterioration. The predictive value of this model was 
assessed  with  receiver-operating-characteristic  (ROC)  analysis  and  calibration. 
To correct for overestimated regression coefficients, the models were (internally) 
validated by bootstrapping techniques and shrinkage.
We included 703 women, of whom 244 (34.7%) had progression to severe disease. 
After multivariable analysis nulliparity (OR 1.87), maternal age (OR 1.05 per year), 
gestational age (OR 0.88 per week), previous abortion (OR 1.26), ethnicity (OR 2.05 
for non-Caucasian ethnicity), diastolic and systolic blood pressure (OR 1.04 and 1.02 
per mmHg), and the laboratory parameters proteinuria, haemoglobin, platelets, uric 
acid and alanine aminotransferase (ALT) were included in the final model. The area 
under the ROC-curve of this model was 0.71 (95% CI 0.67-0.74). Even though the 
goodness of fit was moderate (p=0.40) internal validation showed the model could 
hold in the overall population. From these results we conclude that after external 
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validation and proof of generalisability, these predictors may be used in obstetric 
clinical management in women with GH or mild PE at term.
Chapter 7 describes a case-control study, in which we aimed to evaluate whether 
eclampsia  can  be  predicted  in  women  with  GH  or  mild  PE  at  term.  Accurate 
prediction of eclampsia is of major importance because in the Netherlands it is 
still the most feared pregnancy complication with an incidence of 6.2 per 10.000 
deliveries. This is markedly increased as compared with other Western European 
countries.  For  this  case-control  study  we  selected  cases  with  GH  or  mild  PE 
who developed eclampsia from the LEMMoN study, a nationwide cohort study 
on severe maternal morbidity. Controls with GH or mild PE who did not develop 
eclampsia were selected from the HYPITAT study. Risk indicators for eclampsia, 
identified in multivariable logistic regression, were used to assess the predictive 
capacity of our model with ROC-curve analysis. Model optimism was assessed 
with bootstrapping.
We compared 76 cases to 1149 controls. In the multivariable analysis maternal 
age (OR 0.93 per year), ethnicity (OR 2.8 for non-Caucasian ethnicity), systolic 
blood  pressure  (1.1  per  mm  Hg),  proteinuria  (OR  3.4  and  6.2  for  2+  and  3+ 
respectively), uric acid (OR 1.8 per unit), creatinine (OR 1.02 per unit), aspartate 
aminotransferase (AST) (OR 1.03 per unit) and lactate dehydrogenase (LDH) (OR 
1.01 per unit) showed a statistically significant association with the occurrence of 
eclampsia. Other variables included in the model were previous fetal loss (OR 4.5), 
previous miscarriage (OR 0.66), gestational age (1.3 per week) and low platelet 
count (OR 0.995 per unit). For some continuous variables a clear cut off point for 
increased risk of developing eclampsia was found: systolic blood pressure >155 
mmHg, creatinine >74 μmol/L, AST >30 U/L and LDH >400 U/L. The area under 
the ROC-curve of this model was 0.92 (95% CI 0.89-0.95). Bootstrapping showed 
minimal optimism of the model, indicating that the model holds for the overall 
population. We concluded that eclampsia can be predicted in women with GH or 
mild PE at term. The identified predictors may provide physicians guidance to start 
prophylactic treatment with magnesium sulphate or to induce labour without delay.
Like  eclampsia,  postpartum  haemorrhage  (PPH)  can  also  generate  serious 
morbidity, with ultimately maternal death. Besides this, PPH has been recognized 
as an important risk factor in pregnant women with hypertensive disorders. In 
the HYPITAT trial 10% of women with GH or mild PE at term were complicated 
with PPH, whereas only 1 to 2% risk of HPP is observed in low risk populations. 
These two reasons make identification of women at increased risk for PPH of major 
importance. Therefore, we investigated in Chapter 8 whether PPH can be predicted 
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after delivery. For this cohort study we used data from the HYPITAT trial as well.
Multiple  imputation  techniques  were  used  for  missing  data.  Two  models 
were created to assess the predictive capacity of PPH. Model A included only 
antepartum variables, whereas model B included both antepartum and intrapartum 
variables. Logistic regression was performed to predict the occurrence of PPH and 
bootstrapping to assess model optimism. The predictive capacity of the models 
was assessed with ROC analysis and calibration.
We included 1132 women, of whom 118 (10.4%) had PPH. Maternal age (OR 1.03 
per year), body mass index (OR 0.97 per kg), gestational age at randomisation (OR 
1.19 per week), proteinuria (OR 3.06 for +++ on dipstick), platelets (OR 0.997 per 
unit) and AST (OR 0.98 per unit) were independent antepartum predictors of PPH. 
Intrapartum variables incorporated in the model were gestational age at delivery 
(OR 1.21 per week), birth weight (OR 1.36 per kg), mode of delivery (OR 1.06 and 1.67 
for vaginal instrumental and caesarean delivery, respectively) and episiotomy (OR 
2.1). Model A showed moderate discrimination, with an area under the ROC-curve 
of 0.63 (95% CI 0.57-0.69), whereas model B was slightly superior (AUC 0.69, 95% 
CI 0.63-0.74). Calibration was poor for model A, but better for model B (Hosmer-
Lemeshow  p=0.17  and  0.57).  Bootstrapping  indicated  some  overfitting.  From 
these results we concluded that in women with GH or mild PE at term, PPH can 
be predicted from antepartum and intrapartum variables. The identified predictors 
should alert clinicians managing labour in these women
In the last two chapters of this thesis two specific laboratory tests are highlighted, 
in which we aimed to determine the accuracy of these tests for predicting adverse 
outcomes  in  PE.  Chapter  9  presents  a  bivariate  meta-analysis  and  decision 
analysis of the accuracy of serum uric acid as a predicting test for severe maternal 
morbidity  in  women  diagnosed  with  PE.  For  this  study  an  existing  systematic 
review on the subject was updated. First a summary ROC-curve was estimated 
and  subsequently  a  clinical  decision  analysis  was  performed.  Three  strategies 
were modelled: (I) expectant monitoring until spontaneous delivery; (II) induction of 
labour; (III) serum uric acid as test for predicting maternal complication. In strategy 
III, labour was induced in case of increased serum uric acid levels, otherwise women 
were  managed  expectantly.  The  decision  whether  to  use  the  policy  expectant 
monitoring, induction of labour, or to test serum uric acid levels, is based on the 
expected utility of each strategy. This expected utility depends on the probability 
of occurrence of severe maternal complications (i.e. severe hypertension, HELLP 
syndrome and eclampsia) and the mode of delivery (spontaneous delivery versus 
caesarean section). Valuation of the outcomes was performed using a distress ratio, 
21812
chapter
which expresses how much worse a complication of PE is valued as compared to 
a caesarean section.
For the period until 2007 our search revealed eight primary articles, which met 
the inclusion criteria. In total 1565 women with PE were included in this study. 
The most common threshold of serum uric acid was 350 μmol/l. The AUC was 
68%, which was used in the clinical decision analysis. If the distress ratio was 10, 
the strategy regarding serum uric acid would be the preferred strategy when the 
probability of complications was between 2.9 and 6.3%. At higher complication 
rates induction of labour would be preferred, whereas at lower complication rates 
expectant management would be the best treatment option. These findings were 
stable in sensitivity analyses, using different distress ratios. We concluded that 
serum uric acid seems to be a useful test in the management of PE under realistic 
assumptions, based on our decision analysis.
Liver function tests are the second laboratory tests which are elucidated by us. 
These tests are currently routinely performed in most obstetric units as part of 
the battery of tests in women with PE. However, systematic reviews exploring 
the accuracy of liver enzymes to predict complications of PE have never been 
published.  Therefore,  we  conducted  a  systematic  review  to  obtain  precise 
estimates of maternal serum liver enzyme levels to predict adverse maternal and 
fetal complications in women with PE, which is presented in Chapter 10. After an 
electronic search in Medline, Embase and the Cochrane Library and a complete 
examination of the manuscripts, obtained by two independent reviewers, thirteen 
primary studies were identified with a total of 3507 women. For the prediction 
of adverse maternal and fetal outcomes 30 and 19 2 x 2 tables were assessed. 
Eclampsia was the commonest adverse maternal outcome that was reported. The 
commonest  reported  adverse  fetal  outcomes  were  neonatal  death,  respiratory 
distress syndrome and intraventricular haemorrhage. The AUC for predicting any 
adverse maternal outcome was 0.79 (95% CI 0.51–0.93) and for predicting any 
adverse fetal  outcome  it  was  0.65 (95% CI 0.26–0.90).  For both  maternal  and 
fetal  outcomes  the  test  specificity  was  better  than  sensitivity.  In  conclusion, 
liver  function  tests  performed  better  in  predicting  adverse  maternal  than  fetal 
outcomes in women with PE. Presence of raised liver enzymes was associated 
with an increased probability of maternal and fetal complications, but normal liver 
enzymes did not rule out disease.
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Nederlandse samenvatting
Dit proefschrift is opgesplitst in twee hoofddelen. In deel I worden de resultaten 
van een gerandomiseerde studie getoond. Deze studie heet de HYPITAT-studie 
(HYpertension  and  Pre-eclampsia  Intervention  Trial  At  Term).  Deel  II  van  dit 
proefschrift behandelt de predictie van ernstige maternale morbiditeit bij vrouwen 
met een zwangerschap die gecompliceerd is door zwangerschapshypertensie of 
(milde) preëclampsie.
DEEL I
De gerandomiseerde trial: HYpertension and Pre-eclampsia Intervention 
Trial At Term (HYPITAT)
Zwangerschapshypertensie  en  preëclampsie  (PE)  compliceren  6-8%  van  alle 
zwangerschappen.  Deze  aandoeningen  vormen  in  Nederland  de  belangrijkste 
oorzaak  van  maternale  morbiditeit  en  mortaliteit.  Vaak  is  het  ziektebeeld  mild 
en  wordt  de  diagnose  gesteld  in  de  aterme  periode.  Soms  treden  ernstige 
complicaties  op,  zoals  eclampsie,  abruptio  placentae  en  het  HELLP-syndroom 
(‘haemolysis,  elevated  liver  enzymes  and  low  platelets’).  Wereldwijd  is  er 
tot  nu  geen  overeenstemming  over  het  beste  beleid  bij  vrouwen  met  een 
zwangerschapshypertensie  of  milde  PE  vanaf  36  weken  amenorroe.  Inleiden 
van  de  baring  zou  enerzijds  maternale  complicaties  kunnen  reduceren,  maar 
anderzijds de kans op een sectio caesarea en op neonatale complicaties kunnen 
verhogen. In Nederland werden voor uitvoering van de trial twee verschillende 
behandelmethoden gebruikt: bij ongeveer de helft van de vrouwen werd de baring 
ingeleid en bij de andere helft werd er afgewacht. In de Verenigde Staten en andere 
westerse landen werd in deze situatie veel vaker de baring nagestreefd, hoewel dit 
niet gebaseerd was op gerandomiseerd onderzoek.
Door gebrek aan consensus en het inconsequente Nederlandse beleid, was het 
in Nederland mogelijk om een gerandomiseerde studie uit te voeren, waarin de 
effectiviteit van een inleiding van de baring werd vergeleken met een afwachtend 
beleid bij vrouwen met zwangerschapshypertensie of milde PE vanaf 36 weken 
amenorroe.  Deze  multicentrisch  gerandomiseerde  studie,  de  HYPITAT-studie 
(HYpertension  and  Pre-eclampsia  Intervention  Trial  At  Term),  startte  in  oktober 
2005  en  werd  uitgevoerd  binnen  het  verloskundige  consortium,  een  landelijk 
netwerk  voor  verloskundig  onderzoek.  In  totaal  werkten  6  universitaire  en  32 
niet-universitaire ziekenhuizen mee aan dit onderzoek. De studie werd goedgekeurd 
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geregistreerd in het klinische trialregister (ISCTN08132825). Alle patiënten gaven 
schriftelijke  toestemming  voor  deelname.  De  uitvoering  van  dit  project  werd 
mogelijk gemaakt door een subsidie van ZonMW (nummer 945-06-553).
In Hoofdstuk 2 wordt het studieprotocol van de HYPITAT-studie beschreven. 
Vrouwen  vanaf  18  jaar  met  een  eenlingzwangerschap  gecompliceerd  door 
zwangerschapshypertensie of milde PE tussen 36+0 en 41+0 weken amenorroe 
werden geïncludeerd. Zwangerschapshypertensie werd gediagnosticeerd bij een 
diastolische bloeddruk ≥95 mmHg en milde PE bij een diastolische bloeddruk 
≥90 mmHg gecombineerd met proteïnurie; beide twee keer gemeten met een 
tussentijd  van  tenminste  zes  uur.  Er  was  sprake  van  proteïnurie  wanneer  de 
dipstick ≥2+ proteïne liet zien, of wanneer de 24-uurs urine ≥0.3 gram was of bij 
een eiwit/kreatinine ratio (EKR) >30 mg/mmol. Exclusiecriteria waren diastolische 
bloeddruk ≥110 mmHg, systolische bloeddruk ≥170 mmHg, proteïnurie ≥5 gram/24 
uur,  sectiolitteken,  stuitligging,  pre-existente  hypertensie,  diabetes  mellitus, 
diabetes  gravidarum  met  insulinetherapie,  nierziekten,  hart-  en  vaatziekten, 
HIV-seropositiviteit,  HELLP-syndroom,  longoedeem  of  cyanosis,  oligurie  <500 
mL/24 uur, intraveneuze antihypertensiva, CTG-afwijkingen, congenitale afwijkingen 
en intra-uteriene groeirestrictie.
Voor randomisatie werden een vaginaal toucher en cervixlengte meting verricht. 
De randomisatie voor inleiden van de baring dan wel afwachten was gestratificeerd 
voor  centrum,  pariteit  en  aanwezigheid  van  proteïnurie.  Het  inleiden  van  de 
baring geschiedde binnen 24 uur na randomisatie door middel van amniotomie 
of  intraveneuze  oxytocine  bij  een  Bishopscore  >6,  en  door  intracervicale  of 
intravaginale toediening van prostaglandine of ballonkatheter bij een Bishopscore 
≤6.  De  afwachtgroep  werd  volgens  lokaal  protocol  gecontroleerd  totdat  een 
spontaan begin van de baring optrad. Bij een medische indicatie, als maternale 
ziekte of langdurig gebroken vliezen, werd de zwangerschap alsnog beëindigd.
De  primaire  uitkomst  was  een  samengestelde  uitkomstmaat  gedefinieerd  als 
maternale  mortaliteit,  maternale  morbiditeit  (eclampsie,  HELLP-syndroom, 
longoedeem, trombo-embolische ziekte of abruptio placentae), ontwikkeling van 
ernstige PE (tenminste één keer gemeten diastolische bloeddruk ≥110 mmHg, 
systolische bloeddruk ≥170 mmHg of proteïnurie ≥5 g/24 uur) of hemorrhagie 
postpartum.  Secundaire  uitkomsten  waren  de  wijze  van  bevallen,  neonatale 
mortaliteit en morbiditeit, kwaliteit van leven en kosten. Neonatale morbiditeit was 
een samengestelde uitkomstmaat van Apgarscore <7 na 5 minuten, arteriële pH 
<7.05 of IC-opname.
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In totaal waren er 720 vrouwen nodig om een reductie van maternale complicaties 
van  12  naar  6%  aan  te  tonen  (2-zijdige  test,  alpha  0.05;  beta  0.80).  Rekening 
houdend  met  een  verlies  van  5%  in  de  follow-up  werden  er  756  vrouwen 
gerandomiseerd. Het behandeleffect werd uitgedrukt in relatief risico (RR) met 95% 
betrouwbaarheidsintervallen  (BI).  Wij  verrichtten  exploratieve  subgroepanalyses 
voor amenorroe (36-37, 37-38, 38-39, 39-40 en 40-41 weken), pariteit (nulli- versus 
multipara), proteïnurie (zwangerschapshypertensie of PE), systolische bloeddruk 
(<140 and ≥140 mmHg), evenals Bishopscore en cervixlengte op het moment van 
randomisatie. Het ‘intention-to-treat’ principe werd gehanteerd.
Hoofdstuk 3 beschrijft de klinische resultaten van deze studie. Tussen oktober 
2005 en maart 2008 voldeden 1153 vrouwen aan de inclusiecriteria, waarvan 756 
vrouwen (66%) toestemming gaven voor randomisatie. Er werden 377 patiënten 
gerandomiseerd  voor  inleiden  en  379  voor  afwachten.  De  gerandomiseerde 
vrouwen in de inleid- en afwachtgroep hadden vergelijkbare karakteristieken. De 
zwangerschapsduur was in de inleidgroep gemiddeld één week korter dan in de 
afwachtgroep (0.83 [0.46-2.8] vs 6.4 [0.83-19.9] dagen, p<0.001). Bij 10 vrouwen 
(3%) in de inleidgroep startte de baring spontaan. In de afwachtgroep werd de 
baring alsnog ingeleid bij 173 vrouwen (46%); bij 125 vrouwen (72%) om medische 
redenen,  bij  48  vrouwen  (28%)  om  electieve  redenen.  Verslechtering  van  de 
maternale uitkomst trad in de inleidgroep significant minder vaak op dan in de 
afwachtgroep  (31%  vs  44%,  RR  0.71  [95%  BI  0.59-0.86],  p<0.001).  Maternale 
sterfte,  eclampsie  en  abruptio  placentae  kwamen  niet  voor.  Bij  vier  vrouwen 
uit de inleidgroep en elf vrouwen uit de afwachtgroep werd de zwangerschap 
gecompliceerd door het HELLP-syndroom (1% vs 3%, RR 0.37 [95% CI 0.12-1.14]).
Het sectiopercentage in de inleidgroep was lager dan in de afwachtgroep, hoewel 
het verschil niet significant was (14% vs 19%, RR 0.75 [95% BI 0.55-1.04]). Zowel 
in  de  inleidgroep  als  in  de  afwachtgroep  was  het  sectiopercentage  hoger  bij 
vrouwen met een slechte maternale uitkomst. In beide groepen werden evenveel 
kunstverlossingen verricht (13% vs 14%, RR 0.93 [95% CI 0.65-1.33]). De neonatale 
morbiditeit was ook vergelijkbaar (6% vs 8%, RR 0.75 [95% BI 0.45-1.26]). Perinatale 
sterfte trad niet op.
Bijna alle subgroepen toonden een trend naar reductie in maternale complicaties 
na inleiden in vergelijking met afwachten. Alleen tussen 36-37 weken amenorroe 
en bij een ontsluiting van >2 cm was er geen gunstig effect van inleiden op de 
maternale conditie. Hiermee lijkt een inleiding van de baring tegen de verwachting 
in gunstig te zijn voor vrouwen met een onrijpe portio. 
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Nederlandse samenvattingHet inleiden van de baring bij zwangere vrouwen met een zwangerschapsgerelateerde 
hypertensieve  aandoening  vanaf  37  weken  amenorroe  verbetert  de  maternale 
uitkomst in vergelijking met een afwachtend beleid, zonder een verhoogde kans op 
een sectio caesarea.
In  Hoofdstuk  4  wordt  de  gezondheidsgerelateerde  kwaliteit  van  leven 
(HR-QoL) van moeders in de HYPITAT-studie beschreven. Zowel vrouwen uit de 
gerandomiseerde groep als vrouwen uit de niet-gerandomiseerde groep werden 
geïncludeerd in deze studie. De vrouwen werd gevraagd om gevalideerde HR-QoL 
vragenlijsten in te vullen op het moment van inclusie en 6 weken en 6 maanden 
postpartum. De vragenlijsten betroffen de Short Form (SF-36), waarin een ‘fysieke-
componentscore’  en  een  ‘mentale-componentscore’  gerapporteerd  staan,  de 
European  Quality  of  Life  (EuroQoL  6D3L),  de  Hospital  Anxiety  and  Depression 
scale  (HADS),  en  de  Symptom  Check  List  (SCL-90).  In  totaal  werden  er  491 
gerandomiseerde vrouwen en 220 niet-gerandomiseerde vrouwen geanalyseerd. 
Op de fysieke-componentscore verbeterde de kwaliteit van leven in beide groepen 
substantieel  tussen  de  uitgangswaarden  en  6  weken  postpartum  (p<0.001). 
Tussen inleiden en afwachten werd noch op de fysieke-componentscore noch op 
de mentale-componentscore verschil gemeten op 6 weken ( respectievelijk p=0.37 
en p=0.55) en op 6 maanden postpartum (respectievelijk p=0.70 en p=0.67). De 
overige vragenlijsten lieten ook geen systematische verschillen zien in de HR-QoL 
tussen vrouwen die zijn ingeleid en die hebben afgewacht. Er zijn dus geen lange 
termijn verschillen tussen de maternale HR-QoL na inleiden of na afwachten bij 
zwangerschapshypertensie of milde PE na 36 weken zwangerschap.
Naast de onderzoeksvraag van de klinische uitkomsten in de HYPITAT-studie, is het 
ook belangrijk om de economische gevolgen van een inleiding van de baring of een 
afwachtend beleid te onderzoeken bij vrouwen met een zwangerschapsgerelateerde 
hypertensie  na  36  weken  amenorroe.  In  Hoofdstuk  5  worden  de  resultaten 
beschreven  van  de  korte-termijn  kosteneffectiviteitanalyse,  die  naast  de 
HYPITAT-studie werd uitgevoerd. De economische analyse werd verricht vanuit 
maatschappelijk perspectief en de kosten werden vergeleken vanaf het moment 
van randomisatie tot één jaar postpartum. Wij differentieerden de kosten in drie 
categorieën  (direct  medisch,  niet-medisch  en  indirecte  kosten).  De  maternale 
opname werd onderverdeeld in drie fasen: antenataal, perinataal en postnataal, 
tevens werd er onderscheid gemaakt in het niveau van de zorg: intensive care, 
medium care, kraamafdeling of thuiszorg. Voor maternale en neonatale opnames 
waren kostprijzen beschikbaar van één academisch en één perifeer ziekenhuis. 
De  kosten  van  een  uur  verloskamer-  en  operatiekamergebruik  werden  geschat 
door een bottom-up-berekening waarin zowel personeel, materiaal als overhead 
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werden geïntegreerd. Voor andere eenheidskosten, zoals policontroles, thuiszorg 
of reiskosten, werden nationale standaardkostprijzen gebruikt (in euro’s, prijsniveau 
2007). Wij berekenden de totale kosten per patiënt door vermenigvuldiging van 
zorggebruik met eenheidskosten, uitgedrukt in gemiddelde kosten. Antepartum 
waren  de  kosten €1.441,-  per  patiënt  lager  in  de  inleidgroep,  wat  voornamelijk 
werd veroorzaakt door een kortere maternale opname. De bevalling kostte in de 
inleidgroep daarentegen €980,- per patiënt meer; door een langere opnameduur 
op  de  verloskamer.  De  postpartumkosten  waren  €398,-  per  patiënt  lager  in 
de inleidgroep. Er waren geen substantiële verschillen in de follow-up en in de 
niet-medische  kosten.  De  gemiddelde  kosten  per  patiënt  waren  €7.077,-  voor 
inleiden en €7.908,- voor afwachten, een verschil van - €831,- (95% BI -€1561,- tot 
-€144,-). Een inleiding van de baring is dus kostenbesparend in vergelijking met een 
afwachtend beleid.
Belangrijkste conclusies van de HYPITAT-studie
Voor zwangerschappen gecompliceerd door zwangerschapshypertensie of milde 
preëclampsie vanaf een amenorroe van 37 weken, geldt:
•  Inleiden van de baring verbetert de maternale uitkomst in vergelijking met een 
afwachtend beleid (31% vs 44%, RR 0.71 [95% BI 0.59-0.86]).
•  Inleiden van de baring verhoogt het risico op een sectio caesarea niet. Er is 
zelfs een trend naar een lager sectiopercentage na inleiden ten opzichte van 
een afwachtend beleid (14% vs 19%, RR 0.75 [95% BI 0.55-1.04]). Het hogere 
sectiopercentage  in  de  afwachtgroep  wordt  hoofdzakelijk  verklaard  doordat 
vrouwen in deze groep vaker een slechtere maternale conditie ontwikkelen.
•  Ook bij een onrijpe portio is een inleiding de geïndiceerde behandelmethode.
•  Inleiden van de baring leidt niet tot een slechtere maternale kwaliteit van leven 
op de lange termijn.
•  Inleiden is aanzienlijk goedkoper dan afwachten.
DEEL II
Predictie van ernstige maternale morbiditeit bij zwangerschapshypertensie 
of (milde) preëclampsie
De resultaten van de HYPITAT-studie verschaffen duidelijkheid omtrent het beste 
beleid bij vrouwen met een milde zwangerschapsgerelateerde hypertensie aterme, 
namelijk een inleiding van de baring. Het doel van een inleiding is het voorkomen 
van  ernstige  maternale  morbiditeit;  daarom  is  het  van  belang  om  vrouwen 
met  een  hoger  risico  op  een  slechte  maternale  uitkomst  zo  vroeg  mogelijk  te 
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effectievere behandelingen worden ingezet en onnodige interventies kunnen in de 
laagrisicogroepen worden vermeden.
Hoofdstuk 6 beschrijft welke factoren het optreden van een ernstige maternale 
complicatie kunnen voorspellen bij vrouwen met een zwangerschapshypertensie 
of milde PE aterme. Vrouwen met een eenling zwangerschap met een foetus in 
hoofdligging, een amenorroe tussen 36 en 41 weken, bij wie de zwangerschap 
gecompliceerd werd door zwangerschapshypertensie of milde PE en bij wie een 
afwachtend  beleid  werd  gevoerd,  werden  geselecteerd  uit  de  HYPITAT-studie. 
De  uitkomst  die  bestudeerd  werd  was  een  samengestelde  uitkomstmaat  van 
ernstige  maternale  morbiditeit,  gedefinieerd  als  eclampsie,  HELLP-syndroom, 
maternale sterfte en ernstige PE (diastolische bloeddruk ≥110 mmHg, systolische 
bloeddruk ≥170 mmHg of proteïnurie ≥5 g/24 uur). Multipele imputatie technieken 
werden gebruikt voor de missende data. Met behulp van multivariabele logistische 
regressie werden er predictiemodellen gemaakt. De prestatie van de modellen werd 
onderzocht door middel van ‘receiver-operating-characteristic’ (ROC) analyses en 
kalibratie. Om te corrigeren voor een overschatting van de regressie coëfficiënten, 
werden de modellen (intern) gevalideerd door ‘bootstrapping’ technieken.
In  totaal  werden  er  703  vrouwen  geïncludeerd  in  deze  cohort  studie,  waarvan 
244 (35%) vrouwen ernstige maternale morbiditeit ontwikkelden. Onafhankelijke 
predictoren  van  ernstige  maternale  morbiditeit  waren  nullipariteit  (OR  1.87), 
maternale  leeftijd  (OR  1.05  per  jaar),  zwangerschapsduur  (OR  0.88  per  week), 
abortus in de anamnese (OR 1.26), etniciteit (OR 2.05 voor het niet-Kaukasische 
ras),  diastolische  en  systolische  bloeddruk  (OR  1.04  en  1.02  per  mmHg),  en 
verschillende laboratorium parameters als proteïnurie, hemoglobine, trombocyten, 
urinezuur en alanine-aminotransferase (ALAT). De discriminerende waarde van het 
model was goed met een ‘area under curve’ (AUC) van 0.71 (95% CI 0.67-0.74). 
Ondanks  de  matige  kalibratie  (Hosmer-Lemeshow  p=  0.40),  laat  de  interne 
validatie zien dat het model van waarde zou kunnen zijn in de algemene populatie. 
Uit deze resultaten concluderen wij dat na externe validatie en een bewijs van 
generaliseerbaarheid van onze resultaten, de in deze studie gevonden predictoren 
gebruikt kunnen worden in het obstetrische klinische beleid van vrouwen met een 
zwangerschapshypertensie of milde PE aterme.
In Hoofdstuk 7 worden de resultaten getoond van een case-control studie, waarin 
de predictie van eclampsie bij vrouwen met een zwangerschapshypertensie of 
milde PE in de aterme periode is onderzocht. Predictie van eclampsie is belangrijk, 
omdat in Nederland de incidentie van eclampsie 6.2 per 10.000 bevallingen is, een 
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aanzienlijk hoger cijfer dan in andere West-Europese landen. Cases waren vrouwen 
met een zwangerschapshypertensie of milde PE die na een zwangerschapsduur van 
36 weken een eclampsie ontwikkelden. Deze vrouwen werden geselecteerd vanuit 
de LEMMoN-studie, een landelijke studie naar ernstige maternale morbiditeit. De 
controle groep bestond uit vrouwen met een zwangerschapshypertensie of milde 
PE zonder eclampsie, geselecteerd vanuit de HYPITAT-studie. Risico-indicatoren 
voor eclampsie werden geïdentificeerd met multivariabele logistische regressie en 
vervolgens gebruikt om de voorspellende capaciteit van ons model te testen met 
ROC analyse. De interne validatie werd getest met bootstrapping.
Wij  vergeleken  76  cases  met  1149  controles.  Variabelen  met  een  significante 
associatie met eclampsie waren: maternale leeftijd (OR 0.93 per jaar), etniciteit 
(OR  2.8  voor  niet-Kaukasisch  ras),  systolische  bloeddruk  (1.1  per  mm  Hg), 
proteïnurie (OR 3.4 en 6.2 voor 2+ en 3+ respectievelijk), urinezuur (OR 1.8 per 
unit), kreatinine (OR 1.02 per unit), aspartaat aminotransferase (ASAT) (OR 1.03 
per unit) en lactaat dehydrogenase (LDH) (OR 1.01 per unit). Andere variabelen 
die werden geïncludeerd in het predictiemodel waren foetale sterfte in anamnese 
(OR 4.5), miskraam in anamnese (OR 0.66), zwangerschapsduur (1.3 per week) 
en trombocyten (OR 0.995 per unit). Sommige continue variabelen hadden een 
duidelijk afkappunt waarboven het risico op een eclampsie sterk vergroot was: 
systolische bloeddruk >155 mmHg, kreatinine >74 μmol/L, ASAT >30 U/L en LDH 
>400 U/L. De AUC van dit model was 0.92 (95% CI 0.89-0.95) met een minimale 
overschatting van het model. Als conclusie stellen we dat eclampsie voorspelbaar 
is  bij  vrouwen  met  een  zwangerschapshypertensie  of  milde  PE  in  de  aterme 
periode. De geïdentificeerde risico-indicatoren zouden de gynaecoloog leidraad 
kunnen  geven  in  de  profylactische  behandeling  met  magnesiumsulfaat  en  het 
onmiddellijk inleiden van de baring.
Net  als  eclampsie,  kan  hemorrhagie  postpartum  (HPP)  ook  ernstige  maternale 
morbiditeit  genereren,  en  uiteindelijk  leiden  tot  maternale  sterfte.  Daarnaast 
lijkt  HPP  geassocieerd  te  zijn  met  zwangerschapsgerelateerde  hypertensieve 
aandoeningen.  In  de  HYPITAT-studie  ontwikkelde  10%  van  de  vrouwen  met 
zwangerschapshypertensie  of  milde  PE  een  HPP,  een  aanmerkelijk  hoger 
incidentiecijfer dan de 1-2% voor ongecompliceerde zwangerschappen. De twee 
bovengenoemde redenen laten zien dat identificatie van risicofactoren voor het 
optreden van HPP van groot belang is. Daarom onderzochten wij in Hoofdstuk 8 
of predictie van HPP bij vrouwen met een zwangerschapshypertensie of milde PE 
in de aterme periode mogelijk is. HPP werd gedefinieerd als meer dan 1000 ml 
bloedverlies in de eerste 24 uur na de partus. Voor deze cohort studie maakten wij 
gebruik van de HYPITAT database. Wij onderzochten de voorspellende capaciteit 
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B  hebben  wij  naast  de  antepartum  variabelen  ook  de  intra  partum  variabelen 
meegenomen. Multipele imputatie,  logistische  regressie analyse, ROC-analyse, 
kalibratie en bootstrapping werden eveneens toegepast om de predictie van HPP 
te onderzoeken.
In totaal werden er 1132 vrouwen geïncludeerd, waarvan 118 (10.4%) vrouwen een 
HPP kregen. Maternale leeftijd (OR 1.03 per jaar), body mass index (OR 0.97 per 
kg), zwangerschapsduur bij randomisatie (OR 1.19 per week), proteïnurie (OR 3.06 
voor +++ dipstick), trombocyten (OR 0.997 per unit) en ASAT (OR 0.98 per unit) 
waren onafhankelijke, antepartum voorspellers van HPP. Intra partum variabelen 
die werden geïncludeerd in Model B waren zwangerschapsduur bij de bevalling 
(OR  1.21  per  week),  geboortegewicht  (OR  1.36  per  kg),  modus  van  de  partus 
(OR 1.06 en 1.67 voor een kunstbevalling en sectio caesarea, respectievelijk) en 
episiotomie (OR 2.1). Model A liet een matige discriminatie zien, met een AUC van 
0.63 (95% CI 0.57-0.69), terwijl model B beter was (AUC 0.69, 95% CI 0.63-0.74). 
De kalibratie van Model A was slecht en van Model B goed (Hosmer-Lemeshow 
p=0.17 en 0.57), hoewel bootstrapping enige overschatting toonde. Vrouwen met 
een zwangerschapshypertensie of milde PE in de aterme periode hebben een 
verhoogde kans op HPP; de gecombineerde variabelen in de antepartum en intra 
partum periode kunnen samen het a priori risico op HPP verhogen of verlagen. Na 
externe validatie zouden deze voorspellers gebruikt kunnen worden in de kliniek.
In  de  laatste  twee  hoofdstukken  van  dit  proefschrift  worden  twee  specifieke 
laboratoriumtesten  onderzocht.  Wij  hebben  getracht  om  de  waarde  van  deze 
testen te bepalen om zo complicaties bij vrouwen met een PE beter te kunnen 
voorspellen.  Hoofdstuk  9  toont  een  meta-analyse  en  beslisanalyse  waarin  de 
waarde van urinezuur wordt onderzocht om in de toekomst ernstige maternale 
morbiditeit  bij  PE  te  voorspellen.  Voor  dit  onderzoek  werd  een  bestaande 
systematische review geüpdatet. Eerst werd een sROC-curve opgesteld met de 
sensitiviteit en specificiteit van de verschillende 2 x 2 tabellen. Vervolgens werd 
een  klinische  beslisanalyse  uitgevoerd;  opgebouwd  uit  drie  beslistakken:  (I) 
afwachtend beleid, totdat de baring spontaan begint; (II) inleiden van de baring; (III) 
behandeling afhankelijk van de waarde van het urinezuur. In geval van strategie III 
zou een inleiding van de baring volgen bij een hoge waarde van het urinezuur, en 
zou er worden afgewacht bij een normaalwaarde van het urinezuur. De ‘expected 
utility’ van elke strategie bepaalde of er werd afgewacht, of de baring werd ingeleid 
of dat het beleid zou afhangen van de waarde van het urinezuur. Deze expected 
utility was afhankelijk van de kans op een ernstige complicatie (gedefinieerd als 
ernstige  hypertensie,  HELLP-syndroom  of  eclampsie)  en  de  wijze  van  bevallen 
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(spontane  partus  versus  sectio  caesarea).  Voor  de  waardering  van  de  twee 
verschillende uitkomstmaten werd gebruik gemaakt van een ‘distress ratio’, die 
aangeeft dat een ernstige complicatie zwaarder weegt dan een sectio caesarea. 
Bijvoorbeeld: een distress ratio van 10 impliceert dat een ernstige complicatie 10 
keer zwaarder weegt dan een sectio caesarea.
Voor de periode tot 2008 hebben wij acht geschikte artikelen gevonden, die voldeden 
aan de inclusiecriteria. In totaal werden er 1565 vrouwen met PE geïncludeerd. De 
meest voorkomende grenswaarde van urinezuur was 350 μmol. De AUC was 68%, 
deze waarde werd vervolgens gebruikt voor de klinische beslisanalyse. Bepaling 
van het urinezuur zou de beste strategie zijn als de kans op een complicatie zich 
bevindt tussen de 2.9 en 6.3% en er een distress ratio van 10 gehanteerd wordt. 
In geval van een hoger complicatiepercentage is een inleiding van de baring de 
beste behandeling, terwijl een afwachtend beleid juist de voorkeur geniet bij een 
lager  complicatiepercentage.  Sensitiviteitsanalyses  hebben  bovengenoemde 
bevindingen niet beïnvloed. Wij concluderen dat bepaling van de waarde van het 
urinezuur een nuttige test is in de behandeling van zwangere vrouwen met PE.
In  het  laatste  hoofdstuk  worden  de  leverfunctietesten  nader  onderzocht. 
Tegenwoordig  worden  deze  testen  routinematig  uitgevoerd  bij  zwangere 
vrouwen met PE. Echter, systematische review artikelen waarin de waarde van 
leverfunctietesten  wordt  onderzocht  om  ernstige  complicaties  bij  vrouwen 
met een PE te voorspellen, bestonden niet. In Hoofdstuk 10 wordt daarom een 
systematische  review  beschreven  waarin  deze  waarde  van  leverfunctietesten 
is  onderzocht.  Hiervoor  werden  de  elektronische  databases  Medline,  Embase 
en de Cochrane Library geraadpleegd en werden de artikelen beoordeeld door 
twee  onafhankelijke  auteurs.  Dertien  artikelen  voldeden  uiteindelijk  aan  de 
inclusiecriteria en in totaal werden er 3507 vrouwen met PE geïncludeerd. Voor 
een slechte maternale uitkomst en voor een slechte foetale uitkomst werden er 
respectievelijk 30 en 19, 2 x 2 tabellen opgesteld. De AUC voor de voorspelling van 
een slechte maternale uitkomst was 0.79 (95% CI 0.51–0.93) en van een slechte 
foetale uitkomst 0.65 (95% CI 0.26–0.90). De specificiteit van de leverfunctietesten 
was beter dan de sensitiviteit. Wij kunnen nu concluderen dat leverfunctietesten 
beter een slechte maternale uitkomst kunnen voorspellen dan een slechte foetale 
uitkomst  bij  zwangere  vrouwen  met  PE.  Daarbij  zijn  verhoogde  leverenzymen 
geassocieerd  met  een  verhoogd  risico  op  maternale  en  foetale  complicaties, 
echter normale leverfunctietesten sluiten een complicatie niet uit.
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vrouwen met een intra-uteriene groeirestrictie een endotheeldysfunctie hadden 
ontwikkeld in de drie trimesters van de zwangerschap. Helaas zijn alle 2de trimester 
metingen verloren gegaan omdat de laptop met de data werd gestolen. Hiermee 
hebben we zelfs het landelijke nieuws bereikt (SBS6 en RTL 4), maar de dief is niet 
tot inkeer gekomen. Wel hebben we het onderzoek mogen presenteren tijdens 
het SMFM congres in San Francisco en is er uiteindelijk een mooie publicatie in de 
AJOG verschenen. Hartelijk dank voor jouw begeleiding. 
De leden van mijn beoordelingscommissie/ members of my manuscript committee.
Prof. dr. G.H.A. Visser, bedankt voor uw bereidheid om mijn proefschrift kritisch 
te lezen en op zijn wetenschappelijke waarde te beoordelen. Prof. dr. A. Shennan 
and prof. dr. L.A. Magee, thank you kindly for your willingness to critically read my 
thesis and to evaluate its scientific value.
Zonder het Verloskundig Consortium was deze multicenter studie niet van de grond 
gekomen. Ik voel mij ontzettend vereerd dat ik deel heb uit mogen maken van dit 
krachtige samenwerkingsverband van Nederlandse bodem. Het is bijzonder om 
te zien dat dit Verloskundig Consortium in enkele jaren is uitgegroeid tot een zeer 
professionele organisatie met wereldwijde bekendheid. Maya Kruijt en Zelda van 
Dijk, de dames van het Trialbureau in het AMC, ik wil jullie ontzettend bedanken 
voor alle organisatorische werkzaamheden, jullie zijn onmisbaar! 
De HYPITAT trial projectgroep (D. Bijlenga, H. Groen, S.M.C. Vijgen, R. Aardenburg, 
J.G. Aarnoudse, B.M.C. Akerboom, E. van Beek, D.J. Bekedam, P.P. van den Berg, 
K. de Boer, J.M. Burggraaff, K.W.M. Bloemenkamp, F.J.A. Copraij, J.P.R. Doornbos, 
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C.  Willekes,  B.W.J.  Mol,  M.G.  van  Pampus)  wil  ik  bedanken  voor  de  prettige 
samenwerking.
Graag  bedank  ik  alle  researchverloskundigen  en  -verpleegkundigen  van  de 
participerende  ziekenhuizen  voor  hun  grandioze  en  onuitputtelijke  inzet  bij  de 
organisatie van de trial op lokaal niveau. Corine Verhoeven, Jannet Bakker, Clara 
Kolster, Lidewijde Jongmans, Birgit van der Goes, Inge Boot, Nelly leNoble, Gerard 
Zijdeveld,  Joke  van  Rhee,  Marjolein  Verhart,  Roelie  van  Rossum,  Ingrid  Volker, 
Kim Notten, Wilma Keller, Coby van Dam en Cathy Swarte, hartelijk dank voor het 
includeren van patiënten en het invoeren van alle data. Vooral het laatste karwei 
is een enorme klus geweest, waar ik in mijn eentje een meerjarenproces van had 
moeten maken! Bedankt!
Lida  Ulkeman  en  José  Keurentjes,  natuurlijk  behoren  jullie  ook  tot  het 
voorafgaande rijtje, maar graag richt ik tot jullie een persoonlijk woord. Ik prijs mij 
ontzettend gelukkig dat ik met jullie heb mogen samenwerken. Jullie enthousiasme 
en inclusiedrift houden menigeen op de werkvloer scherp. Gelukkig scheiden onze 
wegen zich hier niet en zetten we onze samenwerking voort in de kliniek!
Alle  gynaecologen,  arts-assistenten,  verloskundigen  en  verpleegkundigen 
uit de deelnemende ziekenhuizen aan de HYPITAT trial (Twente Ziekenhuisgroep 
– Almelo, Flevo ziekenhuis – Almere, Academisch Medisch Centrum – Amsterdam, Onze 
Lieve Vrouwe Gasthuis – Amsterdam, St Lucas Andreas ziekenhuis – Amsterdam, Meander 
Medisch  Centrum  –  Amersfoort,  Gelre  Ziekenhuis  –  Apeldoorn,  Rijnstate  ziekenhuis  – 
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Haag, Medisch Centrum Haaglanden - Westeinde – Den Haag, Haga ziekenhuis - Leyenburg 
–  Den  Haag,  Deventer  Ziekenhuis  –  Deventer,  Albert  Schweizer  –  Dordrecht,  Catharina 
Ziekenhuis – Eindhoven, Scheper Ziekenhuis – Emmen, Groene Hart ziekenhuis – Gouda, 
Martini  ziekenhuis  –  Groningen,  Universitair  Medisch  Centrum  Groningen  –  Groningen, 
Kennemer Gasthuis – Haarlem, Atrium Medisch Centrum – Heerlen, Spaarne ziekenhuis 
–  Hoofddorp,  Bethesda  –  Hoogeveen,  Medisch  Centrum  Leeuwarden  –  Leeuwarden, 
Diaconessenhuis – Leiden, Leiden Universitair Medisch Centrum – Leiden, Academisch 
Ziekenhuis Maastricht – Maastricht, St Antonius ziekenhuis – Nieuwegein, St Canisius – 
Nijmegen, St Radboud ziekenhuis – Nijmegen, Maasland Ziekenhuis – Sittard, St. Elisabeth 
Ziekenhuis – Tilburg, Twee Steden Ziekenhuis – Tilburg, Utrecht Medisch Centrum – Utrecht, 
Maxima  Medisch  Centrum  –  Veldhoven,    Vie  Curie  ziekenhuis  –  Venlo,  Zaans  Medisch 
Centrum – Zaandam): hartelijk dank voor jullie medewerking bij het counselen en 
includeren van patiënten voor de trial. 
Arts-onderzoekers  van  het  Consortium.  Denise  Bijlenga,  Sylvia  Vijgen,  Kim 
Boers, Michelle Westerhuis, David van der Ham, Arianne Lim en Carolien Roos, 
gezamenlijk  zijn  we  de  uitdaging  van  het  Consortium  aangegaan.  Inmiddels  is 
het  Consortium  uitgebreid  tot  ongeveer  50  arts-onderzoekers.  Ik  wil  iedereen 246
bedanken voor de goede samenwerking, de gezelligheid en gedachtewisselingen 
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ontwerpen van de logo’s, en natuurlijk bedankt voor hoofdstuk 4, de maternale 
kwaliteit van leven dat een belangrijke toevoeging is aan de klinische resultaten. 
Je bent inmiddels gepromoveerd en je hebt een nieuwe baan, ik wens je daarin 
veel geluk. Sylvia Vijgen, zonder jou was dit boekje er (nog) niet geweest. Jouw 
grootste bijdrage is het databeheer geweest, en daar ben ik je ontzettend dankbaar 
voor.  Verder  is  hoofdstuk  5  jouw  werk,  wederom  een  belangrijke  toevoeging 
aan dit proefschrift. Ook jij hebt inmiddels het Consortium verlaten, veel geluk 
elders! Josje Langenveld (HYPITAT II) en Wietske Hermes (HyRAS), jullie zullen 
nog  meer  helderheid  verschaffen  over  klinische  vraagstukken  betreffende 
hypertensieve aandoeningen tijdens de zwangerschap. Ik wil jullie bedanken voor 
de samenwerking en gezelligheid tijdens congressen en symposia, die hopelijk 
nog lang voort zal duren.
Dr. J.J. Zwart, beste Joost, bedankt voor de cases met eclampsie uit de LEMMoN 
database. Het is ons gelukt om een mooie case-control studie uit te voeren! Prof. 
dr. J. van Roosmalen en dr. K.W.M. Bloemenkamp, beste Jos en Kitty, bedankt 
voor jullie medewerking aan dit artikel.
Dr. S. Thangaratinam, dear Shakila, thank you for involving me in the systematic 
review concerning liver function tests in the prediction of adverse outcomes in 
preeclamptic women.
De secretaresses van de afdeling Obstetrie en Gynaecologie van het UMCG, Jikke 
Adema en Diana Woltinge, bedankt voor jullie hand- en spandiensten met name 
voor de organisatie van het symposium.
Prof. dr. M.J.E. Mourits, beste Marian, bedankt voor de actieve medewerking die 
je mij hebt verleend om mijn wetenschappelijke onderzoek te combineren met de 
opleiding. Verder wil ik je ontzettend bedanken dat je mij op het juiste moment met 
de juiste mensen in contact hebt gebracht.
Gynaecologen, arts-assistenten, verloskundigen, verpleegkundigen en secretares-
ses in het Medisch Centrum Leeuwarden, bedankt voor de fijne tijd die ik als 
AIOS in het MCL heb gehad. Jullie zorgzame betrokkenheid en gezelligheid heb 
ik zeer gewaardeerd. Dr. T. Spinder, beste Taeke, als opleider van mijn eerste 
opleidingsjaar in het MCL wil ik je bedanken voor je steun en hartelijkheid. Tige 
dank! Als ‘âld-rypster’ zijn wij dorpsgenoten. Ik kom zeker een keer langs in Dronrijp 
voor een bakje koffie!247
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Verder wil ik alle gynaecologen, verloskundigen en arts-assistenten bedanken met 
wie ik samen in het Martini Ziekenhuis heb gewerkt. Mede dankzij jullie zijn er in 
korte tijd veel patiënten geïncludeerd voor de HYPITAT studie. Dr. A.J. van Loon, 
beste Aren, als ANIOS ben ik in het Martini Ziekenhuis gestart. Het is een drukke 
periode geweest, waarin zowel de kliniek als het promotieonderzoek nieuw voor 
mij waren; bedankt voor je vertrouwen in mij. 
Collega-onderzoekers  van  de  onderzoekskamer  Y4.240  in  het  UMCG.  In  de 
loop van de jaren zijn er veel onderzoekers voorbij gekomen. Ik wil jullie allemaal 
bedanken voor de gezelligheid. Speciaal Maaike, Judith en Annet, het is erg fijn 
geweest om jullie in de buurt te hebben als klankbord en lotgenoot. Bedankt voor 
jullie waardevolle adviezen en oprechte interesse. Ik hoop dat we nog lang contact 
houden.
Alle nieuwe AIOS collega’s en gynaecologen Obstetrie en Gynaecologie uit het 
UMCG wil ik bedanken voor de leerzame en leuke start van mijn tweede jaar van 
mijn opleiding. Ik kijk ernaar uit om de komende 2,5 jaar met jullie samen te werken!   
Goede vrienden zijn onmisbaar! 
Lieve clubgenootjes, (studie) vrienden, vriendinnetjes van vroeger, en oud-huis-
genoten, bedankt voor jullie interesse, steun, luisterend oor, brede schouders en 
bovenal gezelligheid. Speciaal dank ik de ‘Bunnies’ van de Pijpstraat voor jullie 
hechte vriendschap. Ik heb een ontzettende leuke tijd met jullie gehad, jullie zijn 
topmeiden en ik hoop dat onze vriendschap voor altijd is!
Mijn  paranimfen,  K.  van  der  Tuuk  en  A.  Hornstra.  Lieve  Karin,  wij  vormen 
een  perfect  onderzoeksduo,  want  we  vullen  elkaar  voortreffelijk  aan.  Mijn 
perfectionisme en jouw oog voor het geheel. Aan jouw rechtdoorzee eerlijkheid 
en jouw kwaliteiten om grenzen te stellen, kan ik nog een voorbeeld nemen. Ik 
ben blij dat ik je twee jaar geleden heb leren kennen, niet alleen als collega, maar 
ook als vriendin! Lieve Anke, wat ben ik blij met zo’n lieve vriendin. Wij kennen 
elkaar al vanaf ons tiende jaar en onze band is de laatste jaren alleen maar sterker 
geworden. Ik kan altijd bij je terecht voor een goed gesprek, of gewoon gezellig 
wijntjes drinken. Bedankt dat jullie vandaag naast mij willen staan.  
Mijn schoonfamilie, lieve Tonnie, Henk, Herko, Anne, Fleur, Christiaan, Veronique 
en Karel, ik heb het ontzettend met jullie getroffen. Bedankt voor jullie warmte 
en hartelijkheid. Lieve Vero, naast goede vriendinnen nu ook schoonzusjes, wat 
bijzonder!
Lieve mama, ik ben blij dat jij er vandaag zoals altijd voor me bent en ik weet zeker 
dat papa ontzettend trots op ons zou zijn. Bedankt voor je onvoorwaardelijke liefde, 
je zorgzaamheid en je interesse in mij. Lieve Sander en Oscar, jullie zusje gaat 248
vandaag promoveren, dat hadden jullie vast niet verwacht! Ik voel mij gezegend 
met  zulke  lieve  broers,  die  altijd  voor  mij  klaarstaan.  Lieve  Bernadette,  Elvira, 
Bart en Famke, mijn schoonzusjes, neefje en nichtje, ik ben blij dat jullie ook deel 
uitmaken van de familie. 
Mijn grote liefde Norbert, jij bent de allerbelangrijkste persoon in mijn leven. Zonder 
jouw onvoorwaardelijke steun en liefde in goede, maar zeker ook in slechte tijden, 
stond ik niet zo positief in het leven. Jouw hulp op welk gebied dan ook, jouw 
relativeringsvermogen en jouw warmte kan ik echt niet meer missen. Met jou aan 
mijn zijde voel ik mij de gelukkigste, sterkste en mooiste vrouw op aarde! Ik hoop 
dat we samen al onze dromen waar kunnen maken en dat we een lang en gezond 
leven tegemoet gaan. Kortom, bedankt dat je er bent. Noppie, ik houd van jou!
Groningen, november 2010
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